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Summary
There is growing evidence that several glycolytic enzymes, so-called
housekeeping enzymes, including fructose bisphosphate aldolase (FBA) and
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), despite being devoid of
any apparent secretion signal, may be localised to the cell surface of several
bacterial and fungal species, where they exhibit diverse non-glycolytic biological
functions. However, the mechanism(s) of secretion of such signal-less proteins to
the cell surface or to external environment is not well understood. Whilst their
intracellular functions are well known, it is unclear whether they perform any
additional functions, unconnected to their central role in glycolysis, on the
bacterial surface. It is becoming apparent that such proteins may be immunogenic
and they may be capable of eliciting protective immunity in animal models. As
such, they represent potential vaccine candidates. In a search for novel surface-
exposed proteins as potential vaccine candidates against N. meningitidis
serogroup B, and in accordance with the fact that glycolytic enzymes are putative
virulence factors in some bacterial species, it is hypothesised that meningococcal
FBA and GAPDH-l, may be present on the cell surface and thus may contribute
to the pathogenesis of disease.
In N. meningitidis serogroup B, there is a single gene cbbA (NMB 1869) and two
genes gapA-l and gapA-2, predicted to encode fructose bisphosphate aldolase
and glyceradehyde 3-phosphate dehydrogenase (GAPDH) enzymes, respectively.
Sequence analysis shows that FBA and GAPDH-l are highly conserved at the
amino acid level. The amino acid sequences of FBA from N. meningitidis and
those from Xanthobacter flavus and Synechocystis sp. displayed high identities
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(67 and 65%, respectively), which suggests that the meningococcal FBA (like
those of X flavus and Synechocystis sp.) belongs to bacterial Class-II FBP
aldolases.
The cbbA and gapA-l genes were cloned and over-expressed in host E. coli. FBA
was purified under non-denaturing and denaturing conditions, whilst GAPDH-l
was purified under denaturing conditions. Recombinant native FBA was used in
a coupled enzymic assay confirming that it has fructose bisphosphate aldolase
activity. The purified FBA and GAPDH-l proteins were then used to raise
polyclonal monospecific rabbit antiserum (RaFBA and RaGAPDH-l) for
subsequent characterisation of enzymes with the aim to determine their sub-
cellular localization as well as potential roles in pathogenesis of meningococcal
disease. RaFBA and RaGAPDH-l reacted with ca. 38-kDa and 37-kDa proteins,
respectively, in immunoblot analysis against whole cell lysates from
meningococcal strain MCS8 but not the cbbA and gapA-l isogenic mutants,
respectively, confirming that cbbA and gapA-l are naturally-expressed proteins in
N. meningitidis. Furthermore, expression of cbbA was detected in 26/26 and
GAPDH-l in 17/17 diverse meningococcal strains.
Cell fractionation experiments showed that meningococcal FBA and GAPDH-l
are localized both to the cytoplasm and to the outer membrane. These results
were validated by flow cytometry. The data demonstrated that outer membrane-
localized FBA was surface-accessible to FBA-specific antibodies in encapsulated
N. meningitidis, whereas flow cytometry analysis confirmed that GAPDH-I
could be detected on the cell surface, but only in a siaD-deficient background,
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suggesting that GAPDH-I is inaccessible to antibody in encapsulated
meningococci. Mutational analysis and functional complementation was used to
identify additional functions of FBA and GAPDH-l. The cbbA and gapA-l
knock-out mutant strains were unaffected in their ability to grow in vitro, but
showed a significant reduction in adhesion to HBME and HEp-2 cells compared
to their isogenic parent and complemented derivatives. In a transgenic mouse
model, cbbA mutant strains were shown to be less able to establish bacteraemia
compared to their wild-type parent strains.
In summary, in this study, expression of FBA and GAPDH-l was shown to be
well conserved across diverse isolates of Neisseria species. This study also
demonstrates for the first time that meningococcal glycolytic enzymes, FBA and
GAPDH-l. are surface localised proteins and required for optimal adhesion of
meningococci to host cells. Taken together, these results suggest that FBA and
GAPDH-l may be involved in the pathogenesis of meningococcal disease.
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CHAPTER 1: General Introduction
1
1.1 Introduction
1.2 Historicalbackground
Meningococcal disease (MCD), previously known as cerebrospinal fever, was
first described by Vieusseux in the area around Geneva, Switzerland, in the
spring of 1805. Just two years after this report, epidemics of what appeared to be
the same disease were reported in New England and among the Prussian army.
Following these outbreaks, the disease became widely recognised in Europe, in
parts of Asia and in America (DeVoe, 1982). However, it was not until 1887 that
an equally novel discovery was made by the Austrian pathologist Anton
Weichselbaum, who identified the etiological agent of meningococcal disease by
showing, for the first time, that there was a connection between Neisseria
meningitidis (then known as Diplococcus intracellularis meningitidis) and
'epidemic cerebrospinal meningitidis' (de Souza & Seguro, 2008).
1.3 Cultural and biochemicalcharacteristicsof N. meningltldis
N. meningitidis, (the meningococcus) is a Gram-negative, oxidase and catalase
positive, non-sporing, aflagellate, aerobic diplococcus of approximately 0.8 urn
in diameter. The bacterium may be encapsulated or unencapsulated, and is a
member of the bacterial family Neisseriaceae (Ala'Aldeen & Turner, 2006;
Stephens et al., 2007). This family includes the genera Neisseria, Moraxella,
Kingel/a, and acinetobacter. The genus Neisseria includes two human pathogens,
N. meningitidis and N. gonorrhoeae. N. meningitidis is relatively fastidious in
growth requirements and grows reasonably well on blood, chocolate, Modified
New York City medium, and on Muller-Hinton Agar. Optimum growth
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conditions can be achieved at 35-37°C at pH 7.0-7.4 in a humid environment
with 5-10% CO2 (Ala'Aldeen & Turner, 2006).
1.4 Epidemiology of meningococcal disease
In spite of considerable success in the development of drugs and effective
vaccines, the problem of disease due to N meningitidis is far from solved
(Peltola, 1983) and still remains a serious threat to global health (Fig 1.1)
occurring sporadically throughout the world (Milonovich, 2007). Strains of N
meningitidis have been classified into 13 serogroups on the basis of the
immunological specificity of capsular polysaccharides but invasive
meningococcal infection is limited to the serogroups A, B, C, W-135, Y and more
recently X (Stephens, 2007; Tzanakaki & Mastrantonio, 2007).
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Figure 1. 1 Worldwide distribution of major meningococcal serogroups and
outbreaks of serogroup B by serotype (shaded in purple). The meningitis belt
(dotted line) of Sub-Saharan Africa and other areas of substantial meningococcal
disease in Africa are shown (adapted from reference Stephens et al., 2007).
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The five common serogroups: A, B, C, Y and W-135 are responsible for more
than 90% of the total cases of invasive meningococcal disease in the human
population (Serruto et al., 2004). However, serogroups A, B, and C account for
most of the meningococcal disease throughout the world (Tzanakaki &
Mastrantonio, 2007).
The bacterium is not only a common commensal of the human upper respiratory
tract (nasopharynx) but also an important and devastating human pathogen that
remains a leading cause of bacterial meningitis and septicaemia (Schneider et al.,
2007; Tzanakaki & Mastrantonio, 2007), affecting all age groups but primarily
targeting children and young adults (Harrison, 2006; Soriano-Gabarro et al.,
2002). The only natural reservoir of N meningitidis is the human nasopharyngeal
mucosa. Depending on age, climate, country, socioeconomic status, and other
factors, it is carried by approximately 10% of adult population in the nasopharynx
(Schoen et al., 2007; van Deuren et al., 2000), where it usually resides as a
harmless commensal (Girard et al., 2006), without causing any detectable
symptoms (Caugant et al., 2007). However, in a small number of colonized
persons, the organism can traverse the mucosal tissues to gain access into
bloodstream to cause septicaemia/meningococcemia and/or subsequently
progresses to the cerebrospinal fluid (CSF) by mechanisms that are not clearly
understood, to cause meningitis (Nassif, 1999). The traversal of these barriers are
essential steps in the pathogenesis of meningococcal meningitis (Sokolova et al.,
2004). The invasive disease is very rare and only occurs when the following
conditions are fulfilled: (i) contact with a virulent strain, (ii) colonization by that
strain, (iii) penetration of the bacterium through the mucosa, and (iv) survival and
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eventually outgrowth of the meningococcus in the bloodstream (van Deuren et
al., 2000). The septicaemia / meningococcemia and meningitis caused by the
meningococcus are collectively known as meningococcal disease.
Serogroup A meningococcus has remained a major cause of meningococcal
disease in the so called "African Meningitis Belt", which spans several sub-
saharan countries, and also in parts of Asia (Schoen et al., 2007; Stephens, 2007).
The African Meningitis Belt was first described by Lapyeysonnie in 1963, and
initially comprised Burkina Faso, Ghana, Togo, Benin, Niger, Nigeria, Chad,
Cameroon, Central African Republic, and the Sudan. Later it was extended to
include Ethiopia, Mali, Guinea, Senegal and Gambia, which is now known as
"The Expanded Meningitis Belt" (van Deuren et al., 2000). Outbreaks within the
African Meningitis Belt have been reported to prevail in the dry season and
gradually reduce in the rainy season (Stephens, 2007).
Serogroup B disease accounts for a substantial portion of cases in the United
States, with half of the invasive infections occurring in infants (Harrison, 2006),
and also remains the major cause of sporadic or endemic disease in many
industrialized countries, accounting for 30-70% of cases of disease (Schoen et al.,
2007). Prolonged outbreaks have been described in Europe, Cuba, Chile, and
recently in New Zealand, where it has caused significant morbidity and mortality
(Stephens, 2007).
Serogroup C strains cause small scale outbreaks worldwide. However, it has been
associated with an endemic pattern of disease since the 1990s, causing multiple
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outbreaks in schools and in the community in North America and Europe
(Harrison, 2006).
Serogroup Y cases have substantially increased in number in recent years,
accounting for 30% of the cases in United States (Schoen et al., 2007). This
serogroup has also classically been associated with cases of meningococcal
pneumonia (Harrison, 2006).
Another relatively uncommon meningococcal serogroup is W-135, which
currently accounts for fewer than five percent of all cases worldwide (Rosenstein
et al., 2001). The first international outbreak of serogroup W-135 meningococcal
disease was reported among pilgrims to the Hajj in Saudi Arabia during 2000-
2001, and in Burkina Paso in 2002 (Chiou et al., 2006; Taha et al., 2003).
Serogroup W-135 causes a relatively small number of cases in the United States
(Harrison, 2006), and is similarly uncommon in Europe.
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1.5 Pathogenesisof meningococcaldisease
There are a multitude of molecular/cellular receptors and mediators that are
involved in the outcome of host-meningococcal interactions (Emonts et al., 2003;
van der Flier et al., 2003). These factors work in concert with various strongly
interacting pathways within the vascular tree and in the subarchnoid space (Van
Amersfoort et al., 2003). A key factor in meningococcal pathogenesis is the
ability of bacteria to attach to host cell receptors, which is a complex
phenomenon and involves different adhesive factors depending upon the
environment that meningococci encounter with the host cell (Serruto et al.,
2003). The primary attachment is mediated by Type IV pili that act as
'meningococcal sensory organ' establishing the primary cellular communication
between the organism and host target cells (Nassif, 2000).
1.5.1 Colonisation
N. meningitidis, an obligate human commensal, colonizes the nasopharynx (Fig.
1.2) and spreads from person to person by direct contact or via respiratory
droplets ( from a distance up to approximately 1 metre) from infected (with a
potentially pathogenic strain) but asymptomatic carriers to other healthy
individuals (Caugant et al., 2007). The human naso-oropharyngeal mucosa serves
as the reservoir for the spread of meningococci in the population. A number of
molecules are required by the bacteria to enable them to colonise and/or infect the
host, including adhesins, which are key factors that are required for initial
colonisation of human mucosal sites (Virji, 2009).
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Colonisation of the upper respiratory mucosal surfaces by N. meningitidis is the
first step in the establishment of a human carrier state and invasive
meningococcal disease (Stephens, 2009). Colonisation by the meningococcus
occurs both at the exterior surface of the mucosal cell and intra- or subepithially
(van Deuren et al., 2000). Colonization of the oropharynx by meningococci
produces an antibody response from the three major immunoglobulin classes
within a few weeks after acquisition of the bacterium and may act as an
immunizing event (Kremastinou et al., 1999). Most oropharyngeal carriers not
only develop homologous antibodies but also develop heterologous antibodies to
other meningococcal strains (Goldschneider et al., 1969). Damage to
nasopharyngeal ciliated epithelium may be an important first step in
meningococcal colonization of the human nasopharynx (Rayner et aI., 1995;
Stephens et al., 1986).
Active or passive tobacco smoke exposure independently increases the risk of
carriage and developing meningococcal disease (Fischer et al., 1997; Haneberg et
al., 1983; Stuart et al., 1989).
1.5.2 Adhesion
Adhesion to human mucosal surfaces is essential for meningococcal survival.
Stephens et al., developed a human nasopharyngeal organ culture model and
found that meningococci specifically bind non-ciliated columnar epithelial cells
and induce pseudopodia that ultimately result in internalization of meningococci
within these cells (Stephens et al., 1983).
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The identified meningococcal adhesins include Pili, PilC, PilQ, Opa, Opc, LOS,
Factor Hsbinding protein, PorA, HrpA, PorB and NadA and their proposed host
receptors include platelet activating factor, CD46, CEACAMl, vitronectin and
u-actinin integrins, complement receptor 3, laminin and the CD scavenger
receptor (reviewed in Stephens, 2009). Pili are major adhesins that contribute to
meningocoocal attachment to mucosal cells. Stephens and McGee found that
pilated meningococcal strains consistently attached to human nasopharyngeal
cells in greater numbers than meningococci without pili suggesting that pili are
important mediators of meningococcal attachment to host tissues. However, the
number and distribution of receptor sites for pili or pili-associated meningococcal
ligands differ among human cells and may determine sites of meningococcal
colonization (Stephens & McGee, 1981). Pili have been shown to bind to
receptors on nasopharyngeal cells, i.e. the membrane co-factor protein or CD46
(Kallstrom et al., 1997) and this binding induces signal transduction pathways in
host cells (Kallstrom et al., 1998)
After attachment, meningococci continue to proliferate on the surface of human
non-ciliated epithelial cells, resulting in the formation of small microcolonies at
the site of initial attachment. Intimate adherence of meningococci to the host
epithelial cells result in the formation of cortical plaques (Stephens, 2009) and
leads to the recruitment of factors ultimately responsible for the formation and
extension of epithelial cell pseudopodia that engulf the meningococcus (Doulet et
al., 2006). After initial binding, intimate association is mediated via class 5 outer
membrane proteins (OMPs) such as opacity proteins, Opa and Ope with
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CD661CEACAMs and integrins, respectively, on the surface of the epithelial
cells (Virji et al., 1996).
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Figure 1. 2 Stages in the pathogenesis of N meningitidis. N meningitidis may be
acquired through the inhalation of respiratory droplets. The organism establishes
intimate contact with non-ciliated mucosal epithelial cells of the upper respiratory
tract, where it may enter the cells briefly before migrating back to the apical
surfaces of the cells for transmission to a new host. Asymptomatic carriage is
common in healthy adults in which bacteria that enter the body by crossing the
epithelial barrier are eliminated. Besides transcytosis, N meningitidis can cross
the epithelium either directly following damage to the monolayer integrity or
through phagocytes in a 'Trojan horse' manner. In susceptible individuals, once
inside the blood, N meningitidis may survive, multiply rapidly and disseminate
throughout the body. Meningococcal passage across the brain vascular
endothelium (or the epithelium of the choroid plexus) may then occur, resulting
in infection of the meninges and the cerebrospinal fluid (adapted from reference
Virji, 2009).
1.5.3 Invasion
Meningococci traverse the mucosal epithelium via phagocytic vacuoles (Fig 1.2)
as a result of endocytosis (McGee et al., 1983; Nassif & So, 1995; Stephens et
al., 1983; Stephens & Farley, 1991). During invasion several bacterial factors
have been demonstrated to modulate the metabolism of the mucosal cells (Virji,
1996). Two virulence factors appear to be essential for meningeal invasion by N
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meningitidis: the capsular polysaccharide, and type IV pili (Nassif et al., 1994;
Virji et al., 1991). Type IV pili play a pivotal role in meningeal invasion, which
is associated with an increase in the expression of PilC (Hardy et al., 2000; Pron
et al., 1997). Capsulated piliated bacteria adhere to the apical surface of the cells
and only a small proportion of the bacteria are internalized. This adhesion is
associated with the formation of 'cortical plaques' beneath bacterial colonies on
the apical surface (Merz et al., 1999). The formation of the cortical
plaque-associated cell membrane protrusions results from the organization of
specific molecular complexes involving the molecular linkers ezrin and moesin
(known as ERM [ezrin-radixin-moesin] proteins), along with the clustering of
several membrane-integral proteins, including CD44, intracellular adhesion
molecule (ICAM)I, and cortical actin polymerization (Eugene et al., 2002;
Hoffmann et al., 2001; Lambotin et al.• 2005; Merz et al., 1999). Some
lipooligosaccharide (LOS) mutant meningococcal strains, show structurally
altered actin polymerization and are defective in the recruitment and
phosphorylation of cortactin, thus are poorly invasive (Hoffmann et al., 200 1)~
1.5.4 Survival of meningococcus in bloodstream
Meningococci can survive and proliferate in the bloodstream through the
expression of particular bacterial virulence factors or because of naivety or
specific immune system defects in the host (van Deuren et al., 2000). The steps
of meningococcal intracellular survival and transcytosis through the basolateral
tissues and dissemination into the bloodstream are less well studied. Following
the successful traversal of nasopharyngeal mucosa, N. meningitidis progresses to
sub-epithelial tissue and may gain access to the bloodstream. Once viable
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meningococci have reached the bloodstream, the bacterium, in order to protect
itself in such a hostile environment, requires the expression of the capsule which
is known to protect against complement-mediated bacteriolysis and phagocytosis
(Klein et al., 1996). In addition some class 1 OMPs hamper ingestion of
meningococcus by neutrophils via down-regulation of the Fey receptor and the
Cl and C3 receptor (Bjerknes et al., 1995). Meningococcal intracellular survival
is determined by factors including IgAl protease, which degrades lysosome-
associated membrane proteins (LAMPs), thus preventing phagosomal maturation,
and up-regulation of expression of capsule (Hopper et aI., 2000). Furthermore,
IgAl protease appears to break IgA1, releasing monomeric Faba fragments, that
can block the interaction of IgG and IgM (Mulks & Plaut, 1978).
Intracellular meningococci reside within a membranous vacuole and are capable
of translocating through the epithelial layers within 18-40 h (Stephens et al.,
1983; Stephens et al., 2007). Following internalization N. meningitidis are
capable of intracellular replication and this is due in part to the capacity of the
organism to acquire iron through specialized transport systems, such as the
hemoglobin-binding receptor (HmbR), transferring-binding protein (TbpAB) and
lactoferrin-binding protein (LbpAB) (Perkins-Balding et al., 2004).
1.5.5 Nasopharayngeal carriage and mucosal immunity
The meningococcus has its natural habitat in the mucus membranes of the
oropharynx of the human host. Those harbouring the organism are usually
asymptomatic and are commonly referred to as 'carriers'. The frequency of
carriage in the normal population ranges from 10-30% during non-epidemic
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periods but may approach 100% during epidemics (DeVoe, 1982). The duration
of meningococcal carriage can vary from days to months (Cartwright et al., 1987;
Stephens, 1999). The probability of meningococcal disease after the acquisition
of N meningitidis declines very sharply, such that invasive disease becomes
unlikely 10-14 days after acquisition (Stephens, 2009). Meningococcal carriage is
affected by age, intimate personal contacts, crowding (eg, bars, dormitories) and
smoking (Tzeng & Stephens, 2000; Yazdankhah & Caugant, 2004). Damage to
upper respiratory tract by co-infections (e,g. mycoplasma, influenza, and other
respiratory viral infections), smoking, very low humidity, drying of mucosal
surfaces, and trauma induced by dust, predisposes to carriage and meningococcal
disease (Artenstein et al., 1967; Greenwood et al., 1985; Moore et al., 1990;
Young et al., 1972).
The first and most important line of defense against infection with N
meningitidis is the integrity of the mucosal membrane. The increased incidences
at the end of the dry season in Africa have been attributed to the dryness of the
air, which probably influences the integrity of the mucosal membranes of
nasopharynx (Verheul et al., 1993). Asymptomatic carriage by N. lactamica, a
non-pathogenic species of Neisseria, occurs especially during early childhood
and is associated with a rise in antibody titers to pathogenic meningococci, and
these cross-reactive antibodies may be useful in the development of natural
immunity to N meningitidis (Gold et al., 1978; Goldschneider et al., 1969). Rates
of carriage of N lactamica increase from 3.8% in 3-month old infants to a peak
of 21.0% at 18 months and then decline to 1.8% by 14-17 years of age. However,
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in the same population, the prevalence of N. meningitidis average 0.71% during
the first four years oflife and increase to 5.4% in teenagers (Gold et al., 1978).
1.5.6 Host susceptibility
The presence of sufficient pre-existing immunity or ability to rapidly generate a
relevant immune response limits new acquisition to the mucosal surface, whereas
immunological naivety is permissive for invasion (Wall, 2001). The most well
known host factors that predispose invasive meningococcal disease include
deficiencies in the terminal complement pathway (C5-C9) and in properdin.
(Fijen et al., 1999; Sjoholm et al., 1982). Disappearance of maternally transferred
antibodies increases the risk of invasive meningococcal disease in infants and
young children (Stephens et al., 2007).
A number of additional host factors have been recognised to be associated with
increased risk of meningococcal disease. These include polymorphisms in genes
encoding for Fey-receptor II (CD32), Fey-receptor III (CDI6), mannose-binding
lectin, TLR4, and plasminogen activator inhibitor (PAl-I) (Emonts et al., 2003;
Faber et al., 2006; Fijen et al., 2000; Hibberd et al., 1999; Read et aI., 2001;
Smimova et al., 2003; Tully et al., 2006). Furthermore, viral (influenza) and
mycoplasma respiratory infections can predispose to meningocoocal disease,
perhaps by damaging mucosal surfaces, altering dynamics of adherence, and
spread and impairing mucosal immunity (Moore et al., 1990). Infectious agents
such as enteric bacteria may induce cross-reacting IgA antibodies, which
competitively inhibit the binding of bactericidal IgG and IgM antibodies to the
meningococcus (Wenzel et al., 1973).
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1.6 Clinical manifestations of invasive meningococcal disease
N. meningitidis causes a spectrum of disease ranging from benign self-limited
meningococcemia to fulminant septic shock, multiple organ failure, and death
(can happen within 6 h after the symptoms). Among the wide range of clinical
manifestations of meningococcal disease, the two most common are meningitis
and septicaemia (Kirsch et al., 1996), which may co-exist.
1.6.1 Meningococcal septicaemia
Meningococcal septicaemia is the most severe form of infection, characterized by
wide spread haematogenous dissemination, but is less common than meningitis.
Meningococcal septicaemia may be: transient, chronic and fulminant. The
clinical course of severe meningococcaemia is rapidly progressive, with the time
from onset of fever until death often as short as 12 h (Kirsch et al., 1996).
Transient meningococcaemia is characterized by fever and non-specific rash, and
is usually detected as an unexpected result from blood culture. Both fever and
rash can disappear within 2-5 days without treatment (Stephens et al., 2007).
Chronic meningococcaemia is rare infection that can lasts from weeks to months
without meningeal symptoms. The symptoms include intermittent fever,
arthralgia, signs of vasculitis, and a non-specific maculopapular rash. Symptoms
may disappear for days and then re-appear (Harwood et 01.,2005; Stephens et al.,
2007).
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Fulminant meningococcal septicaemia is characterised by a rapid proliferation of
meningococci in the circulation, resulting in very high concentrations of bacteria
(105-108 ml") and meningococcal endotoxin (101-103 EU ml") (Brandtzaeg et
al., 1989; Brandtzaeg et al., 200 I; Stephens et al., 2007).
Patients suffering from fulminant meningococcal septicaemia may present with
severe, persistent shock, lasting more than 24 h or until death, and no distinct
clinical signs of meningitis. Due to the presence of few meningococci in the
cerebrospinal fluid (CSF), pleocytosis is negligible (Brandtzaeg et al., 1989;
Brandtzaeg et al., 1992; Stephens et al., 2007). Other clinical presenting features
include impaired renal, adrenal, and pulmonary function and disseminated
intravascular coagulation with thrombotic lesions in the skin, limbs, kidneys,
adrenals, choroids plexus, and occasionally the lungs (Hazelzet et al., 1996;
Stephens et al., 2007). The septemic inflammatory response leads to progressive
circulatory collapse and severe coagulopathy. Patients may suffer from vascular
complications that can lead to loss of digits or limbs, and survivors can be
severely handicapped (Brandtzaeg et al., 1989; Hazelzet et al., 1996; Hazelzet et
al., 1998).
1.6.2 Meningococcal meningitis
Meningitis is the most common clinical presentation of invasive meningococcal
disease; more than 60% of patients in industrialized countries develop meningitis
without shock. In developing countries, the proportion of patients with meningitis
is much higher than that in developed countries (Stephens et al., 2007). In
meningococcal meningitis bacteria are localized primarily to the meningeal
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compartment, resulting in a clinical picture indistinguishable from other forms of
bacterial meningitis (Kirsch et al., 1996).
Patients with meningitis usually have a low concentration of meningococci «103
ml") and endotoxin «3 EU ml") in plasma but high concentrations in CSF
(Brandtzaeg et al., 1989; Brandtzaeg et al., 1992; Ovstebo et al., 2004), leading
to a compartmentalised inflammatory response in the subarchnoid space, with a
pronounced increase in the concentrations of tumor necrosis factor a (TNF-a),
interleukins (IL-I p, IL-6, IL-8, and IL-I0), different chemokines, and other
mediators (Stephens et al., 2007).
In adult patients with meningococcal meningitis the following symptoms and
signs predominate: headache, fever, vomiting, photophobia, neck stiffness,
positive Kernig's and Brudzinski's signs, and lethargy. In infants and younger
children, non-specific symptoms including poor feeding, irritability, a high
pitched cry and a bulging fontanelle are typical findings. Seizures may occur in
up to 20% of cases and meningitis is a cause of a first episode of status
epilepticus in 12% of cases (Nadel & Kroll, 2007).
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1.7 Diagnosis and chemotherapy of meningococcal disease
Clinical diagnosis of meningococcal disease largely relies on the recognition of
symptoms such as fever, rash and meningeal signs and altered mental status, and
is confirmed by pleocytosis, gram stain with and without culture of cerebrospinal
fluid, or blood or skin lesions (Stephens et al., 2007). In early stages of
meningococcal disease diagnosis is, however, extremely difficult especially when
there is no epidemic outbreak of the disease, and requires a high degree of
suspicion, as symptoms may be similar to other conditions (e.g. Influenza and
other viral infections), and specific signs may be absent. In a recent study on
clinical recognition of meningococcal disease in children and adolescents it was
shown that classical features developed later on in disease progression (median
time of onset 13-22 h after symptoms began), where as early less-specific
features of sepsis such as leg pain, cold hands and feet and abnormal skin colour
first developed after a median period of 8 h in the majority of children
(Thompson et al., 2006).
Cultures of blood, or CSF, (in the absence of contraindications for lumber
puncture), and skin lesion aspirates may confirm the diagnosis (Nadel & Kroll,
2007). Latex agglutination assays on blood, eSF, or urine have been used as
adjunctive diagnostic tests but have a poor sensitivity and specificity (Perkins et
al., 1995). Meningococcal peR is now widely used in developed countries for
diagnosis.
As soon as the disease is first suspected based on suggestive clinical features,
initial treatment with antimicrobials should not be delayed whilst waiting for the
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results of laboratory investigations. Penicillin resistance is rare amongst clinical
isolates of N. meningitidis in the UK. Benzylpenicillin or a third generation
cephalosporin such as ceftriaxone is usually used for specific treatment. The
recommended duration of antibiotic therapy for meningococcal disease is 7 days
for both meningococcal meningitis and septicaemia (Nadel & Kroll, 2007). Until
the diagnosis is established, the patients must be treated empirically with broad
spectrum bactericidal antibiotics (such as cefotaxime or ceftriaxone and
amoxicillin [for Listeria cover] depending on age) (Peltola et al., 1989).
1.8 Classificationof N. meningifidls
Several classification systems, to aid in epidemiological studies, have been
developed for N. meningitidis. The most clinically relevant and well established
is a serological typing method that divides strains immunologically into
serogroups, serotypes, and serosubtypes, based on antigenic differences in their
capsule, PorB protein, PorA protein, and LOS, respectively. For example, a
serogroup B serotype 4, serosubtype 15 and immunotype lOis written as
B:4:P1.IS:LIO (Ala'Aldeen & Turner, 2006).
Multi-locus enzyme electrophoresis (MLEE) uses the natural electrophoretic
mobility of various cytoplasmic enzymes whose molecular weights vary between
different strains of meningococci. Using MLEE it was possible to classify
meningococci with similar characteristics into clonal families, designated
electrophoretic type (ET) (Caugant et al., 1986a; Caugant et al., 1986b).
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A genotyping method based on sequence analysis called multi-locus sequence
typing (MLST) has also been developed for N. meningitidis (Maiden et al.,
1998). The method has been a valuable approach in revealing associations
between isolates, showing the existence of distinct clones over-represented in
certain communities (Chiou et al., 2006; Feavers et aI., 1999; Maiden et al.,
1998; Murphy et al., 2003; Nicolas et al., 2001).
MLST, an adaptation of multi-locus enzyme electrophoresis, is fully portable and
data stored in a single expanding central multi-locus sequence database can be
interrogated electronically via the internet providing a powerful resource for
global epidemiology (Maiden et al., 1998).
MLST is based on DNA sequence variation in specific regions of seven
housekeeping genes (abcZ, adk, aroE, fumC, gdh, pdhC, pgm) that range from
433 to 501 bp in length. For each gene fragment, different sequences are assigned
as distinct alleles, and each isolate is defined by the combination of alleles at each
of the seven housekeeping loci. This is known as the allelic profile or sequence
type (ST). The STs are assigned to lineages using the BURST software
(http://neisseria.mlst.net) (Baethgen et al., 2008).
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1.9 Virulence factors of N. meningitidis
The meningococcus can avoid the host defense mechanisms through the
expression of several surface components and secretion of various molecules as
well as shedding complex vesicle structures (blebs) that may modulate or deflect
the immune system (Wall, 2001). It can also undergo phase and antigenic
variation (Berrington et al., 2002; Jennings et al., 1999), and is able to use host
factors for its own protection and growth. Some of the bacterial factors that may
be employed by the meningococcus to evade immune killing and in establishment
of infection are discussed below.
1.9.1 Capsule
The polysaccharide capsule is a major virulence factor and plays a crucial role in
invasive meningococcal disease. The capsule confers resistance to a number of
arms of the immune system (Schneider et al., 2007). The capsule of the
pathogenic meningococcal serogroups differs in both chemical structure and
antigenenic properties (Morley & Pollard, 2001). Capsule is the basis for
immunological serogrouping and confers resistance to the meningococcus against
phagocytosis, complement-mediated lysis and offers protection to the cells
against environmental insults (McNeil et al., 1994; Morley & Pollard, 20ot;
Schoen et al.) Thirteen structurally distinct capsular serogroups have been
described and six (A, H, C, W-135, Y, and X) of which cause the invasive
meningococcal disease (Stephens et al., 2007). Of six invasive meningoccoal
serogroups, the capsule of four serpgroups (S, C, Y, and W-135) , except
serogroup A, is composed of sialic acid derivatives, which bestows the organism
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antiphagocytic properties enhancing its survival in the bloodstream or central
nervous system (Stephens, 2009).
1.9.2 Lipooligosaccbaride
Meningococcal lipopolysaccharide (LPS, endotoxin). also referred to as
lipooligosaccharide (LOS), is composed of an oligosaccharide (OS) portion with
a phosphorylated diheptose (Hep) core attached to the toxic lipid A moiety
embedded in the outer membrane (Griffiss et al., 1988; Stephens, 2009).
Meningococcal lipid A is responsible for much of the biological activity and
toxicity of meningococcal endotoxin. Neisserial lipopolysaccharide lacks
repeating O-antigens and is thus often referred to as LOS. The core
oligosaccharide of meningococcal LOS and the two short chains are attached to
the two inner core heptose residues. The oligosaccharide chains vary in
composition and are the basis for immuno-typing meningococcal strains (Tzeng
& Stephens, 2000). Meningococcal LOS is subject to phase variation of its
terminal structures allowing switching between immunotypes, which is proposed
to have functional significance in disease (Berrington et al., 2002).
1.9.3 Pili
Pili (bair-like projections; also known as fimbriae) (Fig 1.3) are thin filamentous
protein structures on the surface of N meningittdis and are composed of repeating
identical subunits (pilins) of approximately 17 to 21 kDa. The meningococcal pili
belong to the type IV family of pilins. Recent systematic genetic analysis has
identified 15 proteins that are involved in the biogenesis, assembly and
disassembly of pili (known as pi! proteins) (Virji, 2009). The meningococcal pili
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playa key role in mediating the interaction of the bacterial cell with host cellular
membranes leading to the bloodstream invasion from the nasopharynx, and the
traversal across the blood-brain barrier (BBB) (Nassif, 1999). In addition to
adhesion, pili are involved in several other functions. For example, they facilitate
uptake of foreign DNA from the extracellular milieu, thereby increasing the
transformation frequency of bacteria, and are also responsible for twitching
motility (Frye et al., 2006; Fussenegger et al., 1997). N meningitidis is
genetically capable of producing antigenically different pilins. There are two
types of pilin designated class I and class II, produced by a single meningococcal
cell (Nassif, 1999).
Figure 1. 3 Prominent outer membrane components of N meningitidis that
influence bacterial interaction with host cells, (a) Pili traverse the capsule and are
the most prominent adhesins of encapsulated N meningitidis. In addition, the
integral outer membrane (OM) adhesins, Opa and Ope, are also known to
mediate interactions with specific host-cell receptors. Lipopolysaccharide may
interfere with the adhesion functions of OM proteins, but can also contribute to
cellular interactions by interacting with various cellular receptors. (B) A cross-
section of a pilus fibre showing that variable domains (V) and glycans (0) as well
as other substitutions (not shown) are located externally, whereas the constant
domains are buried within the fibre, protected from the host environment
(adapted from reference Virji, 2009).
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1.9.4 Major outer membrane proteins
Meningococcal outer membrane proteins have been grouped into five major
classes based on their apparent molecular weights on sodium dodecyl sulphate
(SDS) polyacrylamide gels and peptide analysis (Tsai et al., 1981). All five
classes of OMPs have been studied as potential vaccine candidates in N.
meningitidis (Chiou et al., 2006).
All meningococci express either a class 2 or class 3 outer membrane protein
named PorB and most strains also express a class 1 outer membrane protein
named PorA (Hitchcock, 1989). A two-dimensional secondary structure
containing eight surface exposed loops (I-VIII) has been predicted for PorA and
most variability is thought to occur in variable regions 1 and 2 (VRI and VR2)
which correspond to loops I and IV, respectively (Feavers et al., 1992; Maiden et
al., 1991). In addition, a third variable region, designated VR3 has been reported
to be present on the top ofloop V (van der Ley et al., 1991), however, the genetic
variability of this region appears to be lower than that of VR 1 and VR2 (de
Filippis et al., 2007).
The outer membrane protein PorB of N. meningitidis is a pore-forming protein
which has various effects on eukaryotic cells. It has been shown to (1) up-
regulate the surface expression of the co-stimulatory molecule CD86 and of
MHC class II (which are TLRZIMyD88 dependent and related to the porin's
immune-potentiating ability), (2) be involved in prevention of apoptosis by
modulating the mitochondrial membrane potential, and (3) form pores in
eukaryotic cells (Massari et al., 2005).
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The classl PorA and Class 2/3 PorB proteins have been studied most because
they are also used in the meningococcal typing scheme for the serosubtype and
serotype, respectively. Both proteins contain variable and hyper variable regions
(Diggle & Clarke, 2006).
Reduction modifiable protein M was formally known as the class 4 outer
membrane protein of N. meningitidis. The protein shows 94.2% homology with
protein III of N. gonorrhoeae, with both proteins having two potential disulfide
loops. The protein also shares low-level homology with Escherichia coli OmpA
(Klugman et aI., 1989).
The N. meningitidis opa (opacity) proteins and Ope (opacity protein Sc), (Fig 3.1)
are highly immunogenic, trimeric or tetrameric basic outer membrane proteins
with a similar molecular mass of ca. 30 kDa, which migrate aberrantly slowly on
sodium dodeeyl sulphate polyacrylamide gel electrophoresis (SOS-PAGE) unless
they have been fully denatured by boiling (Achtman et al., 1988). Opa proteins
are distinguished from the Opc protein because they have very little sequence
similarity (Olyhoek et al., 1991) The opa and ope proteins play an important role
in adhesion and invasion of host epithelial, endothelial and phagocytic cells (de
Jonge et al., 2003; Nassif, 1999; Prince et al., 2001).
1.9.5 Non-capsular virulent factors ofN. meningitidis
1.9.5.1 Neisseria hia homologue A (NhhA)
NhhA is a well-conserved outer membrane, autotransporter protein, which was
identified as a homologue of the adhesin AIDA-I of E. coli in N. meningitidis.
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This gene was designated nhhA (Neisseria hia homologue) due to its close
homology to the Hia and Hsf adhesin of non-typeable H injluenzae (Peak et al.,
2000). Antibodies to NhhA can be detected from the sera of healthy carriers as
well as patients suggesting that NhhA is expressed during colonization of
humans.
1.9.5.2 Adhesion and penetration protein (App)
App stands for Adhesion and penetration protein (App). The gene was so named
because of its homology to Hap (Haemophilus adherence and penetration
protein). App is a highly conserved, surface-localised, immunogenic protein,
which belongs to the autotransporter family of proteins (Hadi et al., 2001). App
was identified by genome analysis and by screening of a N. meningitidis
expression library using polyclonal antisera raised against the OMPs from N.
meningitidis (Hadi et al., 2001). App appears to be expressed during invasive
disease, as sera from convalescent patients contain antibodies that recognize
recombinant App. App has also been demonstrated to function as adhesin in N.
meningitidis. It binds to epithelial cells, but not endothelial cells (Serruto et al.,
2003).
1.9.5.3 Autotransporled serine Protease A (AspA/Na/P)
AspA is a 112-kDa phase variable classical autotransporter protein containing a
subtilisin-type serine protease motif in the passenger domain. AspA was
bioinforrnatically identified from the genome of N. meningitidis serogroup A. It
shares significant homology with autotransported serine protease of Serratia
marcescens. Although the aspA gene is phase variable, its amino acid sequence
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appears to be well conserved in serogroup A, B, and C meningococci (Turner et
al.,2002).
As the signal peptide of AspA contains a lipoprotein motif, the protein was also
designated NalP (Neisserial autotransporter lipoprotein) (van Ulsen et al., 2003).
The protease activity is required for release of the passenger domain of AspA
from the cell surface. The autocatalytic release was abolished by substitution of
alanine for active-site serine (8426 in AspA from strain MCS8 was mutated to an
alanine residue) (Turner et al., 2002; van Ulsen et al., 2003). The presence of
anti-AspA antibodies in sera of convalescent patients suggest that AspA is
expressed during invasive disease.
1.9.5.4 Factor H binding Protein (jHbp)
The factor H-binding protein (fHbp), previously referred as genome-derived
neisserial antigen 1870 (GNA1870) (Masignani et al., 2003) or lipoprotein 2086
(Fletcher et al., 2004), was identified by recent genomic studies carried out to
search for promising vaccine candidates for serogroup B disease (Masignani et
al., 2003; Pizza et al., 2000). The fHbp gene encodes a 27-kDa surface
lipoprotein, which is present on the surface of all strains of N. meningitidis
(Beemink et al., 2007; Fletcher et al., 2004; Masignani et al., 2003). The protein
appears to elicit protective bactericidal antibodies that both activate classical
complement pathway bacteriolysis and inhibit binding of the complement down-
regulatory protein factor H (fH) to the bacterial surface (Welsch et al., 2008). The
fHbp is the sole receptor for fH on the meningococcus, and recruitment of fH
contributes to the ability of the meningococcus to avoid innate immune responses
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by inhibiting complement-mediated lysis in human plasma (Madico et al., 2006;
Schneider et al., 2006).
1.9.5.5 T-cell stimulating protein A (TspA)
TspA is an immunogenic, T-cell and B-cell-stimulating protein of N. meningitidis
(Robinson et al., 2005). TspA was identified by screening N. meningitidis using a
polyclonal antisera raised against fractionated proteins of N. meningitidis (Kizil
et al.. 1999). Homology searches revealed that TspA is a member of the FimV
family of proteins. TspA is a highly conserved antigen that is universally
expressed by meningococci and shown to mediate optimal adhesion of N.
meningitidis to cultured epithelial and endothelial cells (Oldfield et al., 2007).
1.9.5.6HrpA-HrpB system
A functional two-partner secretion system (TPS), haemagglutininihaemolysin-
related protein A (HrpA)-HrpB, composed of the secreted effector protein HrpA
and its cognate transporter HrpB, has recently been found in all N. meningitidis
strains and shown to contribute to adhesion of un-encapsulated bacteria to
epithelial cell lines. It also appears to be essential for intracellular survival of the
N. meningitidis (Schmitt et al., 2007; Tala et al., 2008).
1.9.5.7 Neisseria Adhesin A (NadA)
Neisserial adhesion A (NadA), a surface-exposed protein, was identified as a
homologue of UspA2 from Moraxella catarrhalis and of YadA from Yersinia
enterocolitica (van Ulsen et al., 2001; van Ulsen & Tommassen, 2006). NadA is
present in 50% of meningococcal isolates obtained from patients (and is more
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commonly associated with three hypervirulent clusters ET-37, ET-S and cluster
A4) than with carriage isolates (16%). The nadA gene encodes a protein of ca.
360 amino-acid residues, which forms high molecular weight oligomers and
appears to mediate cellular adhesion (Capecchi et al., 2005). NadA has also been
shown to induce strong protective bactericidal antibodies suggesting that this
protein may represent a novel vaccine antigen for meningococcal disease caused
by three hypervirulent lineages (Comanducci et al., 2002).
1.9.5.8 Meningococcal Serine Protease A (MspAJ
MspA, also described as AusI, is a phase-variable serine protease, which was
identified by in silico genome analysis of N meningitidis serogroup B strain
MC58 (Turner et al., 2006).
1.9.5.9 Iron-acquiring proteins
Transferrin binding proteins (TbpA & B) and lactoferin binding proteins (LbpA
& LbpB) are outer membrane proteins that are expressed by meningococci in
iron-restricted environments during infection for iron acquisition. Antibodies to
Tbps can be detected in sera from carriers and in convalescent sera (Ala'Aldeen et
al., 1994; Gorringe et al., 1995) and these antibodies were shown to possess
opsonic activity (Lehmann et al., 1999), In laboratory animals, antibodies to Tbps
were shown to be bactericidal (Ala'Aldeen & Borriello, 1996; Danve et al., 1993)
and were able to block iron uptake by the organism (Pintor et al., 1996). The
vaccine potential of these proteins lies in their limited antigenic heterogeneity
(Ala'Aldeen, 1996; Rokbi et al., 1997). Preliminary data from adult studies
suggest that they are safe and immunogenic (Pollard & Frasch, 2001).
29
Neisseria spp. may also express lactoferrin binding proteins: LbpA (Pettersson et
al., 1993; Pettersson et al., 1994) and LbpB (Pettersson et al., 1998). Lactoferrin,
a major human iron carrier protein, is present on mucosal surfaces and is
presumably an important source of iron for N. meningitidis during its colonisation
of the nasopharynx (Johnson et al., 1999). LbpA is highly conserved and
essential for iron uptake from lactoferrin (Biswas & Sparling, 1995; Bonnah &
Schryvers, 1998).
1.10 Blebing and autolysis
Meningococci are characterized by frequent vesiculation of the outer membrane
and/or shedding of endotoxin (McAllister & Stephens, 1993). The shedding of
endotoxin from N. meningitidis is a strain specific virulence factor and occurs by
a specific process called blebing. These blebs contain outer membrane protein
and LOS and the amount of blebing varies considerably between strains
(Andersen et al., 1981). Blebing appears to contribute to the rapid initiation of the
inflammatory cascades of sepsis. Blebing may also be related to the natural
autolysis of meningococci that occurs in stationary growth phase, resulting in
release of DNA and facilitating genetic transformation (Tzeng & Stephens,
2000).
1.11 Animal models for meningococcal infection
Animal models are often required to understand the mechanisms of pathogenesis,
and to develop novel therapies and prevention regimes. Thus, relevant models
are key factors for deciphering microbial virulence (Bakaletz, 2004). Several
animal models have been developed and used for studying the pathogenesis of
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meningococcal disease. These include monkeys, guinea pigs, chicken embryos,
adult and infant mice, and infant rats (Arko, 1989). Of these, the mouse and
infant rat systems appears to be the most suitable for laboratory experiments
(Nassif & So, 1995). None of the present models, however, completely satisfy all
the criteria required for an ideal animal model. Harter and Petersdorf (Harter &
Petersdorf, 1960) have described the criteria for an ideal animal model as
follows:
(i) The portal of entry and route of dissemination of the organism must be similar
to those in man, (ii) the bacterium must be pathogenic for man as well as
experimental animals, (iii) the course of the disease must be relatively predictable
and of sufficient duration to permit evaluation of therapy, (iv) the disease must be
reproducible within the limits of biological variation, (v) the lesions in the
experimental infection must be morphologically similar to those in man, and (vi)
the technique must be relatively simple. Unfortunately, it is unlikely that anyone
animal model can meet all of these requirements for studies on meningococcal
disease.
Recently, two transgenic mice models, one expressing human CD46 (Johansson
et al., 2003) and another expressing human transferrin (Zarantonelli et al., 2007),
have been developed. These are potentially useful tools for studying pathogenesis
and evaluating vaccine candidates. The transgenic mice expressing CD46 were
shown to be susceptible to meningococcal disease after intranasal, but not
intraperitoneal challenge, suggesting that human CD46 facilitates pilus-dependent
interactions at the epithelial mucosa (Johansson et al., 2003). Since iron is
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essential for meningococcal growth, the transgenic mouse model expressing
human transferrin may represent an important advance for in vivo studies of
meningococcal virulence and immunogenicity factors (Zarantonelli et al., 2007).
1.12 Meningococcal vaccines
Prevention of meningococcal disease can effectively be accomplished by
vaccination. The first major success towards vaccination against meningococcal
disease was achieved in the 1960s by Gotschlich and co-workers, who
successfully demonstrated the importance of anti-polysaccharide antibodies in the
human immune response against serogroup A and C disease (Morley & Pollard,
2001). Meningococcal serogroup A, C, W-135 and Y infections can be prevented
by vaccines based on the respective capsular polysaccharides.
1.12.1 Plain polysaccharide vaccines
Meningococcal purified polysaccharide vaccines have been used widely since the
development of a highly immunogenic vaccine for serogroups A and C in 1969
by Gotshlich et al., (Gotschlich et al., 1969a). The vaccines have been shown to
be safe and efficacious in preventing disease in US military recruits, and have
also been used in an attempt to minimize the serogroup A epidemics in Africa.
The efficacy has been estimated at 85 to 100 percent among older children and
adults (Artensteinetal., 1970; Peltolaetal., 1977; Wahdanetal., 1977}.
There are, however, some important limitations associated with meningococcal
polysaccharide vaccines: (1) the serogroup C polysaccharide is poorly
immunogenic in young children (King et al., 1996; Maslanka et al., 1998), with
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little or no efficacy among children younger than 24 months of age (Gold et al.,
1977; MacLennan et al., 1999), (2) they are unable to induce long-acting T
cell-dependent immunologic memory (Reingold et al., 1985) and, hence, offer
only a relatively short duration of protection, especially in young children, (3)
the repeated doses of polysaccharide vaccine may induce a degree of
hyporesponsiveness. However, the clinical relevance of this finding is unclear
(King et al., 1996; Maslanka et al., 1998), (4) some studies conducted among
military recruits suggested that the meningococcal polysaccharide vaccines may
decrease short-term acquisition of carriage (Gotschlich et al., 1969b), however,
these vaccines failed to produce long-term protection against carriage and, are
thus unable to induce herd immunity (Hassan-King et al., 1988; Moore et al.,
1988). In addition to bivalent polysaccharide vaccines, an outbreak in the
meningitis belt during 2003 with serogroup W-135 prompted the development of
a trivalent AlCfW-135 and tetravalent AlCfW-1351Y polysaccharide vaccines
(Girard et al., 2006).
1.12.2 Meningococcal conjugate vaccines
Efforts to overcome the poor immunogenicity of capsular polysaccharide
vaccines led to development of conjugate vaccines. The premise for the
development of new conjugated meningococcal vaccines was based on the
experience gained with Hib (H. influaenzae type b) conjugated vaccine, which
has succeeded in virtually eliminating Hib disease in young children in many
countries (Adams et al., 1993; Peltola et al., 1992). Conjugation of
polysaccharides to protein carriers appears to change the nature of the antibody
response from a T-cell-independent to a T-cell-dependent response. The
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conjugate vaccines are, therefore, typically T-cell dependant and confer major
immunologic improvements over plain polysaccharide vaccines (Lesinski &
Westerink, 200 1a; Lesinski & Westerink, 2001b). Meningococcal serogroup C
conjugate vaccines have been developed using a genetically detoxified diptheria
toxin (CMRI97) or tetanus toxoid as the protein-carrier (Anderson et al., 1994;
Safadi & Barros, 2006). In November 1999, the United Kingdom became the first
country to introduce a conjugate vaccine against serogroup C meningococcal
disease into the childhood immunization program (Miller et al., 2001). Later on,
in January 2005, a quadrivalent meningococcal conjugate vaccine (MCV4) was
developed and licensed (Harrison, 2006). Meningococcal conjugate vaccines
have been demonstrated to be safe, and shown to elicit an improved immune
response in infants (Anderson et al., 1994; Campagne et al., 2000; Fairley et al.,
1996; Lieberman et al., 1996; Richmond et al., 1999). They also possess prime
immunologic memory, and lead to a booster response to subsequent doses
(Borrow et al., 2000; Twumasi et al., 1995).
1.12.3 Meningococcal serogroup B vaccine
The capsular polysaccharide of meningococcal serogroup B differs from the
others because of its structural homology with human embryonal neural tissue
(Wyle et al., 1972). This mimicry rules out the use of polysaccharide-protein
conjugate vaccines as an effective strategy to combat serogroup B disease
because of the theoretical danger of induction of auto-antibodies that cross-react
with glycosylated host antigens (Jodar et al., 2002). Therefore, currently there is
no universal vaccine available against serogroup B disease. Instead vaccine
research has focused on protein-based vaccines composed of outer membrane
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vesicles (OMVs) purified from the bacterium. Due to the high sequence and
antigenic variability of the antigens present in the OMVs, these vaccines mostly
induce immunity against the highly variable PorA membrane protein, and
efficacy trials have shown serosubtype-specific protection (Serruto et al., 2003).
However, the OMV-based vaccine produced by the Finlay Institute in Cuba
(commercially marketed at VA-MENGOC-BC), which contains outer membrane
proteins and capsular polysaccharide of meningococcal serogroup C, is believed
to have contributed to the rapid decline of the epidemic in Cuba (Isabel et al.,
1999), and has also been shown to be efficacious in subjects of more than 4 years
of age in Brazil where heterologous strains were circulating (de Moraes et al.,
1992). In addition, a recently introduced bivalent meningococcal OMV vaccine
has offered a wide vaccine coverage particularly of the circulating strains in
Europe and is able to induce bactericidal antibodies not only against the vaccine-
homologouslPorA-related strains but also against heterologous strains (Boutriau
et al., 2007). Although currently available vaccines based on OMVs may induce
a functional immune response against serogroup B, none of these vaccines are
universally protective due to the great heterogeneity of the surface-exposed
regions of many of the outer membrane proteins. An alternative approach to
OMV vaccines has been to the use of 'reverse vaccinology' to identify conserved,
immunogenic OMPs, which can be developed as protein subunit vaccines
(Rappuoli, 2000; Serruto et al., 2004).
Two promising vaccines are currently being assessed in phase II and III clinical
trials. One of these vaccines (developed by Novartis) is a multi-component
vaccine, which includes a combination of five antigens and OMVs from the
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NZ98/254 strain of N. meningitidis serogroup B (Giuliani et al., 2006). The other
(produced by Wyeth) contains two variants of a single lipoprotein (rLP2086 also
known to as GNA1870/tHbp) (Richmond P, 2008). In addition, numerous other
outer membrane proteins such as OpcA, NspA, and iron regulated proteins (TbpA
and B, FbpA, FetA) are being evaluated and explored for use as potential
meningococcal vaccine candidates.
1.13 Genome sequence of meningococci
The meningococci genome consists of about 2.1-2.2 million bases encoding
approximately 2000 genes (Parkhill et al., 2000; Tettelin et al., 2000). The
genome sequences of N. meningitidis strain MeS8 (serogroup B) (Tettelin et al.,
2000), strain Z2491 (serogroup A) (Parkhill et al., 2000) and strain FAM18
(serogroup e) (Bentley et al., 2007) have been published. In addition, the
annotated genome sequence of obligate commensal species N. lactamica has also
been made publicly available. The three sequenced meningococcal genomes
differ from each other by approximately 9-10% and from the N. gonorrhoeae
genome by roughly the same amount (Stephens et al., 2007). The chromosome of
N. meningitidis strain MeS8 is almost 100 kb larger than the other two sequenced
strains mainly due to large duplication of about 30 kb comprising 36 coding
sequences (NMBl124-NMBI1S9 duplicated in NMB1162-NMB1197) and the
acquisition of two additional islands of horizontally transferred DNA (IHT-B
17.1 kb and IHT-e 32.6kb). Both of these islands are absent in the genomes of
strains Z2491 and FAM18 (Schoen et al., 2007).
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1.14 Protein secretion pathways in N. meningitidis
Protein secretion in bacteria plays an essential role in nutrient acquisition,
survival in and adaptation to different environments, inter- and intraspecies
communication, and virulence. For example, in N. meningitids, secreted proteins
are involved in adherence of the bacteria to host cells or required to suppress the
host's defense mechanisms (Dautin & Bernstein, 2007; van Ulsen & Tommassen,
2006). Gram-negative bacteria use several different pathways for secretion of the
exoproteins. These pathways are categorized as Type-I, II, III, IV, autotransporter
pathway and two-partner secretion (TSP) pathway (type-V) (Henderson et al.,
2004; van Ulsen & Tommassen, 2006). N. meningitidis uses three of the six
known protein secretion pathways: the autotransporter pathway (AT) and the two
partner secretion pathway (collectively known as Type V secretion pathway) and
the type one secretion pathway (van Ulsen & Tommassen, 2006). Like all
Gram-negative bacteria, meningococci are bounded by two hydrophobic barriers,
the inner membrane (1M) and the outer membrane (OM), which are separated by
the periplasmic space containing peptidoglycan (Morley & Pollard, 2001). Thus,
the pathways allowing the extracellular secretion of proteins from Gram-negative
bacteria must traverse three distinct compartments: the inner membrane, the
periplasm and the outer membrane, which separate the cytoplasm (the site of
synthesis) from the exterior of the cell (Lory, 1992). However, an increasing
number of cytoplasmic proteins (including some that are normally considered to
be house-keeping enzymes with a primary biological role in the cytoplasmic
compartment) have been reported to be secreted either to the cell surface or into
the extracellular environment independently of any recognized classical secretion
pathway.
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Figure 1. 4 Overview of secretion systems in Gram-negative bacteria. Protein
transport across the outer membrane of Gram-negative bacteria can be subdivided
into Sec-independent and Sec-dependent pathways. The three main terminal
branches allowing further transport of Sec-transported periplasmic intermediates
are: the chaperone/usher (CU) pathway for the synthesis of fimbrial adhesins, the
autotransporter pathway and the complex type II secretion system. No stable
periplasmic intermediates are found in type I, type III and type IV secretion
systems. Each of the three export mechanisms features a protein-conducting
channel able to span the two bacterial membranes and, in the case of type III and
type IV, one additional membrane of the host cell. Examples for pathogens
utilizing the various secretion systems are indicated at the bottom of the figure
(adapted from reference Gerlach & Hensel, 2007).
1.14.1 Type 1 secretion system
The type one secretion system (or ATP-binding cassette [ABC] transporters) is
hetrotrimeric complex composed of three proteins: an cytoplasmic
membrane-embedded ABC transporter, a pore- forming outer
membrane-embedded channel protein, and an adapter or membrane-fusion
protein (Gerlach & Hensel, 2007; van Ulsen & Tommassen, 2006). These
proteins are represented in E. coli HlyB, ToIC, and HlyD, respectively (Binet et
al., 1997). A well-known protein secreted via type 1 is the u-haemolysin (HlyA)
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of E. coli (Goebel & Hedgpeth, 1982). Secretion of HlyA, and similar effector
molecules occurs in a Sec-independent, continuous process across both the
cytoplasmic and outer membrane (Henderson et al., 2004). These proteins
completely bypass the periplasm and are directly secreted from the cytoplasm
(Binet et al., 1997). A wide range of substrates (proteinaceous and non-
proteinaceous) varying in size between 78 to 8682 residues are secreted in a
single step from the cytoplasm to the extracellular space, without a stable
periplasmic intermediate (Gerlach & Hensel, 2007; van Ulsen & Tommassen,
2006).
1.14.2 Autotransporter secretion system
The autotransporters, a family of secreted proteins from Gram-negative bacteria,
are synthesized as a single polypeptide containing all the information required for
their export and secretion (Henderson et al., 1998). The primary structure of these
proteins is basically modular and composed of three functional domains: the
amino-terminal leader sequence, the secreted mature protein (passenger domain)
and translocation unit that forms a ~-barrel pore to allow secretion of the
passenger protein (Desvaux et al., 2004). Autotransporter secretion was first
described for the 19A1 proteases of N. gonorrhoeae (Pohlner et al., 1987). The
signal sequence present at the end ofN-terminus directs the autotransporter to the
Sec machinery for the transport across the cytoplasmic membrane and its further
export into the periplasm (Brandon et al., 2003; Henderson et al., 1998). The
passenger domain of the autotransporters has been shown to confer various
phenotypes and the last domain is the translocation unit that facilitates
translocation of the passenger domain through the outer membrane (Henderson et
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al., 2004). The term 'autotransporter' was coined because of the apparent absence
of a dedicated secretion machine (van Ulsen & Tommassen, 2006). However,
recent work has shown accessory periplasmic proteins are important (Ruiz-Perez
et al., 2009).
1.14.3 Two-Partner secretion system
Two-partner secretion (TPS) systems export large 'exoproteins' rich in beta-
helical structure (TpsA family members) across the outer membranes of Gram-
negative bacteria using channel-forming ~-barrel proteins (TpsB family
members). Like autotransporter proteins, most of these proteins are associated
with virulence traits and their characterized diverse functions include
autoaggregation, biofilm formation, iron acquisition, adherence to host tissues,
cytolysis, immunomodulation, binding of heme and/or hemopexin, and contact-
dependent inhibition (Aoki et al., 2005; Henderson et al., 2004; Jacob-Dubuisson
et al., 2004). The first member of the TPS family to be characterized was the
ShlB (HlyB) protein of Serratia marcescens, which exports the ShlA hemolysin
from the periplasm of the Gram-negative bacterial envelope into the external
medium (Poole et al., 1988).
The hallmarks of TPS systems are the presence of (1) an N-proximal
250-residue-Iong 'TPS' domain where specific secretion signals in the substrate
protein are found and (2) a ~-barrel channel (TpsB) homologue (Clantin et al.,
2004; Jacob-Dubuisson et al., 2001). Usually, the genes encoding these two
proteins occur within an operon. The TPS domain is essential for secretion and
mediates interactions between the TpsA protein and its TpsB partner (Hodak et
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aI., 2006). The TpsA protein is exported across the cytoplasmic membrane by the
Sec machinery (Chevalier et al., 2004; Grass & St Geme, 2000). Its TPS domain
then interacts with the periplasmic domain of the TpsB partner, which triggers
channel opening and initiates the translocation of the TpsA protein, probably in
an extended conformation through the TpsB pore (Clantin et al., 2007; Guedin et
al., 2000; Meli et al., 2006).
In silico analyses have revealed that a large number of TspA proteins are encoded
in various bacterial genomes, ranging from those of plant pathogens such as
Xylella fastidiosa and Ralstonia solanacearum to those of human pathogens such
as N. meningitidis and Y. pestis (Jacob-Dubuisson et al., 2004; Locht et al., 2001)
Taken together, these findings demonstrate that TPS systems are present in nearly
all groups of Gram-negative bacteria (hence, they probably participate in
processes other than virulence) and that TpsB proteins belong to a large family of
outer membrane protein-translocating porin type proteins with members in the
animal, plant and fungal kingdoms, making this general secretion mechanism the
most widely distributed in nature (Yen et al., 2002).
1.15 Non·Classical secretion of proteins In bacteria
Most proteins destined to be released in the extracellular media contain an
N-terminal or C-terminal classical signal peptide, which mediates the export of
envelope-associated as well as some secreted, proteins, across the inner
membrane via the Sec-dependant pathway (van Ulsen & Tommassen, 2006).
However, almost two decades ago, a small number of eukaryotic proteins lacking
N-terminal signal peptide or other identifiable targeting peptides were shown to
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be secreted and thus localised extracellularly. This phenomenon, termed
leaderless secretion and later non-classical secretion was initially identified in
eukaryotes (Bendtsen & Wooldridge, 2009). For some years only eukaryotes
were known to secrete proteins via alternative or non-classical secretory routes.
Strikingly, a similar phenomenon was later observed in the bacterial kingdom. It
is apparent that non-classical secretion does not follow a simple route of secretion
but that proteins can be secreted via different rather undefined secretion systems
in prokaryotic as well as eukaryotic organisms (Bendtsen & Wooldridge, 2009).
The GInA glutamine synthetase of Mycobacterium tuberculosis was the first
published example of apparent bacterial non-classical protein secretion, whilst in
Mycobacterium smegmatis, GInA is localized solely to the cytoplasm of the
bacterium (Harth & Horwitz, 1997). The proteomic research on Bacillus subtilus
has revealed that twenty four proteins with highly divergent functions are
secreted to the extracellular environment without having classical Sec-signal
peptides (Bendtsen & Wooldridge, 2009). Furthermore, an alternative secretion
system has also been identified in Listeria monocytogenes (Lenz et al., 2003).
Recently, proteins lacking known secretion signals have also been shown to be
secreted by yeast cells via alternative/non-conventional secretion mechanisms
(Nombela et al., 2006).
A growing number of diverse proteins have been identified which are
multifunctional. Such proteins have been named 'moon-lighting proteins'.
(Jeffery, 1999; Jeffery, 2003; Jeffery, 2009). Moonlighting proteins are a diverse
set of proteins that include glycolytic enzymes, chaperones, transcription factors,
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and proteins with many other types of functions (Nombela et al., 2006). An
interesting example is phosphoglucose isomerise (PGI), a cytosolic glycolytic
enzyme that catalyses the second step of glycolysis. A secreted form of this
protein has been shown to act as cytokine in eukaryotes (Amraei & Nabi, 2002).
Thus, some of the proteins found to be secreted via non-classical system may
play a different role in the unexpected location than that of their role in the
cytoplasm (Schaumburg et al., 2004).
A less well-defined method of protein secretion may be mediated by OMVs
released from the outer cellular membrane of Gram-negative bacteria. This
phenomenon, also called membrane blebbing ( or vesicle-mediated secretion) has
now been found in a range of Gram-negative bacteria (Kuehn & Kesty, 2005).
The OMVs from pathogenic bacteria appears to contain adhesins, toxins, and
immunomodulatory compounds, and they have been shown to directly mediate
bacterial binding and invasion, cause cytotoxicity, and modulate the host immune
response (Bendtsen & Wooldridge, 2009; Kuehn & Kesty, 2005). Two of the
well characterised examples of vesicle-mediated secretion include ClyA of E. coli
(Wai et al., 2003) and VacA of Helicobacter pylori (Keenan et al., 2000).
Furthermore, Actinobacillus actimycocetemcomitans has also been shown to
secrete leukotoxin, a membranolytic cytotoxin, via membrane blebs and these
toxins are likely to be incorporated into host cell membranes (Demuth et al.,
2003; Kato et al., 2002).
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1.16 Multi-faceted (moon-lighting) roles of glycolytic enzymes
Several studies have provided intriguing evidence of the unexpected nature and
location of glycolytic enzymes on the surface of numerous microbial pathogens
(Bergmann et al., 2004; Ling et al., 2004; Lottenberg et al., 1992; Pancholi &
Fischetti, 1992; Pancholi & Fischetti, 1998; Pancholi V, 2003). However, little is
known about the molecular mechanisms of the multi-faceted roles of glycolytic
enzymes, specifically regarding the relationship between their glycolytic and
non-glycolytic functions (Kim & Dang, 2005). Glycolytic enzymes, such as
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), enolase and fructose
bisphosphate aldolase (FBA) have been reported as potential virulence factors in
a variety of organisms (Pancholi & Chhatwal, 2003). Although long recognized
for their cytosolic role in glycolysis and gluconeogenesis, dual (or 'moon-
lighting') functions have been increasingly recognized. In particular, glycolytic
enzymes have been found on the bacterial cell surface (despite lacking
identifiable secretion signals) where they interact directly with host soluble
proteins and surface ligands. However, the mechanisms by which these cytosolic
enzymes are translocated and retained on the cell surface of pathogens are not yet
understood.
1.16.1 The glycolytic pathway is non-functional in N. meningitidis
Glycolysis is the main pathway for carbohydrate degradation (glucose) in nearly
all organisms. The end product of glycolysis is pyruvate. The conversion of
glucose into pyruvate requires a cascade of nine enzymatic reactions and most of
these reactions are reversible during the gluconeogenic cycle (Fourrat et al.,
2007). Glycolysis can be generally separated into two phases, the priming phase
44
and the energy-yielding phase. The priming phase uses two moles of ATP to
convert glucose to fructose- 1, 6-bisphosphate. In the second phase, fructose-l,6-
bisphosphate is further converted stepwise into pyruvate with the production of
four moles of ATP and two moles ofNADH (Fig 1.6) (Kim & Dang, 2005).
Genome-based studies on meningococcal strain MC58 revealed that glycolysis
(also known as the Embden Meyerhof Parnas [EMP] pathway) is not involved in
pyruvate synthesis in N meningitidis. This is because of the absence of one
essential enzyme in the pathway: phosphofructokinase (EC 2.7.1.11) (Fig 1.5).
The generation of pyruvate from glucose has, instead, been shown to occur
through the Entner Douderoff (EO) and the Pentose Phosphate (PP) pathways
(Fig 1.5), confirming that EMP (glycolysis) is non-functional in N meningitidis
(Baart et al., 2007).
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Figure 1. 5 Central metabolism of N meningitidis. The dashed arrow indicates
phosphofructokinase (PFK), which is not present in N meningitidis. The red box
area indicates the site of enzymes (FBA and GAPDH-l) under study. (adapted
from reference Baart et al., 2007).
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1.16.2 Fructose 1, 6-bisphosphate aldolase (FDA)
Fructose 1, 6-bisphosphate aldolase (E.CA.1.2.l3) is the best studied glycolytic
enzyme in the aldolases family. FBA catalyses the reversible cleavage of fructose
1,6 bisphosphate into two triose sugars: dihydroxyacetone phosphate
(glycerine-P) and glyceraldehyde 3-phosphate (Fig 1.6) (Ramsaywak et al., 2004;
Wehmeier, 2001; Zgiby et al., 2000). Aldolases can be broadly divided into two
groups with different catalytic mechanisms, designated Class-I and Class-II
(Arakaki et al., 2004; Thomson et al., 1998). The Class-I enzymes utilize an
active site lysine to stabilize a reaction intermediate via schiff-base formation,
and are usually found in higher eukaryotic organisms. The Class-II enzymes,
however, have an absolute requirement for a divalent ion, usually zinc (Zgiby et
al., 2000) and are usually found in prokaryotic organisms and lower eukaryotes
such as fungi and some green algae grown under heterotrophic conditions (Plater
et al., 1999; Ramsaywak et al., 2004; Sauve & Sygusch, 2001). Most organisms
contain only one class of FBA, although a few possess enzymes of both classes.
E. coli (Thomson et al., 1998)., Streptococcus pneumoniae (Isabel et al., 1999)
Corynebacterium synechocystis sp. PCC 6803 (Nakahara et al., 2003) and some
others are reported to express both types of enzymes. Among the Class- I
enzymes found in mammals, there are three tissue-specific isozymes of aldolase
that have similar molecular masses and catalytic mechanisms: aldolase A
(expressed primarily in muscles and red blood cells), aldolase B (expressed
primarily in liver, kidney and small intestine) and aldolase C (expressed mainly
in brain, smooth muscle, and neuronal tissues (Arakaki et al., 2004).
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The class-Il family has been sub-divided, in this case into two groups depending
on their sequences; they are known as Type A and Type B (Nakahara et al., 2003;
Sauve & Sygusch, 2001). Since the Class-II aldolases are not found in animals, it
has been suggested that they could provide a possible therapeutic and vaccine
targets (Blom et al., 1996; Ramsaywak et al., 2004).
In addition to its metabolic function, studies have demonstrated that FBA is
present on the surface of several microbial pathogens and may facilitate their
adhesion to host tissues by interacting directly with host surface ligands. For
example, in S. pneumoniae, surface-associated FBA was shown to bind to a large
7-transpass transmembrane receptor belonging to the cadherin superfamily (Blau
et al., 2007) and also shown to be immunogenic in humans and capable of
inducing a protective immune response against S. pneumoniae in mice (Ling et
al., 2004). In addition, FBA was found to be a surface-localized immunogenic
protein in S. suis (Zongfu et al., 2008) and a possible role for FBA in immunity to
a nematode parasite Onchocerca volvulus has also been reported (McCarthy et
al.,2002).
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Figure 1.6 Schematic diagram shwoing glycolytic pathway in a eukaryotic cell.
Glycolysis is an ancient metabolic pathway in which one mole of glucose is
catabolised to two moles of each pyruvate, NADH and ATP. Under aerobic
conditions, pyruvate is further oxidized by mitochondrial enzymes to carbon
dioxide and water. (Abbreviations: ENOl, enolase1; FBA, Fructose bisphosphate
aldolase, GAPDH-1, glyceraldehyde-3-phosphate dehydrogenase; GPI, glucose-
6-phosphate isomerase; HK, hexokinase; LDH, lactate dehydrogenase; PFK,
phosphofructokinase; PGK, phosphoglycerate kinase; PGM, phosphoglycerate
mutase; PK, pyruvate kinase; TPI, triose phosphate isomerase) (adapted from
reference Kim & Dang, 2005) .
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1.16.3 Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is a glycolytic enzyme
which catalyzes the conversion of glyceraldehyde 3-phosphate to 1, 3-
diphosphoglycerate. The most common form is the NAD+-dependent enzyme
(Ee 1.2.1.12) found in all organisms studied so far and which is usually located
in the cytoplasm (Kim & Dang, 2005). In addition to its well-established
metabolic function, recent studies have demonstrated unexpected, non-glycolytic
functions of GAPDH in physiological and pathological processes (Kim & Dang,
2005; Sirover, 1999).
The localisation of GAPDH on the surface of a pathogen was first described in
the Gram-positive pathogen, S. pyogenes (Lottenberg et al., 1992; Pancholi V,
2003). In this organism, surface-exposed GAPDH binds several mammalian
proteins including the uPARlCD87 membrane protein on pharyngeal cells (Jin et
al., 2005; Lottenberg et al., 1992; Pancholi & Fischetti, 1992; Winram &
Lottenberg, 1996), regulates intracellular host cell signaling events (Pancholi &
Fischetti, 1997) and contributes to host immune evasion (Terao et al., 2006).
GAPDH was subsequently identified on the surface of other Gram-positive
bacteria including staphylococci (Modun & Williams, 1999; Modun et al., 2000),
S. agalactiae (Seifert et al., 2003) and Listeria monocytogenes (Schaumburg et
al., 2004). In addition, surface localization of GAPDH has been reported in
enterohemorrhagic (EHEC) and enteropathogenic (EPEe) Escherichia coli; the
protein of these pathogens has been observed to bind to human plasminogen and
fibrinogen, suggesting a role in pathogenesis (Egea et al., 2007). Similar to the
surface 10calized-GAPDHs from other species, the EHEe and EPEe GAPDH
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proteins possess NAD-ribosylating activity (Aguilera et al., 2009). In
Mycoplasma genitalium, surface-associated GAPDH is important for adhesion to
human mucin (Alvarez et al., 2003), and in Lactobacillus plantarum, a normal
inhabitant of the human gastrointestinal tract, GAPDH was shown to be involved
in adherence to gastric mucin and Caco-2 cells (Kinoshita et al., 2008; Ramiah et
al., 2008). Interestingly, the major fimbriae of Porphyromonas gingivalis bind to
GAPDH on the surface of several oral streptococci, and this interaction is
important for colonization of the oral cavity (Nagata et al., 2009). Fungi also
express GAPDH on their cell surface, for example, the GAPDH of Candida
albicans was shown to be associated with the cell wall and involved in mediating
adhesion to fibronectin, laminin and plasminogen (Gil-Navarro et al., 1997;
Gozalbo et al., 1998; Jonathan et al., 2003). GAPDH has also been found on the
surface ofthe single-celled protozoan, Trichomonas vaginalis, and shown to bind
extracellular matrix components, including fibronectin (Lama et al., 2009). Thus,
GAPDH is a multi-functional protein displayed on the surface of several fungi
and Gram-positive pathogens, which contributes to their adhesion to host cells
and may act as virulence factor (Egea et al., 2007).
1.17 Aims of the Project
The aim of this study was to investigate the molecular, immunological, and
functional attributes of two of the glycolytic pathway enzymes, namely FBA and
GAPDH of N. meningitidis.
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CHAPTER 2: Cloning and expression of cbbA and gapA-1
and purification of their products
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2.1 Introduction
Glycolytic enzymes, which along with other enzymes involved in central
metabolism, are sometimes called 'housekeeping enzymes' are classical
cytoplasmic proteins that are found in all cell types. These enzymes are known to
be constitutively expressed and localised mainly to the cytoplasm of the cell.
There is growing evidence that several so-called housekeeping enzymes,
including fructose bisphosphate aldolase (FBA) and glyceraldehydes-3-phosphate
dehydrogenase (GAPDH), are often localised to the surface of bacterial
pathogens. Whilst their intracellular functions are well known, it is unclear
whether they perform any additional functions on the bacterial surface.
Fructose 1, 6-bisphosphate aldolase catalyses the reversible cleavage of fructose
1,6-bisphosphate into two triose sugars: dihydroxyacetone phosphate (glycerine-
P) and glyceraldehyde 3-phosphate in the glycolysis cycle (Ramsaywak et al.,
2004; Wehmeier, 2001; Zgiby et al., 2000). Besides performing a key role in
glycolytic cycle, aldolases have also been shown to be localised to the surface of
numerous bacterial and fungal pathogens. In S. pneumoniae surface-localized
FBA was shown to bind the host cell ligand Flamingo cadherin (Blau et al.,
2007), and was also found to be a surface-localized immunogenic protein in S.
suis (Zongfu et al., 2008).
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is a cytoplasmic
glycolytic enzyme that converts glyceraldehyde 3-phosphate to 1, 3-
bisphosphoglycerate coupled with the reduction of NAD+ to NADH. Recent
studies have demonstrated unexpected, non-glycolytic, functions of GAPDH in
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physiological and pathological processes (Kim & Dang, 2005). Several reports
have shown that in some Gram-positive bacteria and fungi extracellular GAPDH
interacts with various host components, including plasminogen, the cytoskeletal
proteins actin and myosin, and extracellular matrix proteins including fibronectin
(Gozalbo et al., 1998; Pancholi & Fischetti, 1992; Schaumburg et al., 2004;
Seifert et al., 2003; Winram & Lottenberg, 1996). The GAPDH of Mycoplasma
bovis has been shown to induce an immune response in infected cattle (Perez-
Casal & Prysliak, 2007). Moreover, other cytosolic proteins: Enolase, DnaK, and
peroxiredoxin, of N. meningitidis serogroup B, have recently been reported
localised to the outer membrane, where they can act as plasminogen receptors
(Knaust et al., 2007). Thus, FBA and GAPDH-l may be multifunctional proteins
with a role in central metabolism and an additional role unconnected to their
primary role which is associated with an alternative sub-cellular localisation.
Such proteins have been described as 'moonlighting proteins' (Jeffery, 1999;
Jeffery, 2003; Jeffery, 2009).
The aims of this chapter were to clone and over-express cbbA and gapA-I, to
affinity purify full length recombinant FBA and GAPDH-l, and to raise
polyclonal antisera against the purified proteins to facilitate subsequent
characterisation studies.
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2. 2 Materialsand Methods
2.2.1 Bacterial strains, growth conditions, and media
E. coli strains and plasmids used in this chapter are described in Table 2.2. E.
coli strains were routinely grown at 37°C in Lysogeny Broth (LB) (Bertani,
2004) or on LB agar. Where appropriate, antibiotics were used at the following
concentrations: ampicillin (lOO ug ml'), kanamycin (30 ug mrl). Where
appropriate, blue/white selection of transformants in cloning experiments was
achieved using IPTG (Roche) and X-gal at 0.5 mM and 80 J.1gml", respectively:
All liquid cultures were aerated by agitation at 200 revolutions per minute (rpm)
in a shaking incubator.
2.2.2 Extraction of chromosomal DNA
Chromosomal DNA was prepared by using a DNeasy Blood & Tissue kit
(Qiagen) using the protocol for bacterial cells recommended by the manufacturer.
Briefly, overnight culture of N. meningitidis grown on chocolate agar plates was
scraped off the plate with a sterile loop and re-suspended in 180 J.11of ATL buffer
(provided in kit) and 20 J.11of Proteinase K to disrupt the cells. The sample was
then heated at 56°C until the complete lysis of cells was achieved. The lysate was
applied to DNeasy spin column. The bound DNA was washed twice using the
buffers provided in the kit. The bound DNA was eluted in 200 J.11of elution
buffer.
2.2.3 Extraction of plasmid DNA
E. coli JMI09, harboring the desired plasmid, were streaked out from -80
glycerol stock on to LB agar plates containing appropriate antibiotic and
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incubated overnight at 37°C . The following day, a single colony was used to
inoculate a 10 ml of LB broth supplemented with 100 ug ml" ampicillin. The
broth culture was incubated at 37°C overnight with shaking at 200 rpm. Small-
scale purification of high copy number plasmids was achieved using 5 ml
overnight cultures using a QIAprep spin kit (Qiagen) according to the
manufacturer's instructions. In case of low copy number plasmids or large-scale
(70-100 ug) plasmid purification, GeneElute the Midi Prep kit (Sigma) was used
according to manufacturer's recommendation.
2.2.4 Quantification of DNA and protein
The concentration of purified PCR products, plasmid, genomic DNA and purified
proteins was quantified using a NanoDrop (ND-IOOO) spectrophotometer
(Agilent Technologies).
2.2.5 Polymerase chain reaction (peR)
All peR reactions were performed in a 25 III final volume using sterile 0.2 ml
thin-walled peR tubes and cycled using a elOOO model Thermal Cycler
(BID-RAD). A master mix containing all of the peR components except
template DNA was prepared in a pre-chilled, sterile micro centrifuge tube and
thoroughly mixed by vortex. Following a brief centrifugation, a 24 J.LIaliquot of
master mix was dispensed into chilled peR tubes and 1 III appropriate template
DNA. The solution was mixed by gently stirring with a pipette tip and kept on ice
prior to placement in the thermal cycler. Unless otherwise stated, all PCR
mixtures contained: 100 ng of chromosomal DNA or l-lO ng of Plasmid DNA;
each of the respective primers to a final concentration of 200 nM; 2.5 J.LIlOx
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Expand buffer (Roche); dNTPs (Roche or Promega) to a final concentration of
200 IlM, Expand Hi Fidelity DNA polymerase 0.2 III (3.5 U Ilrl) (Roche) and the
reaction mixture was made up to a final volume of 25 III with dH20. The peR
conditions were: initial template denaturation step of 3 min at 95°C, followed by
30 cycles of incubation, annealing at 48°C for 1 min, primer extension at 68°C
for 3.5 min, and 94°C for 45s, with final incubation at 48°e for I min and 68°C
for 10 min.
2.2.6 Agarose gel electrophoresis
An agarose gel (0.8-1%) was prepared according to the standard protocol. DNA
ladders 2-Log (New England BioLabs) and 0.5 kb (Fermentas) were run
alongside the samples to enable analysis of DNA fragment size in the samples.
Gels were viewed using an Uvitec gel documentation system.
2.2.7 Purification of peR and Gel-extracted DNAproducts
DNA fragments generated by PCR or restriction endonuclease digestion were
purified using a QIAquick® peR purification kit (Qiagen) according to
manufacturer's recommendations. For gel extraction of DNA fragments
amplified by peR or generated by restriction digestion, samples were separated
by agarose gel electrophoresis and the band of interest was excised with Gene
catcher Tips (Web Scientific) and purified using a Gel extraction Kit (Qiagen)
according to manufacturer's instructions.
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2.2.8 Cloning of cbbA in N-terminal Histidine-tag vector
A 1,06S-bp DNA fragment corresponding to the cbbA coding sequences was
amplified by peR using genomic DNA of N. meningitidis strain MeS8 and the
primer pair FBA_El and FBA_E2 incorporating BamH 1 and KpnI sites,
respectively (Table 2.1). The peR reaction was performed as described in
Section 2.5. The DNA fragment was purified and ligated to the pEXPNT-TOPO
expression vector (Invitrogen) according to the manufacturer's instructions.
Screening for a successful clone was performed by colony peR amplification of
the desired DNA fragment, restriction digestion with BamHI and KpnI and
subsequent DNA sequencing. A construct in which cbbA was correctly oriented
for translation was chosen and used to transform E. coli BL21 (DE3) pLysS
according to the manufacturer's instructions. The pEXPINT-TOPO-based
constructs drive expression of the recombinant protein with N-terminal 6-
histidine tag under the control of phage T7 promoter.
2.2.9 Cloning of cbbA in C-terminal Histidine-tag vector
A DNA fragment corresponding to the cbbA coding sequence was amplified by
peR using genomic DNA of N. meningitidis strain MC58 and the primers
FBA_pQE70 (F) and FBA_pQE70(R) incorporating SphI and BgnI sites,
respectively (Table 2.1). The peR reaction was performed as described in
Section 2.5. The peR conditions used to amplify this insert were: initial template
denaturation step of 3 min at 95°e, followed by 30 cycles of incubation,
annealing at Sloe for 1 min, primer extension at 68°e for 2.5 min, and 94°C for
4Ss, with final incubation at si'c for 1 min and 68°e for 10 min. The pQE70
vector was linearized by digestion (section 2.10) with SphI and Bgm. The
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plasmid pSAT-FBA was constructed by ligating SphI and BglII-digested, gel-
purified cbbA peR product with pQE70 (Appendix B) according to the
manufacturer's instructions (Qiagen). Positive clones were screened for the
successful ligation of cbbA by colony peR, restriction digestion with SphI and
BglII and DNA sequencing to determine in frame ligation. A clone that contained
cbbA in the correct orientation for translation and in frame with the start codon of
the vector was selected and used to transform E. coli BL21 (DE3) pLysS
(Invitrogen) according to the manufacturer's instructions.
2.2.10 Restriction endonuclease digestion
Restriction digestion reactions were routinely carried out in a 10 J.ll final volume.
Unless otherwise stated, 100-200 ng of DNA (for screening purpose) and 1 ug of
DNA (for using in sub-cloning), was digested either as a single digest or double
digest with appropriate enzymes and compatible buffers. Restriction
endonuclease enzymes and buffers were purchased from New England Biolabs or
Roche and used according to the directions of the manufacturer.
Table 2. 1 List of primers used in work described in this chapter
~". (/ Restriction
Primer DNA sequence' it
. , . SI e
Expression of chbA
FBA_El(F) 5'-CGCGGATCCATGGCACTCGTATCCATGCG- 3'
FBA_E2(R) 5'-CGCGGTACCGTCGTCCGAACGGCGG- 3'
FBA_pQE70 (F) 5'-CGCGGATCCATGGCACTCGTATCCATGCG-3'
FBA_pQE70 (R) 5' -CGCGGT ACCGTCGTCCGAACGGCGG-3'
BamHI
KpnI
SphI
Bgill
Expression of gapA-l
NMB0207(F) 5' -CGCGGA TCCATGGGCATCAAAGTCGCCATC-3'
NMB0207(R) 5'-CGCGTCGACTTATTTGAGCGGGCGCACTIC-3'
BamHI
Sal!
"Sequences in bold identify restriction enzyme sites.
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Table 2. 2 Bacterial strains and plasmids used in work described in this
chapter
SO/I id D 0 0 Source ortrams p asnu s escrrption ..
rererence
E. coli strains
JMI09 endAl recAI gyrA96 thi hsdRl7 (rK- Promega
rK-)relAI supE44 ~(lac-proAB) [F'
traD36 proAB laqIqZ~MI5]
TOPIOF' F'lacIqTnlO(TetR) mcrA ~(mrr- Invitrogen
hsdRMS-mcrBC) <D801acZ~M15
MacX74 recAI araDl39 ~(ara-
leu)7697 galU galK rpsL endAl
nupG
BL21(DE3)pLysS F- ompT hsdSB (rB-mB-) gal dcm Invitrogen
(DE3) pLysS (CamR)
Plasmids
pQE70 Cloning vector encoding resistance to Qiagen
ampicillin
pEXPINT-TOPO Expression vector encoding Invitrogen
resistance to ampicillin
pCRlNT -TOPO Expression vector encoding Invitrogen
resistance to ampicillin
pSAT-FBA MCS8 cbbA gene cloned in pQE70 This study
pDT-GapAl MC58 gapA-l gene cloned in This study
pCRlNT -TOPO
pSAT-l MC58 cbbA gene cloned in This study
pEXPINT-TOPO
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2.2.11 Ligation Reaction
Appropriate amounts of vector and insert DNA were combined in a 1:I or 1:3
ratios in a sterile microcentrifuge tube and the reaction was assembled in 10J.11
final volume. A typical ligation reaction contained; 100 ng insert, 50-100 ng
plasmid DNA, IJ.11T4 DNA ligase (Roche or Promega), 1 J.11salt solution in case
of TOPO cloning, 1 J.1110 x ligation buffer (Roche), and where required dH20
was added to make a final volume of 10 J.11.The ligation reaction was incubated
at 16°C for Ih and then overnight at 4°C. An aliquot of 1.5 J.11was used to
transform E. coli JM 109 competent cells.
Where appropriate, Antarctic phosphatase ([AP] New England BioLabs) was
used to catalyze the removal of the 5' phosphate groups from linear DNA
fragments to prevent self-ligation. The procedure was carried out according to the
manufacturer's recommendations. Typical reactions contained 1 J.11[= 10 U] of
AP, approximately 1 J.1gof vector DNA, 5 J.11of lOx AP buffer and nuclease-free
deionized water to a final volume of 50 J.11.This was incubated at 37°C for 15
min followed by purification using the QIAquick PCR purification kit (Qiagen)
2.2.12 Transformation
Briefly, an aliquot of 100 J.11of frozen competent E. coli cells JMI09 (Promega),
One shot Top 10 and BL21 (DE3) pLysS (Invitrogen) was thawed on ice 5 min
prior to transformation. 100 ng of plasmid DNA was added to cells and mixed
gently by stirring with a pipette tip. The cells were incubated on ice for 20 min
followed by heat shock at 42°C in water bath for 50 s without shaking.
Immediately after heat treatment, the cells were transferred on to ice for 2 min.
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To the cells was added a 450 ul of room temperature (RT) S.O.C medium
(Invitrogen) and the cell suspension was incubated at 37°C for 1.5 hr with
shaking at 250 rpm. The transformation reaction was plated out as 1001l1,150 Ill,
and 200 Ill, on LB agar containing appropriate antibiotic and incubated overnight
at 37°C.
2.2.13 DNA sequencing
DNA constructs were sequenced in both directions using specific primers at the
School of Biomedical Sciences (University of Nottingham) on an ABI 377
automated DNA sequencer.
2.2.14 Pilot expression of the recombinant rFBA and rGAPDH-l
E. coli strain BL21 (DE3) pLysS harboring appropriate expression plasmid were
grown overnight in LB broth containing 100 ug mrl ampicillin. The following
day, 500 III of the overnight culture was inoculated into fresh 10 ml
LB/ampicillin broth. The cultures were allowed to grow to mid log phase (OD6oo
= 0.6). The culture tube was split into two 5 ml culture aliquots and IPTG was
added to a final concentration of 1 mM to one of the cultures. The culture tubes
were then incubated at 37°C for 4 h with shaking and 500 III aliquot was removed
from each culture at times 0, 1, 2, 3, and 4 h, and cell were harvested by
centrifugation at 13,000 x g . The cell pellets were either stored at -20°C or
resuspended in 100 III of 1x SDS-PAGE sample Buffer (Appendix A). The
samples were heated to 100°C for 5 min and subsequently resolved by
SDS-PAGE followed by immunoblot analysis.
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2.2.15 Sodium dodecyl sulfate polyacrylamide gel electrophoresis
The recombinant proteins were electrophretically separated by 10-12%
SDS-PAGE (Appendix A) using Mini- Protean III equipment (BID-RAD)
following the method of Laemmli (Laemmli, 1970). The protein samples were
prepared by mixing bacterial cell pellets with 1 x SDS-PAGE sample buffer
(Appendix A) and heated at 100°C for 5 min. An aliquot of 10JlI of sample was
loaded into each well of the gel and 10JlI of pre-stained protein markers (New
England Biolabs) were loaded into an adjacent lane. Proteins separated by
SDS-PAGE were visualized by staining with SimplyBlue SafeStain (Invitrogen)
or PageBlue™ Protein Stain Solution (Fermentas) according to the
manufacturer's instructions. Gels were scanned using a GS-800 calibrated
densitometer (BIO-RAO).
2.2.16 Immunoblot analysis
For Immunoblot analysis, the protein mixtures separated by 10% SOS-PAGE
were transferred onto a nitrocellulose membrane (Amersham Biosciences) in
semi-dry blotting buffer (Appendix A) using a Trans-Blot SD semidry transfer
cell (BIO-RAO) at a constant currant of 14 rnA for approximately 30 min. The
membranes were incubated in blocking solution (Appendix A) or 1% Bovine
serum albumin (BSA) (Sigma) for 30 min at RT. The membranes were then
probed with mouse anti-pentahistidine antibody (Qiagen) or rabbit primary
antibody diluted 1:10,000 and 1:1000, respectively, in blocking buffer and
incubated overnight with shaking at 4°C. The following day, the membrane was
washed three times 15 min each with PBS containing 0.05% Tween-20
(PBS-Tween), and incubated into secondary antibody (anti-mouse IgG
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conjugated to alkaline-phosphtase or anti-rabbit conjugated to alkaline
phosphtase) (Sigma) at the concentration of 1:30,000 for 2 h at RT. After 2 h the
membrane was washed thrice with PBS-Tween for 15 min each time. The
membrane was then developed using the BCIP (5-bromo-4- chloro-3-
indolylphosphate)-Nitro Blue Tetrazolium liquid substrate (PerkinElmer™). The
membrane was finally washed with dHzO and a digital image of the membrane
was taken using a OS-800 calibrated densitometer (BIO-RAD).
2.2.17 Protein purification under denaturing conditions
The large-scale expression of recombinant His-tagged proteins for purification
was performed using the common expression protocol. Briefly, a single colony of
E. coli BL21 (DE3) pLysS harboring the expression plasmid was inoculated into
10 ml LB containing ampicillin (lOO J.1gml") and grown at 37°C overnight. One
litre of LB broth containing ampicillin was then inoculated with 10 ml of an
overnight starter culture and grown to mid log phase (OD600 = 0.6), and induced
by addition of IPTO to a final concentration of 1 mM. After 3h of induction the
cells were harvested by centrifugation (8,000 x g for 10 min at 4°C) using an
Allegra™ X-22R centrifuge (Beckman Coulter) and the cell pellet was then
either stored at -20°C or used for purification. Protein purification was achieved
by re-suspending the culture pellet from 20 ml culture in 1 ml lysis buffer (B)
(Appendix A) and sonicated (10 son, 20 s off pulses for 5 min on ice) using a
(SoniPrep sonicater MSE 150) to disrupt the cells. The lysate from disrupted cells
was centrifuged at 8,000 x g for 30 min at 4°C. The supernatant was collected in
a sterile Eppendorf tube for purification of the recombinant protein. Purification
was carried out using a Ni-NTA spin kit (Qiagen). Firstly, Ni-NTA spin columns
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were equilibrated with 600 ul of buffer B, and centrifuged at 700 x g for 2 min to
drain the buffer and then 600 J.lI of supernatant collected from the lysate of
disrupted cells was loaded into pre-equilibrated columns and centrifuged at 700 x
g for 2 min. The flow through was collected and saved in a separate Eppendorf
tube for SDS-PAGE analysis. Secondly, the spin columns were washed twice
with approximately 600 J.lI of buffer C (Appendix A) to release non-specific
proteins. The third and last step was elution of pure proteins bound to spin
column with buffer E (Appendix A). The protein elutes were stored at -20°C
2.2.18 Protein purification under native conditions
Briefly, the culture pellet from a l-litre culture of E. coli BL21 (DE3) pLysS cells
containing pSAT-FBA and induced with IPTG for 3 h, was resuspended in the
lysis buffer (Appendix A) and the cells were then disrupted by sonication (lOs
on, 20s offpulses for 10 min on ice) in ice water. Soluble and insoluble fractions
were separated by centrifugation (8,000 x g for 30 min at 4°C). Five hundred III
of Hispure™ cobalt resin (Thermo) was centrifuged at 2,000 x g for 1 min to
drain the storage buffer and then the resin was added to the soluble fraction
containing the recombinant FBA. The supernatant-resin mixture was then
incubated overnight at 4°C to allow binding of the tagged protein to the resin.
The following day, the mixture was passed through gravity purification columns
(Sigma). The flow through was collected and re-applied to the column to
maximize protein binding. The resin was then extensively washed with
approximately 10 column volumes of wash buffer (Appendix A) to minimize the
yield of contaminating proteins in the eluted fraction. The protein bound to the
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resin was then eluted in elution buffer (Appendix A). The purity of the protein
was examined by SDS-PAGE.
2.2.19 Protein purification by gel electro-elution
The partially purified samples of rGAPDH-l were resolved in a single lane on
10% SDS-PAGE. The gel was stained briefly with SimplyBlue SafeStain
(Invitrogen). The band corresponding to the recombinant protein of interest was
identified according to its size estimated by comparing with the molecular weight
markers. The protein band with an apparent molecular mass of ca. 37-kDa
demonstrating rGAPDH-l was excised out from gel and further cut into small
slices. For electro-elution, the gel slices were transferred to aD-tube (D-Tube
Dialyzer midi, MWCO 6-8 kDa, Novagen) containing filter sterile 1x SOS-
running buffer (Appendix A) and electro-elution was performed at constant
voltage of 110 volts for 2 h in a agarose gel casting tank filled with 1 x SDS
running buffer. The eluted protein was aspirated from the 0-Tubes and dialysed
in clean O-tubes against PBS for 48 h at 4°C and then concentrated using
centrifugal filter device (Microcon, Amicon Bioseparation, 5,000 Da MWCO).
2.2.20 Raising polyclonaJ antiserum against FDA and GAPDH-l
Rabbit polyclonal antibodies against the denatured purified recombinant FBA and
GAPOH-I and non-denatured purified FBA proteins were raised in New Zealand
white female rabbits. Typically, rabbits were immunized three times at 2-week
intervals with 30 J.1g of protein emulsified in Freud's Complete (first
immunization) or incomplete adjuvant. After two doses, the rabbits were test
bled, boosted once more, and sacrificed 10 days later.
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2.2.21 Protein and nucleic acid sequence analysis
The genome database of N. meningitidis MCS8 was interrogated at
http://cmr.jcvi.org/cgi-binlCMRlGenomePage.cgi?org=gnm. Sequence homology
data were obtained using the CLUSTALX software (http://www-igbmc.u-
strasbg.fr/BioInfo/ClustaIX). Protein secretion signals were analyzed using the
SignalP 3.0 server available at http://www.cbs.dtu.dklservices/SignaIP/
(Emanuelsson et al., 2007). The SoftBerry Bacterial Promoter Prediction
algorithm- (http://linuxl.softberry.comlberry.phtml?topic=bprom&group=progra
ms&subgroup=gfindb) was used to examine DNA segments for potential
promoter sequences. Other DNA and protein sequence analyses, and primers
designing, were carried out using the DNAman package of programs (Lynnon
BioSoft).
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2.3 Results
2.3.1 Sequence analysis of the cbbA and flanking DNA and FBA protein
In N. meningitidis strain MeS8, the cbbA gene (NMBI869) is 1,065 bp long
encoding a predicted protein of354 amino acids (Fig 2.1) and has a G+C content
of 56.18%. The cbbA gene is downstream of xerC (NMB 1868) predicted to
encode the XerC integrase/recombinase and upstream of NMB 1870, which
encodes factor H-binding protein, fHbp (Madico et al., 2006). This genetic
organization appears to be conserved in published genomes of N. meningitidis
Z2491 (serogroup A), N. meningitidis FAM18 (serogroup e) and N. gonorrhoeae
FAI090 strains. However, the gene encoding for fHbp is annotated as putative
lipoprotein and/or hypothetical open-reading frame. Sequences >94% identical to
the MC58 cbbA gene are found in the genomic sequences of the serogroup e
meningococcal strain FAM18 (GenBank accession no. YP_974462; (Bentleyet
al., 2007», the ST-4821 strain 053442 (GenBank accession no. YP_001598513;
(Peng et al., 2008» and the group A strain Z2491 (GenBank accession no.
YP_002342063; (Parkhill et al., 2000). Additionally sequences >93% identical to
MCS8 cbbA are found in the gonococcal strain FAI090 (94% identical; GenBank
accession no. YP_207215), and N. lactamica strain ATCe 23970 (93% identical;
GenBank accession no. ZP_03723075) sequences confirming that cbbA is highly
conserved across Neisseria species. At the amino acid level, FBA sequences from
meningococcal strains Z2491, MeS8, FAM18 and 053442, and the gonococcal
strain FA1090, are > 99% identical. By alignment, the neisserial FBA
(NMBI869) was 67 and 65% identical to class-lIB FBA enzymes from
Xanthobacter flavus and Synechocystis sp., respectively, but was only 21%
identical to the E. coli class-HA FBA, confirming that the neisserial FBA is a
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class-lIB enzyme. As expected for a class-II FBA, a conserved putative zinc-
binding site (Berry & Marshall, 1993) was also identified (HSI_XX_ H84). Using
the SignalP software, FBA was predicted to be a non-secreted protein by the
SignaIP-HMM program
2.3.2 Cloning and expression of cbbA in pEXPINT-TOPO
The cbbA gene comprises of 1,065 bp, which encodes a protein of a 354 amino
acids (a.a). The entire ORF was successfully amplified by PCR (Fig 2.2). A
single band with the expected molecular weight of ca. l-kb was observed by
agarose gel electrophoresis. The peR product was ligated to the pEXP-NT/TOPO
expression vector followed by transformation of E. coli JMI09 cells for plasmid
proliferation and subsequent screening for the successful clones.
The pExp-NTrrOPO expression vector, unlike pGEM-T Easy, lacks the
whitelblue phenotype based screening system; therefore, the screening for the
successful clones was initially attempted by colony PCR (Fig 2.3 A). Several
recombinant clones were identified to contain the cbbA insert by observing a
DNA fragment corresponding to cbbA alongside a band amplified with the same
primers using MC58 DNA as a positive control. In order to confirm the colony
PCR results and to ascertain the orientation of cbbA, recombinant clones were
selected and used to extract plasmid DNA for restriction analysis and. subsequent
partial sequencing.
Six clones were subjected to further verification by restriction digestion analysis.
The restriction sites BamHI and KpnI (present in FBA_El and E2 primers
respectively) were used to ascertain the orientation of the desired insert. Insertion
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of cbbA in the same orientation as the T7 promoter of the vector was expected to
produce single linear fragments of ea 3.7 kb in a double digest with BamHI and
KpnI. In contrast, insertion of cbbA in a reverse orientation to the vector yielded
the expected two DNA fragments of ca. 1 kb and 2.7 kb. Out of six clones
analysed by colony peR, three were identified to contain cbbA in the desired
orientation whilst the remaining three produced two DNA bands consistent with
the reverse orientation (Fig 2.3 B).
One plasmid containing cbbA in correct orientation was designated pSAT-1.
Finally, the sequence and orientation of the cloned cbbA was confirmed by DNA
sequencing. The plasmid pSAT-l was partially sequenced using the T7 forward
and reverse primers. Sequencing demonstrated that pSAT -1 contained the cbbA
in frame with the His-tag of the vector and in correct orientation under the control
of phage T7 promoter for expression of the recombinant protein.
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Figure 2. 1 Agarose gel analysis showing (A) the PCR amplification of cbbA.
Chromosomal DNA was prepared from N meningitidis MCS8 and used to
amplify out cbbA by PCR. Lane 1, DNA ladder, lane 2, PCR product
corresponding to cbbA. (B) colony peR amplification of cbbA, putative
transform ant colonies were used for peR amplification of cbbA, lane 1, DNA
markers, lane 2, peR product of cbbA from MC58 chromosomal DNA (Control),
lanes, 3-9, putative transformant colonies. The DNA product in lanes 7 and 9 was
of the expected size suggesting successful cloning of cbbA (C) restriction
digestion of pSAT-1, plasmid DNA was used to veri fy the cloning of cbbA using
the BamHI and KpnI. Lane 1, DNA markers, lanes 2-7, putative pSAT-l digested
with BamHI and KpnI.
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Expression of rFBA was successfully achieved in E. coli BL2l (DE3) pLysS
cells harboring the plasmid pSAT-l following induction with IPTG. Expression
was checked by SOS-PAGE followed by either staining or immunoblot analysis.
A recombinant protein band with apparent molecular weight of ca. 38-kDa
corresponding to the rFBA was observed in induced samples on the SOS gel after
staining with SimplyBlue 8afeStain (Fig 2.4). Immunoblot analysis also detected
the tagged recombinant protein corresponding to the full length rFBA. A faint
protein band was also observed in un-induced samples. This was probably due to
leaky expression of the gene without induction as it was absent in negative
control cells containing the same vector without the insert (Fig 3.5).
The solubility of the expressed rFBA was determined by resuspending the cell
pellet in PBS. Following 30 min incubation at room RT, cells were disrupted by
sonication and centrifuged to separate soluble and insoluble fractions. Both
fractions were collected separately and analysed by 80S-PAGE (Fig 2.6 A)
followed by immunoblot analysis using anti-penta histidine antibodies (Fig 2.6
B). A strong protein band corresponding to FBA was detected in insoluble
fraction whereas a weak band was present in soluble fraction of expressed protein
suggesting that the rFBA protein was expressed mostly as insoluble protein.
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Figure 2. 2 SDS-polyacrylamide gel showing pilot expression of FBA. Whole
cell lysate of E. coli strain BL21 (DE3) pLysS containing the plasmid pSAT-1,
non-induced and IPTG-induced samples were separated by 10% SDS-PAGE.
Lane 1,protein markers; lanes 2-4, whole cell lysate of non-induced cultures after
, 1, 2, and 3 h, respectively; lane 5, lysate from E. coli containing empty vector,
lanes 6-8 whole cell lysate of IPTG-induced cultures after I, 2, and 3 h,
respectively. The protein was expressed within 1 h after induction and the
expression reached maximum level at 3 h.
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Figure 2. 3 Immunoblot analysis showing the pilot expression of FBA. Whole
cell proteins were separated by 10% SDS-PAGE and then transferred on to
nitrocellulose membrane followed by probing with anti-penta histidine
antibodies. Lane 1, protein markers; lane 2-4, un-induced samples lane 5, lysate
from E. coli containing empty vector, lanes 6-8 induced samples.
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Figure 2.4 Solubility of the rFBA E. coli BL21(DE3) pLysS harboring pSAT-I
were induced with I mM IPTG and incubated at 37°C for 3 h. (A) Protein were
resolved by 10% SDS-PAGE Lane I, protein markers; lanes 2 pellet (insoluble
fraction; inclusion bodies); lane 3, supernatant fraction. (soluble fraction), (B)
Immunoblot analysis of protein resolved by SDS-PAGE. Lane 1, protein
markers; lane 2, pellet (insoluble fraction; inclusion bodies); lane 3, supernatant
fraction. This is showing that FBA was expressed as insoluble protein.
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2.3.3 Purification of rFBA under denaturing conditions
Due to the insoluble nature of recombinant protein, purification was performed
under denaturing conditions. The 20 ml culture pellet of E. coli harbouring
pSAT-1 was induced with IPTG in a mid log phase and further grown for 3h.
Following sonication of the harvested cells, purification of the recombinant
protein was successfully achieved under denaturing conditions using affinity
chromatography (Fig 2.7). The protein was eluted in elution buffer containing
urea. After purification urea was removed by dialysis against PBS using D-tube-
dialyzer. Purified protein was analysed by SDS-PAGE to confirm the purity and
integrity of the purified protein.
kDa 1
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Figure 2. 5 SDS-polyacrylamide gel demonstrating affinity purification ofrFBA.
E. coli strain BL21 containing plasmid pSAT-1 were grown until the exponential
phase and induced with 1 mM IPTG. After 3 h of induction, cells were harvested
by centrifugation and purified using a Qiagen Ni-NTA spin kit under denaturing
conditions and the samples were separated by 10% SDS-PAGE. Lane 1, protein
markers; lane 2, whole cell lysate of E. coli harboring pSAT-l; lane 3, flow
through; lane 4, first wash; lane 5 second wash; lane 6, protein markers, lane 7
first eluate; and lane 8 second eluate. The eluate showed the single protein band
representing the full sized rFBA
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2.3.4 peR amplification and cloning of chhA in pQE70
Although N-tenninally His-tagged rFBA was successfully expressed and
subsequently purified under denaturing conditions, in order to examine the
functional activity of the recombinant protein and to generate polyclonal
antibodies against conformational epitopes of the protein, cbbA was re-cloned
with C-tenninal 6 x His-tag in an endeavour to express recombinant proteins in
soluble form to facilitate subsequent purification under native conditions. The
cbbA gene was amplified by PCR using primers incorporating SphI and BgflI
restriction sites to facilitate the ligation with pQE70. The purified, digested cbbA
product was successfully ligated to pQE70 after both molecules were digested
with SphI and BglII followed by transformation of E. coli JM109 cells. A number
of recombinant clones were selected and screened for the presence of cbbA in
order to confirm successful cloning. Screening was initially performed by colony
PCR of putative transformants colonies. Several recombinant clones produced an
expected band of ca. l-kb were then selected and propagated for purification of
plasmid DNA. The plasmid DNA was subjected to further confirmation by
restriction digestion analysis using SphI and Bgm. As expected two DNA bands
corresponding to cbbA and vector backbone were observed by agarose gel
analysis demonstrating the successful ligation. Finally, one of the positive clones
was sequenced. The sequencing results confirmed that the ligation was in frame
with the start codon of the vector and the sequences were identical to that of the
cbbA. This clone was selected for expression of recombinant protein and
subsequent purification under non-denaturing conditions.
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Figure 2. 6 Agarose gel analysis demonstrating the (A) PCR amplification of
cbbA. Chromosomal DNA was prepared from N meningitidis MC58 and used to
amplify the entire open reading frame of cbbA for cloning into pQE70. Lane 1,
DNA markers, lane 2, PCR product of cbbA. (B) colony PCR amplification of
cbbA. Screening for cbbA cloning was performed by colony peR amplification of
cbbA from putative transformants colonies. Lane 1, DNA markers, lane 2-7, cbbA
amplified by colony PCR, (C) the restriction digestion of pSAT -9. Plasmid DNA
was isolated from E. coli harboring pSAT-9 and used to confirm the cloning of
cbbA in pQE70. Lane 1, DNA markers, Lane 2, Sph[ & BglII-digested pSA T-9.
Lane 2 shows the expected two bands confirming the successful ligation of cbbA
with pQE70
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2.3.5 Expression and purification of rFBA under native conditions
E. coli BL2I (DE3) pLysS cells harboring the plasmid pSAT-FBA were used to
express rFBA. Optimal expression was achieved after 3 h induction with IPTG.
Expression was confirmed by SOS-polyacrylamide gel followed by immunoblot
analysis. Despite the high levels of expression, no formation of inclusion bodies
was detected (data not shown).
The Recombinant FBA from a I-litre culture of E. coli harboring pSAT-FBA was
purified under native conditions. After sonication of the harvested cells,
purification of the recombinant protein was performed by affinity
chromatography. The protein was eluted in elution buffer containing imidazole.
After purification the imidazole was removed by dialysis against the same buffer
(minus imidazole) using BD-dialyzer tubes. Purified protein was analysed by
SOS-PAGE to confirm the purity and predicted molecular weight. SOS-PAGE
analysis demonstrated a strong recombinant protein band with an apparent
molecular weight of ca. 38-kDa corresponding to the FBA (Fig 2.9A).
Immunoblot analysis using anti-penta histidine and RaFBA antisera also detected
the protein band representing rFBA (Fig 2.9B & C respectively). The purified
protein was used to examine enzymic activity of natively purified protein and to
raise polyclonal antisera to facilitate subsequent characterisation.
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Figure 2. 7 SDS-PAGE and immunoblot analysis demonstrating the rFBA
purified under native conditions. (A) SDS-PAGE (l0%) analysis confirms the
purity of the recombinant FBA purified under native conditions. (B) Immunoblot
analysis shows that recombinant FBA is recognized by RaFBA (C) and anti-
penta histidine antibodies.
2.3.6 Sequence analysis of gapA-l, flanking DNA and GAPDH-! protein
In N. meningitidis strain MeS8; the 1,032-bp gapA-l gene (Fig 2. I0)
(NMB0207) has a Gf-C content of 58 % and encodes a predicted protein of 343
amino acids (estimated molecular weight 37.0 kDa). The gapA-l gene is
downstream of, and in the opposite orientation to, aat (NMB0206) predicted to
encode the leucyl/phenylalanyl-tRNA-protein transferase and upstream of, and in
the same orientation as, NMB0208, which is predicted to encode an electron
transport protein, ferredoxin (4Fe-4S-type). The same genetic organization occurs
in N meningitidis Z2491 (serogroup A), N meningitidis FAM18 (serogroup C).
Sequences >98% identical to the Me58 gapA-l gene are found in the genomic
sequences of the group A strain Z2491 (Parkhill et al., 2000), the serogroup e
meningococcal strain FAM18 (Bentley et al., 2007), and the ST-4821 strain
053442 (Peng et al., 2008). Additionally, gapA-l orthologues are found in the
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gonococcal strain FA1090 (98% identical) and N. lactamica strain ATCC 23970
(90% identical) confirming that gapA-l is highly conserved across Neisseria
species. At the amino acid level, GAPDH-l sequences from meningococcal
strains MCS8, Z2491, FAMI8, 053442, and the gonococcal strain FAl090 are
>97% identical. As expected, the highly conserved GAPDH active site was
identified eS3ASCITNCL 160), and GAPDH-l shows significant homology to
GAPDH enzymes from higher organisms, including the human GAPDH enzyme
(45% identity). Despite its demonstrated presence on the bacterial surface, the
GAPDH-l of N. meningitidis was not predicted to possess a classical secretion
signal by the SignaIP-HMM and -NN programs. GenBank accession numbers for
the gapA-l sequences analyzed in this study are as follows: YP_97432562
(FAMI8), YP_00160027 (ST-4821 strain 053442), YP_002341615 (Z2491),
YP_208807 (gonococcal strain FAI090) and ZP_03723143 (N. lactamica ATCC
23970).
2.3.7 Cloning and expression of gapA-l of N. meningitidis strain MeS8
The entire open reading frame of gapA-l was amplified by PCR using the
primers NMB0207 (F) & NMB0207 (R) primers (Table 2.1) and cloned into the
pCR-T7/NT-TOPO expression vector to yield pDT-GapA 1. The plasmid
pDT-GapAI was constructed by Dr. David P Turner (unpublished).
In order to express N-terminally 6 x His-tagged recombinant proteins, overnight
culture of E. coli BL2l (DE3) harboring pDT-GapAl were grown to mid log
phase followed by induction with 1mM IPTG and further grown for 3 h. Samples
were taken from induced and un-induced cultures at an hourly interval to monitor
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the optimal expression. Pre-induced and post-induced samples were then
analysed by SDS-polyacrylamide gel including negative control sample (E. coli
BL21 (DE3) pLysS containing pCRT7INT-TOPO vector without insert, treated
under same expression conditions). A protein band of apparent molecular weight
of ca. 37-kDa demonstrating rGAPDH-l was observed in induced samples on
SDS- gel (Fig 2.11) and also a weak band of the same size was present in
uninduced samples suggesting the leaky expression. This band was absent in the
negative control.
The resolved protein samples were subsequently transferred onto nitrocellulose
membrane followed by probing with anti-penta antibodies. A strong immune-
reactive band of predicted molecular mass of ca. 37-kDa corresponding to
rGAPDH was detected by immunoblot analysis.
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Figure 2. 8 SOS-PAGE (10%) analysis showing the expression of GAPOH-l in
induced and un-induced samples, Lane 1, protein markers, lane 2- 4, un-induced
0-3 h sample, respectively, lane 5, control (E. coli harboring empty vector), and
lane 6-8, induced 0-3 h sample, respectively.
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Figure 2. 9 Immunoblot analysis confirming expression of GAPOH-lin induced
and un-induced samples, Lane 1, protein markers, lane 2- 4, un-induced whole
cell proteins, lane 6, control (E. coli containing empty vector), Janes 6-8 whole
cell proteins from induced samples.
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2.3.8 Purification of rGAPDH-l by D-tube Dialyzer
The purification of the rGAPDH-l was performed by using metal affinity
chromatography. The rGAPDH-I was resolved on SDS-PAGE to confirm the
purity and expected size based on predicted molecular weight. A ca.37-kOa band
corresponding to rGAPDH was observed together with several additional protein
bands, which were assumed to be non-specific contaminating proteins. Therefore,
in order to obtain a purified rGAPDH-l for raising polyclonal antiserum the
partially purified elutes containing rGAPOH-I were resolved on SOS-PAGE and
the protein band corresponding to GAPDH-l was excised from the SDS-
polyacrylamide gel, and the gel pieces were used for purification by electro-
eluation using D-tube dialyzers.
The purified protein was analysed by SDS-PAGE and immunoblot analysis. One
gel was stained with SimplyBlue SafeStain and subsequently destained with
dH20 whilst another gel containing the same profile of proteins was used to
transfer the resolved protein onto the nitrocellulose membrane for probing with
either anti-penta histidine and/or Ra-GAPOH-I antibodies. The SOS-PAGE
demonstrated a single band with an apparent molecular weight of 37-kDa
corresponding to rGAPDH-l. The immunoblot analysis demonstrated that anti-
penta histidine recognised the purified protein as rGAPDH.
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Figure 2. 10 SDS-PAGE and immunoblot analysis demonstrating the rGAPDH-l
purified under denaturing conditions. CA) 10% SDS-PAGE analysis confirms the
purity of rGAPDH-I CB) Immunoblot analysis shows that rGAPDH-I IS
recognized by anti-penta histidine antibodies Cc) and by RaGAPDH-l
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2.4 Discussion
This chapter details the cloning of cbbA and gapA-l of N. meningitidis strain
MCS8 and the expression and subsequent purification of their products: FBA and
GAPDH-l. A preliminary strategy adopted towards characterising both FBA and
GAPDH-l proteins was to clone and over express both proteins and subsequently
to raise polyclonal antisera against both proteins. The antisera were then used in a
number of experiments to facilitate identification of the putative roles of both
enzymes in pathogenesis of meningococcal disease. In N. meningitidis strain
MCS8 genome there is a single copy of cbbA (NMB 1869) predicted to encode
FBA protein. The entire open reading frame encoding full length FBA was
successfully cloned in N-tenninally histidine-tagged vector to express the
recombinant protein. The recombinant protein was shown to be optimally
expressed in host E. coli using 1mM IPTG for 3 h. Expression was detected by
immunoblot analysis using anti-penta histidine antibodies. As a negative control,
vector without insert was used to transform E. coli and treated in parallel.
Recombinant protein with apparent molecular weight of 38-kDa corresponding to
FBA was obtained in induced samples. FBA was affinity purified under
denaturing conditions and used to raise polyclonal antiserum in rabbit. The
antiserum was shown to strongly react against purified FBA protein.
Following several unsuccessful attempts to purify under native conditions, the
rFBA was successfully purified under denaturing conditions. Failure to purify
protein under native conditions may possibly be due to the insoluble form of the
protein, as confirmed by finding that majority of the proteins were in the pellet
(inclusion bodies) fraction rather than in supernatant of expressed samples.
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Despite optimisation of expression parameters such as lowering the growth
temperature (20, 25, 30°C), adding less concentration of IPTG (0.5mM) at late
exponential phase which is believed to improve the solubility of recombinant
proteins, several attempts to express the protein in a more soluble form were
unsuccessfuL This insolubility issue was not just the case with meningococcal
FBA, but this enzyme expressed with an N-terminal His-tag from Mycobacterium
tubeculosis was also shown to be functionally inactive and insoluble protein
(Ramsaywak et al., 2004). In that study, to improve the yield of soluble protein
efforts were made to express the tagged FBA at low temperature (15°C) and also
by co-expression with different chaperones (GroES and GroEL; or DnaJ, Dnak,
and grpE). These parameters although were shown to improve a little the yield of
soluble protein but failed to yield an active enzyme (Ramsaywak et al., 2004).
Another possible explanation for inability to purify the protein under native
conditions might also be due to the manner in which the protein is folded in its
native form, such that the histidine-tag is buried within the protein and may not
be exposed sufficiently to be purified by affinity chromatography.
Alternatively, to express recombinant FBA protein in a soluble form to achieve
subsequent purification under native conditions, a DNA fragment corresponding
to full length cbbA was successfully cloned in pQE70. This vector carries 6 x
histidine-tag at C-terminal of the recombinant protein. Recombinant protein
expressed with C-terminal histidine-tag was successfully purified under native
conditions. SDS-PAGE analysis confirmed the expected size and purity by
demonstrating a single band of apparent molecular mass of ca. 38-kDa
corresponding to the recombinant FBA.
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In the published meningococcal genome sequences, there are two genes (gapA-l;
NMB0207 and gapA-2; NMB2159).encoding putative GAPDH enzymes. We
began our investigations by focusing on gapA-l (NMB0207) rather than gapA-2,
because the gapA-l has been shown to be up-regulated in N. meningitidis upon
the contact with human epithelial cell whereas gapA-2 was not found to be
similarly regulated. The gapA-l was successfully cloned in pCR-NTffOPO and
optimal expression of the recombinant protein was achieved by induction with
ImM IPTG for 3 h. The expression was shown to be not under tight IPTG control
as non-induced samples contained a weakly expressed protein band of apparent
molecular weight of ca. 37-kDa. Initial attempts to purify rGAPDH-l under
native conditions were not successful suggesting that the expressed protein was
not folded correctly and appeared to be in insoluble form. Since previous
optimisation attempts to improve expression of the FBA protein in more soluble
form were unsuccessful, protein was therefore purified under denaturing
conditions. The SDS-PAGE analysis of the affinity purified protein demonstrated
several protein bands including the protein band with apparent molecular weight
of ca. 37-kDa corresponding to rGAPDH-l. In order to obtain pure protein for
raising polyclonal antiserum, the purification was carried out by electro-elution
using D-tube dialyzers. The partially purified GAPDH-l was first separated by
polyacrylamide gel from SDS- polyacrylamide gels and then the protein bands
corresponding to the GAPDH-l were excised and eluted. The eluted proteins
were dialyzed against PBS for 48 h. The immunoblot analysis using anti-penta
histidine antibodies recognized a protein bands with apparent molecular weight
of ca. 37-kDa.
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In conclusion, expression plasmids for rFBA and rGAPDH-I were successfully
constructed. The rFBA was over expressed with N-terminal and C-terminal
histidine tags and the recombinant proteins were successfully purified by affinity
chromatography. The purification of N-terminal His-tagged rFBA under native
conditions was unsuccessful, which may be due to the insoluble nature of the
recombinant protein or in accessibility of His-tag to nickel column, however, the
protein was successfully purified under denaturing conditions and used to raise
polyclonal antisera. The rFBA was successfully purified under native conditions
from C-terminally His-tagged vector. This natively purified rFBA was then used
to study the functional/enzymic activity of the protein and used for generating
polyclonal antiserum for using in subsequent characterisation experiments. In
addition, the rGAPDH-I was also over expressed with an N-terminal histidine-
tag, again this protein was found to be in insoluble (inclusion bodies) fraction,
and the purification was performed under denaturing conditions as insoluble
proteins that were subsequently purified by gel electro-elution. The purified
rGAPDH-l was used for raising polyclonal antiserum to facilitate the
characterisation experiments. Taken together, the work described in this chapter,
resulted in the successful production of reagents that would facilitate further
studies into the role of these proteins.
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CHAPTER 3: Mutagenesis and complementation of cbbA
and gapA.10f N.meningitidis
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3.1 Introduction
In this chapter the generation of cbbA and gapA-l null mutants and subsequent
complementation of cbbA and gapA-l mutations at an ectopic site in respective
isogenic null mutants is described. The mutant and complemented strains will be
utilized in subsequent characterization experiments to facilitate a study of the
potential role of FBA and GAPDH-l in pathogenesis of meningococcal disease.
In addition to mutating cbbA in MCS8, the cbbA isogenic mutants were created in
four meningococcal strains of different genetic backgrounds (Z4181, Z4667,
Z4673, and ST-18). The mutated strains were used as negative controls in
immunoblot experiments to assess the expression of cbbA and gapA-l m
meningococcal strains, and in subsequent molecular and immunological
characterisation experiments (Chapter 4 & 5). Whilst the cbbA-isogenic mutants
generated in additional four known MLST -type strains (Z4181 ilcbbA,
Z4667ilcbbA, Z4673ilcbbA, and ST-18ilcbbA) were used in challenge
experiments using a transgenic mouse model to assess the potential role of cbbA
in development of bacteraemia. The transgenic mice express human transferrin,
which is an important source of iron during the course of meningococcal
infection: a process requiring the binding of human transferrin by the
meningococcal transferrin receptor, which is unable to efficiently bind transferrin
of non-human origin (Zarantonelli et al., 2007).
Using the cbbA and gapA-l mutant strains, a potential in vitro role of FBA and
GAPDH-I in adhesion of N meningitidts strain MCS8 to cultured meningothelial
and epithelial cell lines to host cells was investigated. Both mutants exhibited a
reduced capacity to adhere to these cell lines compared to their isogenic wild-
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type parents. To exclude the possibility that the impaired adhesion was not due to
either polar effects or undetected secondary mutations, both cbbA and gapA-l
mutations were complemented at an ectopic site in isogenic-null mutants to
determine whether the replacement of a wild-type copy of each of these genes
could result in restoration of the wild-type phenotype.
The aims of this part of study were to create cbbA and gapA-l mutants in N.
meningitidis and to subsequently complement the mutations in isogenic null
mutant strains and to determine the growth characteristics between wild-type
Me58, mutants and complemented strains.
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3.2 Materialsandmethods
3.2.1 Bacterial strains, growth condition, and media
Bacterial strains and plasmids described in this chapter are listed in (Table 3.1
and 3.3). Growth conditions and media for culturing E. coli are described in
Chapter 2. Meningococcal strains (Table 3.3, stored at -80 in a mixture of 50%
MHB and sterilized glycerol) were grown on Brain Heart Infusion (BHI) agar
and/or Brain Heart Infusion Broth or Muller-Hinton Agar (MHA) or Muller-
Hinton Broth (MHB) or Dulbecco's Modified Eagle Medium (DMEM)
supplemented with Vitox at the concentration suggested by the manufacturer
(Oxoid) or 2% Fetal calf serum (Invitrogen) and where appropriate kanamycin
(50 j.lgml") or erythromycin (5 ug mll) and incubated in an atmosphere of 5%
CO2 at 37°C with or without shaking.
3.2.2 Cloning of cbbA plus flanking DNA
A ca. 2.3-kb fragment of DNA (Fig 3.1 A) consisting of the cbbA gene, 1 kb of
upstream and ca.300 bp of downstream flanking DNA was amplified by PCR
using the primer pair FBA_Ml (F) and FBA_M2(R) (Table 3.2) and N.
meningitidis strain MC58 chromosomal DNA. The PCR was performed as
described in section 2.5 with the following modifications, annealing at 48°C for 1
min, primer extension at 68°C for 4.5 min, and 94°C for 45s. The PCR product
was purified using the QIAquick PCR purification kit (Qiagen) according to
manufacturer's instructions (Section 2.7). The PCR product was used to ligate
with the pGEM-T Easy vector according to the manufacturer's instructions.
Recombinant clones were identified as white colonies on selective agar plates
containing 100 ug ml" ampicillin, 0.5 mM IPTG and 80 ug ml" X-gal. A number
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of clones were selected and confirmed by restriction digestion (Section 2.2.10)
and PCR using the primers FBA_Ml (F) and FBA_M2(R) (Table 3.2). The
resulting plasmid was designated pSAT-2. The plasmid pSAT-2 (Fig 3.1B) was
then used to transform E. coli JMI09 competent cells (Promega) according to the
manufacturer's instructions (Section 2.2.12).
3.2.3 Cloning ofgapA-l plus flanking DNA
A ca. 3-kb region of DNA encompassing gapA-I and l-kb flanking DNA from
either side of the gene and containing a neisserial uptake sequence was amplified
by peR using the primer pair NMB0207 (F) FL and NMB0207 (R) FL (Table
3.2) and chromosomal DNA prepared from N. meningitidis strain MeS8. The
PCR was performed as described in section 2.5 with modifications: annealing at
48°C for 1 min, primer extension at 68°C for 3.5 min, and 94°C for 4Ss, with
final incubation at 48°e for 1 min and 68°C for 10 min. The peR product was
gel-purified using a Gel-extraction kit (Qiagen) according to manufacturer's
instructions. The peR product was then cloned into the pGEM-T Easy vector
(Promega). Putative transformants were identified as white colonies on selective
agar plates (section 3.2.2). Recombinant clones were verified by restriction
digestion analysis and PCR using the primer pair NMB0207 (F) FL and gapA-l
(R) FL (Table 3.2).
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B
pSAT-2
Flank
Inverse peR product
c
Flank pGEM-TEasy Flank
o pSAT-4
Flank
KanR
Figure 3. 1 Schematic diagram representing the mutagenesis strategy for cbbA in
N meningitidis A) A 2.3-kh DNA fragment encompassing cbbA and flanking
DNA B) cloning of cbbA and flanking DNA in pGEM-T Easy to generate pSAT-
2 C) Inverse PCR product containing the flanking DNA and pGEM-T easy vector
for ligation of Kan R resistance marker d) Mutagenic plasmid designated pSAT-4
containing KanR and inverse PCR product.
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Table 3. 1 List of Plasmids used in work described in this chapter.
Plasm ids Resistance Description Source/
Reference
pGEM-TEasy Amp Cloning vector Promega
pJMK30 Amp/kan Source of kanamycin resistance cassette (van Vliet et
al., 1998)
pHYS25 Erym Ectopic complementation vector (Winzer et
al.,2002)
pSAT-2 Amp pOEM -T Easy vector cloned with 2.3 kb This study
insert of FBA plus flanking DNA
pSAT-3 Amp Inverse PCR product of ca. 5kb, digested This study
with BglII and self-ligated by both ends
to make it circularize as plasmid
pSAT-4 Amp/kan pSAT3 cloned with kanamycin This study
resistance cassette of 1.5 kb
pSAT-6 Amp pOEM-T Easy cloned with gapA-I plus This study
2-kb flanking DNA
pSAT-7 Amp pOEM- T Easy vector with 2 kb DNA This study
flaking either side of gapA-l gene
amplified by PCR and self-ligated
pSAT-8 Amp/kan pSAT-7 ligated with KanR gene digested This study
with BamHI
pSAT-ll Amp/ermy pOEM-T Easy cloned with This study
complementation cassette of ca.2.7 kb
pSAT-I2 Amp/ermy pSAT-11 cloned with cbbA along with This study
its native promoter sequences
pSAT-13 Amp/ermy pSAT-11 containing cbbA promoter and This study
BgnJ site for cloning of inserts for
expression under cbbA promoter
pSAT-14 Amp/ermy pSAT-13 cloned withgapA-l within This study
unique BglII site present downstream
the cbbA promoter sequences
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3.2.4 Inverse-PCR mutagenesis of cbbA
The plasmidpSAT -2 was subjected to inverse-Pf'R using the primer pair
FBA_M3 (IR) and FBA_M4 (IF) (Table 3.2, Fig 3.1 e). The rca was performed
as described in section 2.2.5 with the following modifications: annealing at 48°e
for 1 min, primer extension at 68°e for 5 min, and 94°e for 45 s. The peR
product was digested overnight at 25°C with BgnI before being self-ligated. The
resulting plasmid designated pSAT-3 was used to transform E. coli for
propagation and subsequent purification. The purified pSAT-3 was subsequently
digested with BgnI to enable insertion of resistance cassette. The kanamycin
resistance cassette was prepared from the plasmid pJMK30 (van Vliet et al.,
1998) by digestion with BamHI (Section 3.2.6). The BgnI-digested and purified
i-peR product was ligated to BamHI-digested Kanamycin resistance cassette.
The resulting plasmid was designated pSAT-4 (Fig 3.1 D)
3.2.5 Inverse-PCR mutagenesis of gapA-I
The plasmid pSAT -6 was used as a template DNA in inverse peR using the
primer pair gapAl_Ml (IF) and gapAl_M2 (IR) (Table 3.2) and chromosomal
DNA of N. meningitidis strain MeS8. This peR was carried out as described in
section 2.5 with modifications: annealing at 48°e for Imin, primer extension at
68°e for 5 min, and 94°e for 45 s. The inverse peR product was purified and
digested with BgflJ for lh at 37°e and then overnight at 2Soe. The BgnI-digested
i-peR product was then self-ligated using T4 DNA ligase (Roche) to generate
pSAT-7. The resulting plasmid pSAT-7 was purified and subsequently digested
with BgflJ and ligated to 1.5-kb antibiotic cassette (encoding resistance to
kanamycin). The resulting plasmid was designated pSAT-8.
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3.2.6 Preparation of selectable marker
The antibiotic cassette encoding resistance to kanamycin (1.5 kb) was obtained
by restriction digestion of 2 ug of pJMK30 plasmid (Appendix B) with BamHI
followed by preparative gel electrophoresis and gel extraction. The purified
kanamycin resistance cassette (KanR) was then ligated to linearized pSAT-3 and
pSAT-7 to yield pSAT-4 and pSAT-8, respectively.
3.2.7 Construction of ectopic complementation vector
A DNA fragment of ca. 2.7-kb (Fig 3.1) consisting of opa promoter and
erythromycin resistance cassette flanked by two meningococcal genes
(NMBOI02 and NMBOI03) was amplified by PCR using the primer pair
CompCass_(F) and CompCass_(R) (Table 3.2) and plasmid DNA pYHS25
(Winzer et al., 2002) . The PCR was performed as described in section 2.5 with
the following modifications, annealing at 51°C for 1 min, primer extension at
68°C for 4 min, and 94°C for 45s. Prior to cloning into pGEM-T Easy (Promega),
the PCR product was fully sequenced using the primers comcass_Fl and
comcass_RI (Table 3.2). The gel purified PCR product was ligated to pGEM-T
Easy vector (Promega). Screening for successful clones was performed on the
basis of blue/white phenotype. Plasmid DNA from putative transfonnants was
analysed by restriction digestion and DNA sequencing to confirm the successful
cloning. The resulting plasmid was designated pSAT -11(Table 3.1, Fig 3.2).
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ApGEM-TEasy
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pSAT-ll
IIMB0102
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IIMB010~~ FLAG
tiMB0066 (em£)
Figure 3. 2 Schematic diagram representing A) the gene organization of
complementation cassette B) and subsequent cloning of this cassette into the
pGEM-T Easy vector to generate pSAT-ll
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Table 3. 2 List of primers used in work described in this chapter
. Primer DNA sequence" Restrict
. . ..' . -ion site
Mutagenesis of cbbA and gapA-l
FBA_Ml(F) CTGCTGTGCCCGAGC
FBA_M2(R) CCGCTGCTGCAGGCG
FBA_M3(IR) GCGAGATCTTGTGTCTCCTTGGGCAATAGG BgnI
FBA_M4 (IF) GCGAGATCTGCTCCATCCAACTGGG BgnI
FBA_SAT(F) GCGCGCGGGTGGGCTTCGTCATAC
FBA_SAT(R) GTCTTTATGGTCGAGCGGTGCGG
gapAl_Ml(IF) GCGAGATCTGCAACAAACCGTC BgnI
gapAl_Ml(IR) GCGAGATCTGGTTTGTTCCTTTGTTGAGGG BgnI
NMB0207(R)FL GAGAACTGTCATGCGTATTCC
NMB0207(F)FL CCAAACCCAATGCCGCGAATG
gapA-l_Cl(F) GCATACAATTCTGCTAAAATACGC
CFR (R) CAGCGACTGTCAGGCC
Kan-CTR GACAACGCAGACCGTTCCG
Kan-NTR TCGCGGCCTCGAGCAAGACG
Complementation of cbbA and gapA-l
CompCass_F ATGTGGCGGGTTTTGAGTGC
CompCass_R GATTTTTCTTGCGGCGCGGC
FBA_COM(F) CGCGGATCCATGAGCTGTTTATGGTTTTTTGCTG BamID
FBA_COM(R) CGCGGATCCGGCATTTTGTTTACAGGCAACCTG BamID
pSAT-12iPCR(IF)CGCAGATCTGATACCCCCGATGAC BgnI
pSAT-12iPCR(IR)CGCAGATCTCATTTGTGTCTCCTTGG BgnI
gapA1_Comp(F)2 CGCGGATCCATGGGCATCAAAGTC BamID
gapAl_Comp(R)2 CGCGGATCCTTTGTTTGACGGTTTGTTG BamID
ComcassF TCAGCGGGTGCGTCGAGAAGC
ComcassR GCAAATCACAATTCTTGAGCG
NMBO 102(F)2 ATGTGGCGGGTTTTGAGTGC
NMBO1 03(R) TTTGGATTIIICTTGCGGCGC
"Sequences in bold identify restriction enzyme sites.
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3.2.8 Natural transformation in N. meningitidis strain MeS8
N. meningitidis strain MC58 was streaked on chocolate plates and incubated
overnight as described in (section 3.2.1). A single colony was sub-cultured into
fresh Brain-Heart Infusion (BHI) broth supplemented with Vitox (Oxoid) and
incubated overnight in 5% C02 at 37°C. The overnight broth culture of N.
meningitidis strain MC58 was diluted 1:20 in fresh BHI broth and further grown
to an optical density of 0.2. An aliquot of 0.2 ml of the culture was transferred to
a IS-ml tube with conical bottom containing 1.5 ml of BHI agar supplemented
with Vitox. After incubation for 5-6 hrs at 37°C in 5% C02 without shaking, 10
J.11(ca. 1 J.1g)of the mutagenic plasmid DNA was added to the tubes and
incubation was continued for 16 h. The putative transformants were selected on
BHI containing kanamycin 50 J.1gml". Kanamycin-resistant N. meningitidis
colonies were obtained and further analysed by PCR and immunoblotting of
whole cell extracts of the putative mutants.
3.2.9 Complementation of cbbA
To complement the cbbA mutation, cbbA. together with its predicted promoter
sequences, was amplified by PCR from genomic DNA of N. meningitidis strain
MCS8 using the primers FBA_COM (F) and FBA_COM (R) (Table 3.2)
incorporating BamHI restriction sites. The peR was performed as described in
section 2.5 with the following modifications: annealing at 55°C for 1min, primer
extension at 700e for 2.5 min, and 94°e for 45s. The peR product was ligated to
pGEM-T Easy (Promega), excised and then cloned into BamHI-digested pSAT-
11. Positive clones were analysed by colony peR, restriction digestion analysis
and DNA sequencing to confirm in frame ligation. The resulting plasmid was
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designated as pSAT-12 and used to transform MC5S6.cbbA (Section 3.2.8)
introducing a single chromosomal copy of the complementing gene in the
intergenic region between NMBOI02 and NMBOl03 ORFs, which are orientated
in a tail-to-tail fashion. Insertion of the gene at this ectopic site was confirmed by
peR analysis with the primer pair NMBOI02 (F) and NMBOI03 (R) (Table 3.2)
and immunoblotting for the expression of the gene using RaFBA antisera.
3.2.10 Complementation of gapA-l
The plasmid pSAT-12 was subjected to inverse PCR using the primer pair
pSAT-12iPCR (IF) and pSAT-12iPCR (IR) (Table 3.2). The rca was performed
as described in section 2.5 with the following modifications, annealing at 52°C
for I min, primer extension at 68°e for 6.5 min, and 94°C for 45s. The PCR
resulted in deletion of cbbA and introduction of a unique BgnI site to facilitate
the cloning of gapA-l under the promoter of cbbA. The amplicon was digested
with BglII before being self-ligated. This plasmid was designated as pSAT-13.
The gapA-l gene was amplified by PCR from the genomic DNA of
Nimeningitidis strain Me5S using primers gapAl_comp (F) 2 and gapAl_comp
(R) 2 (Table 3.2). The PCR was performed as described in section 2.5 with the
following modifications: annealing at 52°C for 458 min, primer extension at 68°C
for 1.5 min, and 94°C for 45s. The PCR product was purified and digested with
BamHI to enable ligation to BgnI-digested and dephosphorylated linear pSAT-
13. The resulting construct was designated pSAT-14 and used to complement
MC586.gapA-l
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3.2.11 Determining in vitro meningococcal growth
Meningococcal growth characteristics in liquid cultures were conducted by re-
suspending 1:100 overnight cultures of N. meningitidis in 10 ml of MH broth.
The following day, overnight broth culture was diluted in fresh BHI or DMEM
and adjusted to a starting OD6oo of 0.06. The cultures were incubated with
shaking at 200 rpm as described in section 3.2.1. The OD600reading was taken at
hourly intervals for 8h and then at 24h h and experiments were performed in
triplicate.
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pGEM-T Easy
pSAT-12
Figure 3. 3 A map of the pSAT-12 constructed by cloning cbbA into pSAT-l1
and used to complement cbbA mutation in isogenic-mutants. The plasmid
contains ampicillin and erythromycin resistance genes and cbbA promoter for
driving the expression of cbbA gene.
pSAT-14 lNMBo102
41cbbA Promoter
v--.---~ ifio-1
NMB0066 (ermC) FLAG
Figure 3.4 A map of the pSAT-14 constructed by inverse peR using pSAT-12 as
template to substitute the cbbA with gapA-l under the cbbA promoter. The
resulting plasmid containing gapA-1 was designated pSAT-14 and used to
complement gapA-l mutation in isogenic-mutants. The plasmid contains
ampicillin and erythromycin resistance genes and cbbA promoter for driving the
expression of gapA-1.
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Table 3. 3 Bacterial strains used in work described in this chapter
. Strain Description Source or
reference
E. coli
JM109 endAl recAl gyrA96 thi hsdR17 Promega
(rK-rK-)relAl supE44 t:.(lac-proAB)
[F' traD36 proAB laqlqZt:.M1S]
N. meningitidis
MC58 wild-type serogroup B strain (Tettelin et
ai.,2000)
Z4181 Clinical isolate
Z4667 Clinical isolate
Z4673 Clinical isolate
ST-18 Clinical isolate
MC58 DsiaD siaD deletion and replacement with C. Tang
erythromycin cassette Imperial
College
MC58t:.cbbA cbbA deletion and replacement with This study
kanam ycin cassette
Z4l81t:.cbbA cbbA deletion and replacement with This study
kanamycin cassette
Z4667!lcbbA cbbA deletion and replacement with This study
kanam ycin cassette
Z4673!lcbbA cbbA deletion and replacement with This study
kanamycin cassette
ST18!lcbbA cbbA deletion and replacement with This study
kanamycin cassette
MC58!lgapA-l gaA-l deletion and replacement with This study
kanamycin cassette
MC58!lcbbA cbbAEc, MC58!lcbbA complemented with an This study
ectopic copy of cbbA
Z4181!lcbbA cbbAEct Z4181!lcbbA complemented with an This study
ectopic copy of cbbA
ST18t:.cbbA cbbAEct ST18!lcbbA complemented with an This study
ectopic copy of cbbA
MC58t:.gapA-l gapA_IEct MC58!lgapA-l complemented with This study
an ectopic copy of gapA-l
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3.3 Results
3.3.1 Cloning of cbbA plus flanking DNA
In order to create a cbbA knock-out mutant in N. meningitidis strain MeS8, a region
of DNA containing l-kb upstream and ca.300 bp downstream of the start codon of
cbbA was successfully amplified by peR (Fig 3.5A). The fragment contained one
copy of the neisserial DNA uptake sequence (5'-GCeGTCTGAA-3') downstream of
the cbbA gene, which is required for efficient DNA uptake by natural transformation
of N. meningitidis (Elkins et al., 1991). The amplicon was gel-purified and used to
ligate to the pGEM-T Easy vector followed by transformation of E. coli JMI09 to
yield pSAT-2 (Fig 3.1 B).
The positive clones were identified by blue/white screening. The plasmid DNA was
prepared from resulting putative transformants and used to confirm the cloning of the
DNA fragment (cbbA plus flanking DNA) by restriction digestion and peR analysis.
The cloned DNA fragment was subsequently extracted from pSAT-2 after digestion
with Not! (Fig 3.Se). This digestion produced the expected two bands of ca.3 kb and
2.3 kb. In addition, the DNA fragment was amplified by peR (Fig 3.SB) using the
plasmid pSAT-2 as template and the original primer pair used to amplify the product.
Both approaches confirmed the successful ligation of the desired insert to pGEM-T
Easy.
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Figure 3. 5 Agarose gel analysis (A) showing the PCR amplification of a DNA
fragment consisting of cbbA and flanking DNA. Lane 1, DNA markers, lane 2, peR
product of cbbA and flanking DNA. (B) PCR amplification of DNA fragment from
pSAT -2 to confirm ligation, plasmid DNA from putative transform ants was used as a
template for amplification of DNA fragment consisting cbbA and flanking DNA.
Lane 1, DNA markers, lane 2 and 3 test samples. A band representing the desired
amplicon was observed in lane 3 indicating successful ligation in this clone. (C) The
restriction digestion analysis of pSAT-2, Plasmid DNA was prepared from E. coli
harboring putative pSAT -2 and used to verify the cloning of DNA fragment by
digestion with Notl. Lane 1, DNA markers, lanes 2 and 3, putative pSAT -2 digested
with Notl. As expected two bands of expected size were observed in both samples,
confirming the successful ligation of DNA fragment with pGEM- T Easy.
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3.3.2 Mutagenesis of cbbA by inverse peR
The plasmid pSAT-2 was used as template for inverse PCR. This PCR resulted in
deletion of approximately 300bp of the cbbA gene from start codon and
amplification of a 5-kb amplicon (Fig 3.6 A) and the introducing a unique Bgm site.
The product was gel-extracted and digested with Bgm to facilitate self-ligation
followed by transformation of E. coli JMl09 cells. Putative transformants were
selected and analysed by restriction digestion with BglII. Clones that produced bands
corresponding to the expected size of ca.5-kb were designated as pSAT-3 and were
chosen for insertion of a selectable marker. The pSAT-3 plasmid was subsequently
purified and digested with Bgm (Fig 3.6 B) to enable the insertion of selectable
marker encoding resistance to kanamycin.
The selectable marker encoding resistance to kanamycin was isolated from the vector
pJMK30 by digestion with BamHI. However, one difficulty encountered was
obtaining sufficient amounts of the kanamycin cassette, as the vector containing this
cassette appeared to be at a very low copy number. In an attempt to increase the yield
of the vector, 10 ml cultures of E. coli JMl09 competent cells containing the
pJMK30 vector were harvested and used to purify the plasmid followed by elution in
30 JlI rather than 50 ul.
106
1 2 1 2 3
ca.5-kb ca.5-kb
(A) (B)
Figure 3. 6 Agarose gel analysis (A) demonstrating the amplification of a 5-kb peR
product. The plasmid pSAT-2 was used as template DNA for inverse peR. Lane 1,
DNA markers, lane 2, inverse peR product representing pGEM-T Easy vector (3-kb)
and 2-kb DNA flanking cbbA (B) the restriction digestion analysis of pSAT-3.
Plasmid DNA was prepared from putative pSAT-3 transformants and linearized by
digestion with BglII. Lane 1, DNA markers, lane 2, uncut pSAT-3 and lane 3,
BglII-digested pSAT-2. As expected a ca. 5-kb band corresponding to linear pSAT-2
was observed in lane 3.
In order to introduce the marker into the unique BamHI site in the intermediate
vector pSAT-3, the KanR cassette was prepared by digestion of the vector pJMK30
and purified by gel electrophoresis followed by gel extraction. The kanamycin
cassette was obtained with the expected size of 1.5 kb (Fig 3.7A). The BamHI-
digested, purified antibiotic resistance cassette (encoding resistance to kanamycin)
was ligated to the intermediate vector pSAT-3 linearized by digestion with BglII
followed by transformation of E. coli JMI09 competent cells to yield pSAT-4.
Putative transformants were selected on kanamycin plates. Successful ligation of
KanR cassette to BglII-digested linear pSAT-3 was confirmed by restriction digestion
with Sma!. The SmaI site is available in the region of the KanR cassette, therefore an
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expected ca. 6.5 kb single linear band was observed on an agarose gel (Fig 3.7B).
The resulting plasmid was designated pSAT-4. Plasmid DNA was purified from E.
coli harbouring pSAT-4 for further confirmation by peR analysis.
Using the primer pair FBA_Ml (F) and FBA_M2 (R) (Table 3.2) the cloning of
KanR resistance cassette in pSAT-4 was further confirmed by peR amplification of a
ca.3.5 kb band consisting of 1.5 kb representing the KanR cassette and 2-kb of
flanking DNA. A negative control of plasmid (PSAT-2) without the Kan'' cassette
was also used in the same peR reaction. The expected 3.5 kb band was obtained in
all five samples tested whereas the negative control produced the expected 2.0 kb
band representing flanking DNA only (Fig 3.7C). This confirmed that, the Kan"
cassette was successfully cloned in the pSAT-4. The pSAT-4 was then chosen to
mutate the cbbA by natural transformation in N. meningitidis strain MeS8.
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Figure 3. 7 Agarose gel analysis demonstrating (A) restriction digest of pJMK30
vector with BamHI to obtain kanamycin resistance cassette, pJMK30 vector was
prepared and digested with BamHI. BamHl sites are present at both ends of the
kanamycin cassette in pJMK30 vector and could be used to isolate resistance
cassette. Lane 1, DNA markers and lane 2, BamHI-digested pJMK30. The lower
band of ca.l.5 kb represents KanR cassette, whereas the upper band corresponds to
the vector backbone (B) Restriction digest analysis of pSAT-4 to confirm the
presence of Kan" cassette Lane 1, DNA markers, lanes 2 and 4, uncut pSAT-4, lanes
3 & 5, Sma l-digested pSAT-4. An expected ca. 6.5 kb band was observed in lanes
3&5 indicating the successful ligation of KanR cassette in pSAT-4 (C) peR
amplification of KanR cassette and flanking DNA. Lane 1, DNA markers, lanes 2-6
pSAT-4 as template DNA and lane 6, pSAT-3 as template DNA (negative control).
Lanes 2-6 demonstrate an expected 3.5 kb band representing Kan resistance cassette
and flanking DNA, whereas, lane 7 produced 2-kb band.
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3.3.4 Verification of cbbA mutagenesis
The mutation of cbbA was confirmed by the peR analysis and immunoblotting by
probing the whole cell lysate from Me58~WT and MC58.1.cbbA using RaFBA
antisera. Initially, putative cbbA~null mutants were verified for the presence of the
KanR cassette at proper location and orientation of the cloned cassette in the
chromosome by peR analysis using the of cbbA-specific primer pair FBA_El (F)
and FBA_E2 (R) (Table 3.2) to amplify cbbA from the chromosomal DNA of the
putative mutant clones. Chromosomal DNA of N. meningitidis strain MCS8 was also
amplified with the same primer pair as a positive control. The PCR resulted in
amplification of an expected ca. l-kb band from chromosomal DNA of the
Me58-WT strain whilst no band was observed in the mutant samples (Fig 3.8A)
suggesting the successful mutation of cbbA in the putative mutants, which were
designated as MC58.1.cbbA. It was still not clear that the inserted KanR cassette was
in the same orientation as cbbA in the chromosome of the putative mutants. To
determine the orientation of the KanR cassette another PCR using the primer pair
Kan-CI'R and FBA_M2 (R) (Table 3.2) was performed, This peR would be
expected to produce a l-kb product where the orientation of the KanR cassette was
the same as the deleted cbbA. This confirmation was important in order to minimize
the impact of the mutation on the downstream genes (if the KanR was cloned in same
orientation) by facilitating expression of downstream genes in the same operon. An
expected 1-kb band was observed in 9 out of 10DNA samples from putative mutants
(Fig. 3.8B) confirming the presence and the correct orientation of the cloned
selectable marker in putative mutants. Taken together, these results appear to have
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genotypically confirmed that cbbA has been substituted in putative mutant genome
with KanR cassette.
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Figure 3. 8 Agarose gel demonstrating the CA) PCR amplification of cbbA from the
putative mutants. Chromosomal DNA was extracted from putative cbbA mutants and
used to confirm the mutation by PCR amplification of cbbA. Lane 1 DNA markers,
lane 2, MC58-WT DNA, lanes 3-11 putative cbbA mutant DNA. The PCR failed to
produce a band corresponding to cbbA size from putative mutants, except the
positive control of MCS8 chromosomal DNA. CB) orientation and presence of KanR
cassette in putative cbbA knock-out mutants. Chromosomal DNA was prepared from
putative mutants and used to verify the orientation and presence of KanR ea sette by
PCR using primers Kan-CTER and FBA MI(R). This PCR was expected to produce
ca.I-kb product in case of presence of KanR cassette in same orientation as of cbbA
in putative mutants. Lane 1, DNA markers, lane 2, MC58-WT DNA (control), Janes
3-12, putative cbbA mutant DNA. lane 2, failed to produce any band due to absence
of the cassette in the WT, whereas a band of expected size was observed in 3, 5-12
lanes, confirming the successful replacement of cbbA with the KanR in the same
orientation. Lane 4 could not produce any band suggesting that the Karl cassette was
in opposite orientation in this mutant.
111
To confirm that the cbbA gene is not expressed in the isogenic-null mutant strain,
whole cell lysate of MC58-WT and MC58~cbbA were resolved by SDS-PAGE
followed by immunoblot analysis by probing the membranes with RaFBA antisera.
A strongly reactive protein band with an apparent molecular weight of ca. 38-k-Da
was detected in the lysate of the MC58-WT sample which was absent from the lysate
of the MC58L1cbbA extract (Fig 3.9). This demonstrated that the expression of cbbA
has been abolished by the mutation. The RaFBA also detected another protein band
of higher molecular weight than FBA from the lysate of both MC58- WT and
MC58~cbbA, which was presumably non-specific band due to the polyclonal nature
of antisera
1 2 3
. 38-kDa
Figure 3. 9 Immunoblot analysis demonstrating the successful deletion of cbbA in
putative mutants Whole cell extracts were prepared from MC58- WT and MC58-
putative cbbA mutants and resolved on 10% SDS-PAGE followed by
immunoblotting with RaFBA to verify the cbbA deletion. Lane l , protein markers,
lane 2, whole cell extracts from MC58-WT, and lane 3, whole cell extracts from
MC58 cbbA mutant. RaFBA recognized a band of apparent molecular weight of ca.
38-kDa corresponding to FBA in lane 2, whereas the same band was absent in lane 3,
confirming that the cbbA is not expressed in cbbA mutant cells.
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3.3.6 Mutagenesis of cbbA in clinical isolates of N. meningitidis
In addition to mutating cbbA in N meningitidis strain MC58, attempts were made to
mutate cbbA in four additional clinical isolates of N meningitidis. The plasmid
pSAT-4 was used to mutateN meningitidis strains Z4181, Z4667, Z4673, and ST18
by natural transformation and allelic exchange. The putative transformants were
analysed for cbbA mutation and for the presence of KanR resistance marker in the
chromosome by PCR and immunoblot analysis as described above. PCR analysis
(Fig 3.10) showed that cbbA was successfully replaced by kanamycin resistance
marker in all four strains. Furthermore, a band corresponding to the apparent
molecular weight of FBA was observed in all wild-type strains but absent from the
respective isogenic mutants in immunoblots (Fig 3.11) confirming the deletion of
cbbA in these mutants.
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Figure 3. 10 Agarose gel analysis demonstrating the PCR amplification of cbbA
from clinical isolates of N meningitidis- WT and absent in their respective mutants,
Chromosomal DNA was prepared from putative mutant strains and used to verify the
mutation by PCR amplification of cbbA. Lanes I, DNA markers, lanes 2,4,6,8
chromosomal DNA from Z4181, Z4667, Z4673, ST-18 WT strains, respectively,
lanes 3,5,7,9, Z4181, Z4667, Z4673, ST-18 putative cbbA mutant stains,
respectively. The DNA band of ca. I-kb representing cbbA was observed in all
Wwild-type strains but absent in isogenic mutant strains indicating that cbbA was
successfully deleted.
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Figure 3. 11 Immunoblot analysis demonstrating the loss of expression of cbbA in
mutant strains. Whole cell extracts from putative cbbA mutants created in different
clinical isolates of N meningitidis were resolved by 10% SDS-PAGE followed by
immunoblot analysis. Lanes 1, protein markers, lanes 2,4,6,8 Z4181, Z4667, Z4673,
ST-18 WI strains, respectively, lanes 3,5,7,9, putative cbbA mutants in: Z4181,
Z4667, Z4673, SI-18 strains. The lower band of ca. 38-kDa represents FBA, which
is present in all WT strains but absent in all respective mutant strains indicating that
cbbA is not expressed in mutant strains.
3.3.7 Cloning of gapA-l gene plus flanking DNA
In order to create a gapA-l-null mutant in N meningitidis strain Me58, a fragment
of DNA encompassing gapA-l and ca.l-kb of DNA both upstream and downstream
of the start codon of gapA-l was amplified by peR (Fig 3.12A). This amplicon was
purified and ligated with pGEM-T Easy to yield pSAI-6. The plasmid pSAT-6 was
then used to transform E. coli JMI 09 cells and the successful clones were identified
by blue/while selection. Plasmid DNA was prepared from putative transfonnant
clones and analysed by restriction digestion with Sma!. Two Sma! sites are present in
the cloned DNA fragment, thus, as expected two bands of 3.0 and 3.2 kb were
obtained (Fig 3.12B). peR analysis ofpSAI-6 also confirmed the successfuJligation
(Fig 3.12C).
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Figure 3. 12 Agarose gel showing (A) peR amplification of gapA-1 plus flanking
DNA. Lane 1, DNA markers, lane 2, peR product consisting of gapA-l and flanking
DNA. (B) showing the restriction digestion of pSA T-6. Plasmid DNA was prepared
from putative pSAT -6 transfonnants and used to verify the cloning by restriction
digestion with Sma!. Lane 1, DNA markers, lane 2, pSAT-6 plasmid DNA. As
expected two bands (3 and 3.3-kb) were observed in lane 2 confirming the successful
ligation of DNA fragment in pSAT-6 (C) showing the peR amplification of gapA-1
plus flanking DNA from the plasmid construct pSA T-6. Lane 1, DNA markers, lane
2, peR product of gapA-l plus flanking DNA.
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3.3.8 Mutagenesis of gapA-l by inverse peR
The plasmid pSAT-6 was used as template DNA for inverse PCR. This resulted in
amplification of a 5-kb band (Fig 3.13A), deletion of the gapA-J open reading frame
(ORF), and introduction of a unique Bg/II site to facilitate the introduction of
selectable marker encoding resistance to kanamycin. The i-PCR product was
digested with BglII and self-ligated generating a pSAT-7. The pSAT-7 plasmid was
subsequently purified from a transfonnant clone and digested with BgnI to facilitate
the insertion of the KanR cassette (Fig 3.13B). The BgllI digested plasmid was
purified and analysed by agarose gel electrophoresis. The kanamycin resistance
marker was prepared as described previously (Section 3.3.2) and ligated to the
plasmid pSAT-7 digested with BgllI to yield pSAT-8. Plasmid DNA was prepared
from putative pSAT -8 transformants and used to verify the cloning of Kan" cassette
by restriction digestion with SmaI. As expected, three DNA bands were obtained by
this digestion confirming the successful cloning of the kanamycin resistance marker
(Fig 3.13C). The plasmid pSAT-8 was then used to mutategapA-l in N. meningitidis
strain Me58.
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Figure 3. 13 Agarose gel analysis demonstrating (A) the successful amplification of
inverse-PCR product for gapA-l mutagenesis. Plasmid DNA prepared from pSAT-6
was subjected to inverse-PCR to delete gapA-l and amplification of 5-kb amplicon
consisting of DNA flanking the gapA-l and pGEM- T easy vector, (B) the restriction
digestion of pSAT-7. Plasmid DNA was prepared from rutative pSAT-7
transformnts and digested with BglII to enable the insertion of Kan cassette. Lane I,
DNA markers, lane 2, uncut pSAT-7, lane 3, pSAT-7 digested with BglII, lane 3
produced an expected 5-kb band, (C) the restriction digestion anaJysis of pSAT-8,
The plasmid pSAT-8 DNA was prepared and verified by restriction digestion with
Smai for the presence of KanR cassette, lane 1, DNA markers, lanes 2 and 4,
undigested pSAT-8, lanes 3 and 5, Smaf digested pSAT-8. As expected three
products were observed in digested samples confirming the ligation ofKanR•
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3.3.9 Verification of gapA-l mutagenesis
Initially, verification of gapA-I null-mutants was accomplished by peR analysis.
Chromosomal DNA was prepared from putative mutants and used to confirm
deletion of gapA-l by amplifying a band corresponding to gapA-l. As expected this
PCR failed to produce a band of the expected size for gapA-l from the putative
mutants, indicating that the gapA-l ORF has been successfully substituted with the
kanamycin resistance marker, whereas the positive control of MC58-WT produced
an expected ca. lkb band representing gapA-l(Fig 3.24). In addition, PCR analysis
was performed to determine the orientation of the kanamycin resistance marker in
the chromosome of putative mutants using the primers Kan_CTR and gapA-l (R) FL
(Table 2.3). Where necessary, Me58 wild-type DNA was used as a control (Fig
3.25). This PCR resulted in amplification of expected l-kb band from the putative
mutants cloned with the appropriately oriented KanRmarker whereas the MC58-WT
negative control did not produce a band. The gapA-l null mutants were designated
MC58~gapA-1.
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Figure 3. 14 Agarose gel analysis demonstrating the verification of gapA-l deletion.
Chromosomal DNA was prepared from putative mutant strains and used to verify the
deletion of gapA-l by PCR. Lane 1, DNA markers, lane 2, MC58-WT DNA
(positive control), lanes 3-10, putative gapA-l mutant DNA. Lane 2, shows the
expected band corresponding to gapA-l, which is absent in lanes 3-10, confirming
the successful deletion of gapA-l in the mutant DNA.
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Figure 3. 15 Agarose gel analysis demonstrating the presence and orientation of
KanR cassette. Chromosomal DNA was prepared from putative mutant strains and
used to confirm the orientation and presence of KanR cassette by PCR using primer
Kan-CTER and gapA-l_(R) FL. This PCR was expected to produce ca.l-kb product
in case of presence of KanR cassette in same orientation as of gapA-l in putative
mutant strains. Lane 1, DNA markers, lane 2, MCS8-WT DNA (control), lanes 3-11,
DNA from putative gapA-l mutant. Lane 2, failed to produce any band due to
absence of the cassette in the WT, whereas a band of expected size was observed in
2-9 lanes, confirming the successful replacement of gapA-l by the KanR in the same
orientation. Lanes 10 and 11 could not produce any band suggesting that the KanR
cassette was in wrong orientation.
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In order to confirm that gapA-l is not expressed in the isogenic-null mutant strain,
whole cell lysates of MC58-WT and MC58~gapA-l were resolved on SDS-PAGE
followed by immunoblot analysis by probing the membranes with RaGAPDH-l
antiserum. A protein band of apparent molecular weight of ca. 37-k-Da was detected
in the lysate of the MC58-WT sample, which was absent from the lysate of
MC58~gaA-l (Fig 3.16). This confirmed that the expression of gapA-l has been
abolished by the mutation. The RaGAPDH-l also detected a number of additional
protein bands, including one immediately above the gapA-l band in lysates of both
MC58-WT and MC58~cbbA, which were assumed to be non-specific due to the
polyclonal nature of antiserum.
1 2 3
kDa
ca. 37-kDa
Figure 3. 16 Immunoblot analysis demonstrating the successful deletion of gapA-l in
putative mutant strain, Whole cell extracts were prepared from MC58- WT and
gapA-l mutant and resolved on 10% SDS-PAGE followed by immunoblotting with
RaGAPDH-l. Lane 1, protein markers, lane 2, whole cell extracts from Me58-WT,
and lane 3, whole cell extracts from MC58~gapA-l. Ra.GAPDH-l recognized a band
of apparent molecular weight of ca. 37-kDa representing GAPDH-l in lane 2,
whereas the same band was absent in lane 3, confirming that the gapA-l is not
expressed in gapA-l mutant cells.
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3.3.11 Construction of ectopic complementation vector
In order to rule out polar effects on neighbouring genes during phenotypic analysis
of the cbbA and gapA-l mutant strains, the cbbA and gapA-l mutations were
complemented using an ectopic complementation vector (Fig 3.3 and Fig 3.4) in
which the gene of interest may be cloned downstream of the cbbA promoter and
upstream of the ermy gene (encoding resistance to erythromycin). These sequences
are flanked by the genes NMBI02 and NMB103, which are in a tail-to-tail
configuration in both the vector and the meningococcal genome. The construct
facilitates insertion of genes of interest, under the control of the cbbA promoter, into
the meningococcal genome at a site that is unlikely to effect the expression of any
other genes. The complementation cassette was amplified by PCR from the pYHS25.
The 2.7 kb PCR product representing the complementation cassette (Fig. 3.17A, Fig
3.2 A) was gel-purified for cloning into pGEM-T Easy vector followed by
transformation of E. coli JMI09 cells. Positive clones were identified by blue/white
phenotype of the transformants colonies. The resulting ectopic complementation
plasmid was designated as pSAT-ll (Fig 3.2 B).
One successful clone was chosen for plasmid propagation and purification. The
complementation cassette was fully sequenced by using universal M13 (F and R) and
a pair of internal primers (Table 3.2) designed from sequences within the
complementation cassette to confirm the predicted promoter sequences and other
flanking genes. The sequencing results, when aligned with available sequences of the
promoter, revealed that there were differences in the predicted promoter region.
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Therefore, an alternative strategy was devised in which the native promoter of cbbA
was utilised. The plasmid pSAT-ll was digested at the BamHI site immediately
downstream of the predicted opa promoter in the multiple cloning site and an
expected band of a ca.6.5 kb corresponding to the linear pSA T-II was observed (Fig
3.17B). The clone was further confirmed by partial DNA sequencing using a MI3 (F
and R) primers. This pYHS25-based newly constructed plasmid pSAT-ll was used
as basis to clone complementing genes cbbA and gapA-l gene under the cbbA
promoter present immediate downstream ofNMBOl02 for driving the expression of
complementing genes.
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Figure 3. 17 Agarose gel analysis (A) showing the PCR product of complementation
cassette Plasmid DNA was prepared from pYHS25 and used as template for
amplification of a ca.2.7-kb DNA fragment corresponding to complementation
cassette. Lane 1, DNA markers, lane 2, PCR product representing complementation
cassette, (B) restriction digestion analysis of pSAT-I 1 with BarnHI showing the
successful ligation of complementation cassette in pGEM-T Easy, lane I, DNA
markers, lane 2, uncut pSAT-II DNA, and lane 3, BamHI-digested linear pSAT-ll
(ca.6.2 kb).
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3.3.12 peR amplification and cloning of cbbA in pSAT-ll
A ca. 1.1 kb product, consisting of the cbbA and its predicted promoter sequences,
was amplified by PCR (Fig 3.18). The amplicon was purified and ligated into
pGEM-T Easy, excised with BamHI and then introduced into BamHI-digested
linearized pSA T-11. Transformants were selected on agar plates containing
appropriate antibiotics and verified by restriction digestion analysis and subsequent
sequencing of the putative clone to confirm the in-frame ligation. The resulting
plasmid was designated pSAT-12 (Fig 3.3) and used to complement cbbA mutation
in isogenic null mutant by natural transformation and allelic exchange.
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Figure 3. 18 Agarose gel analysis demonstrating the successful PCR amplification of
cbbA from chromosomal DNA of N meningitidis. Chromosomal DNA was prepared
from MC58-WT and used to amplify the cbbA for cloning into pSAT-ll to generate
pSAT-12. Lane 1, DNA markers, lane 2, PCR product of cbbA gene.
Prior to introduction of pSAT-12 into MC58~cbbA by natural transformation,
pSAT 12-harboring E. coli JMI09 cells were grown overnight and the culture pellet
was used to determine the expression of cloned cbbA by immunoblot analysis using
RaFBA antisera. Six different clones were selected for preparation of whole cell
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extracts. The proteins were separated by SOS-PAGE and transferred to a
nitrocellulose membrane for immunoblot analysis with RaFBA antisera. All six
clones were shown to express a protein band with an apparent molecular mass
similar to the expected size of FBA, which was absent in the pSA T-11 (negative
control) suggesting that the FBA is expressed in E. coli from this plasmid without
any induction (Fig 3.19).
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Figure 3. 19 Immunoblot analysis of whole cell lysates from E. coli harbouring
pSAT -12. Whole cell lysates of E. coli were resolved by 10% SOS-PAGE followed
by iimmunoblot analysis to determine the expression ofFBA. Lane 1, DNA markers,
lane 2, MC58-WT whole cell lysate, lanes 3-5, pSAT-12, 1-3 samples, respectively,
lane 6, pSAT-ll (negative control), lanes 7-9, pSAT-12, 4-6 samples, respectively.
As expected all pSAT-12 constructs represented a band equivalent to FBA.
The plasmid pSAT-12 was subsequently introduced into MC58~cbbA by natural
transformation and allelic exchange (Section 3.2.8), introducing a single
chromosomal copy of the complementing gene in the intergenic region between
NMB0102 and NMBOI03, open reading frames orientated in a head-to-head fashion.
In addition, pSAT-12 was used to transform in two other mutants in clinical isolates
of meningococci: Z4181~cbbA and ST18~cbbA. These mutants were created to act
as background in challenging transgenic mice to assess a potential role of FBA in
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development of bacteraemia in these mice. Transformants were selected on selective
BHI agar plates. Successful transformants were sub-cultured and used for DNA
extraction and preparation of whole cell extracts for peR and immunoblot analysis,
respectively. The resulting complemented mutant strains were designated
Me58.1cbbA cbbAEc" Z4181.1cbbA cbbAEct and STl8.1cbbA cbbAEct.
3.3.13 peR analysis of putative N. meningitidis-.1cbbA cbbAEet strains
To confirm the successful complementation of ebb A at ectopic site in isogenic-null
mutants, chromosomal DNA was prepared from the putative complemented strains.
The presence of cbbA was identified by peR amplification of a DNA band
corresponding to cbbA from chromosomal DNA of the complemented mutant strains
using the FBA_pQE70 (F&R) primers and genomic DNA from MeS8-WT and
putative complemented strains and their isogenic-null mutant strains. Agarose gel
analysis demonstrated an expected band of ca. l-kb representing cbbA from
MeS8-WT and complemented mutants, but absent in isogenic-mutant strain (Fig
3.20) confirming the successful complementation of cbbA mutation.
In addition, another PCR using the primers NMB0102 (F) 2 & NMBOI03(R) was
performed to verify the insertion of complementation cassette at the proper location
in the chromosome of complemented strains. Insertion of the complementation
cassette at the proper location was identified by obtaining a ca. 4-kb band in
complemented mutant strains whereas WT and mutant strains were expected to
produce a band of ca. 1.3 kb representing only NMB0102 & NMOI03 PCR product.
125
As expected all three complemented strains produced an expected ca. 4-kb band
whereas WT and mutant strains produced 1.3 kb band further confirming the
insertion of cbbA at desired location in complemented strains (Fig 3.21).
ca. 1.1-kb
Figure 3. 20 Agarose gel analysis demonstrating the amplification of cbbA from
cbbA mutant and their complemented strains. Chromosomal DNA was prepared and
used to amplify cbbA using the primer pair FBA_pQE70 (F and R) and genomic
DNA from N meningitidis- WT (positive control) and Scbb.A (negative control).
Lanes 1,5,9, DNA markers, lanes 2,6,10, MCS8-WT, Z4181-WT, and ST-18-WT
genomic DNA, respectively, lanes 3,7,11, MC58tJ.cbbA, Z4I8ItJ.cbbA, and
ST-18tJ.cbbA , lanes 4, 8, 12, MC58tJ.cbbA cbbAEC\ Z4l81tJ.cbbA cbbAEct and
ST18tJ.cbbA cbbAEC\ respectively.
4-kb
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Figure 3. 21 Agarose gel analysis confirming the insertion of cbbA at d sired
location in complemented strains. Chromosomal DNA was prepared and used to
amplify the complementation cassette using the primer pair NMBO 102 (F) 2 and
NMBOI03 (R) and genomic DNA from complemented mutants strains and N.
meningitidis-WT and Scbb.A. Lanes 1,5,9, DNA markers, lanes 2,6,10, MCSS-WT,
Z4181-WT, and ST-JS-WT genomic DNA, respectively, lanes 3,7,11, M 58 cbbA,
Z41SItJ.cbbA, and ST-18tJ.cbbA , lanes 4,S,12, MC58~cbbA cbbAE \ Z4181 cbbA
cbbA Eet and ST 18~cbbA cbbA Eet , respectively.
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3.3.14 Immunoblot analysis of N. meningitidis-Scbbn cbbAEcl strains
The whole cell extracts were prepared from N. meningitidis-MC58 WT, Z4181,
ST18 wild-type, their respective null-mutants and putative complemented strains and
resolved on 12% SDS-PAGE followed by immunoblot analysis using RaFBA
antisera. All three complemented strains (MC58!1cbbA cbbAEe" Z4181~cbbA cbbAEcl
and ST18!1cbbA cbbAEct) tested were shown to express a protein band corresponding
to apparent molecular weight of ca. 38-kDa representing FBA (Fig 3.22 A,B,C).
These complemented strains will be used to con finn the previously identified
phenotype of cbbA mutant in various characterisation experiments.
ca.38-kDa
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Figure 3. 22 Immunoblot analysis demonstratin~ the expression of cbbA in
complemented mutant strains, MC5 8~cbbA cbbA .ct, Z4181 !1cbbA cbbA Eel and
STl8!1cbbA cbbAEel. Whole cell extracts were resolved by 10% SDS-PAGE
followed by immunoblot analysis using RaFBA. CA)Lane I, grotein marker, lane 2,
MC58-WT, lane 3, MC58~cbbA, lane 4, MC58!1cbbA cbbA "", (B) lane I, protein
marker, lane 2, Z4181-WT, lane 3, Z4181~cbbA, lane 4, Z4181~cbbA cbbAEe,,(C)
Lane 1, protein markers, lane 2, ST-18-WT, lane 3, ST-18~cbbA, Lane 4, ST-
18!1cbbA cbbA Eel.
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3.3.15 Mutagenesis ofpSAT-12 by inverse-PeR
Sequencing of the complementation construct revealed that there were differences in
promoter region compared to the expected sequence. In order to ensure expression of
the cbbA gene, therefore, the cbbA was cloned together with its predicted promoter
sequences. Again, in order to ensure expression of an ectopic copy of gapA-l
inserted into the genome via the complementation vector, the gapA-l locus was
analysed on the MeS8 chromosome in an attempt to identify the native promoter
sequences of gapA-l. Visual inspection revealed that in N. meningitidis strain MeS8
the gapA-l gene is downstream to NMB0208 (predicted to encode ferridoxin), and
bioinfonnatics analysis could not identify a strong promoter sequences upstream of
gapA-l. Therefore, the promoter of cbbA was employed to drive expression of
gapA-I at the ectopic site. Inverse-PflR was performed of the pSAT-12. This
resulted in deletion of cbbA from the ATG start codon to the stop codon and
introduction of unique BgnI site. The i-peR product was digested with BgnI and
self-ligated to yield pSAT-13 intermediate vector. The pSAT-13 was transformed in
E. coli JMI09 for plasmid propagation and subsequent purification. A successful
clone was identified by restriction digestion with BgnI of plasmid DNA prepared
from putative transformants. As expected a band of ca. 6-kb representing linear
pSAT-13 was observed in all five samples tested (Fig 3.23) confirming the deletion
ofcbbA.
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Figure 3. 23 Agarose gel analysis showing the restriction digestion analysis of
pSAT-13 using BglII. Plasmid DNA was purified from E. coli harboring putative
pSAT -13 and used to confirm the deletion of cbbA and presence of BglII site to
facilitate ligation of gapA-1. Lane 1, DNA markers, lanes 2,4,6,8,10 uncut pSAT-13,
lanes 3,5,7,9, and II, pSAT-13 digested with BglII. All lanes containing BglII
digested pSAT-13 produced a plasmid of correct size based on predicted molecular
weight of linear construct. One of the correct clones was chosen and used for
plasmid propagation and purification for cloning of gapA-I in BglIJ site.
3.3.16 peR amplification and cloning of gapA-I in pSAT-13
The promoter-less gapA-1 consisting of 1,032 bp was peR amplified (Fig 3.36). This
peR resulted in amplification of an expected ca. l-kb band representing gapA -1 and
introduction of a unique BamHI site to facilitate the ligation into pSAT -13 (Fig
3.24A). The pSAT-13 plasmid was prepared by digestion with BglII (site present
downstream of cbbA promoter) and gel-purified, followed by dephosphorylation to
prevent self-ligation. The BamHI-digested and purified gapA-1 product was then
ligated to linearized pSAT-I3 to yield pSAT-14, followed by transformation of E.
coli JMI09 cells. The positive clones were identified by colony peR (Fig 3.24B),
and partial sequencing using a primer FBA_eom (F) (Table 3.2) to confirm in frame
ligation. This primer anneals at the start of cbbA promoter available upstream of
gapA-1 to drive the expression of this gene.
129
1 2
10-kb
3.0-kb
1.5-kb
l-kb
0.5-kb
(A)
1 2 3 4 5 6 7 8 9 10
ca. J-kb
(B)
Figure 3. 24 Agarose gel analysis demonstrating «A) the successful amplification of
gapA-I from chromosomal DNA of N meningitidis for ligation into pSAT-13 to
generate pSAT-14. Lane 1, DNA markers, lane 2, PCR product of gapA-I (B) colony
peR amplification of gapA-I from putative transformants. Lane I, DNA marker,
lanes 2-10, PCR product representing the gapA -1. Several clones were identi fled and
further confirmed by sequencing.
After verification of gapA-l cloning in pSAT-14, the expression of gapA-I under the
control of the cbbA-promoter was determined in E. coli 1MI09 cells. Whole cell
proteins were prepared from E. coli 1M 109 cells harboring pSA T-14 and resolved on
10% SDS-PAGE and transferred to nitrocellulose membrane followed by
immunoblotting by probing with RaGAPDH-l antiserum. The pSAT-14 clone was
shown to express a protein band with an apparent molecular mass corresponding to
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the expected size ofGAPDH-l, which was absent in the pSAT-12 (negative control)
indicating that the GAPDH-l is expressed in E. coli under the cbbA promoter (Fig
3.25). The pSAT-14 was then used to complement the gapA-l mutation in
Me58f1gapA-l by natural transformation and allelic exchange. The putative
complemented transformants were selected on selective BHl agar plates. The
chromosomal DNA was prepared from putative complemented mutants for peR
analysis.
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Figure 3. 25 Immunoblot analysis demonstrating the expression of gapA-I in E. coli
harboring pSAT-14, Whole cell extracts were prepared from E. coli containing
pSAT-14 and reolved by 10% SOS-PAGE to verify the expression of gapA-1 by
immunoblot analysis using RaGAPDH-l. Lane 1, DNA markers, Lane 2, whole cell
extracts from Me58-WT, lane 3, whole cell extracts from E. coli harboring pSAT-12
(Negative control), lane 4, and whole cell extracts from E. coli harboring pSAT-14.
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3.3.17 PCR analysis of putative MC58~gapA-l gapA_IEcl
In order to verify the successful complementation of gapA-I at ectopic site in
isogenic-null mutants, chromosomal DNA was prepared from the putative
complemented and isogenic-null mutant strains and used to amplify the DNA band
corresponding to gapA-I using a pair of gapA-I-specific primers. Agarose gel
analysis demonstrated an expected band of ca. l-kb representing the gapA-I from
complemented mutants that was absent in the isogenic-mutant strain (Fig 3.26A)
confirming the successful complementation of gapA-I mutation.
In addition, another peR using the primers NMBOI02 (F) 2 & NMBOI03(R) was
performed to verify the insertion of the complementation cassette at the proper
location in the chromosome of complemented strains. Insertion of the
complementation cassette at the proper location was expected to produce ea 4-kb
band in complemented mutant strains whereas mutant strain was expected to produce
a band of ea 1.3 kb representing only NMBOI02 & NMOI03 peR product. As
expected the complemented strain produced an expected ca. 4-kb band whereas the
mutant strains produced a l.3-kb band (Fig 3.26B) further confirming the insertion
of gapA -1 at the desired location in the chromosome of complemented strains.
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Figure 3. 26 Agarose gel analysis demonstrating CA) the peR amplification from the
gapA-l mutant and complemented strain. Genomic DNA was extracted from
putative gapA-l complemented strains to confirm the complementation of gapA-l in
peR amplification of gapA-l. Lane 1, DNA markers, Lane 2, Me586.gapA-1
gapA_rEct, and Lane 3, MC586.gapA-l. Lane 2 shows a band of apparent molecular
weight of gapA-l confirming the successful complementation, whereas no band was
observed in the mutant strain (B) Confirmation of the insertion of gapA-l at desired
location in the chromosome of complemented strain. Genomic DNA was extracted
from putative gapA-l complemented strain for PCR amplification of gapn-], Lane I,
DNA markers, lane 2, MC586.gapA-l, and Jane 3, MC586.gapA-l gapA_JEc". Lane 3
shows a band corresponding to complementation cassette, whereas an expected 1.3-
kb DNA fragment corresponding to NMBOI02 & NMB0103 was observed in Lane
2.
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3.3.18 Determining the growth characteristics of meningococcal strains
Before undertaking phenotypic analysis of the cbbA and gapA-l mutants, it was first
essential to demonstrate that mutations of these genes did not significantly affect the
growth rate of N meningitidis. Growth and colonial characteristics of mutant strains
were assessed by visual inspection of colony morphology on agar plates and
monitoring the rate of growth in liquid culture. The mutant strains demonstrated
similar colony morphology and colour to that of wild-type strain MeS8 (data not
shown). The wild-type MeS8, isogenic cbbA and gapA-l null mutant and
complemented strains were then grown in BHI broth or OMEM with a starting OD600
adjusted to 0.06. Growth rate was assessed by measurement of 00600 of samples that
were removed from the culture at hourly intervals. The growth rate of the strains
with deletion of cbbA and gapA-l was not substantially different to that observed for
wild-type MeS8 and complemented strains. All strains were observed to grow to a
similar 00600 by the final time point of eight and 24 h. These experiments were
performed in triplicate and the results are presented in (Figure 3.27). In order to
further explore whether the addition of normal human serum may have any effect on
the growth of wild-type and mutant strains, meningococcal growth was monitored in
OMEM or DMEM supplemented with 10% human serum. Again, no substantial
differences between the growth rates of wild-type MeS8 and either cbbA and gapA-l
mutants were observed (data not shown).
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Figure 3. 27 Growth characteristics of meningococcal mutant and complemented
strains compared to their wild-type parent strain. (A) N meningitidis strain MC58-
WT, MC58LlcbbA, MC58LlcbbA cbbAEc( (B) N meningitidis strain MC58-WT,
MC58LlgapA-l, MC58LlgapA-l gapA_IEC( were grown in BHI broth in triplicate and
OD reading was taken at hourly intervals for 24 hrs. No substantial differences were
observed demonstrating that the cbbA and gapA-l mutation has no effect on in vitro
maximal growth of N meningitidis strain.
135
3.4 Discussion:
This chapter describes the mutagenesis of cbbA and gapA-l in N. meningitidis. The
mutant strains were used to facilitate the functional characterisation of the products
of these genes in a number of in vitro and in vivo experiments (described in detail in
Chapter 4 & 5). The mutagenic plasmids were generated by cloning DNA fragments
flanking the cbbA and gapA-l, which contained one naturally-occurring Neisserial
uptake sequences. The cbbA and gapA-l mutants were successfully generated in N.
meningitidis strain MCS8. Additionally, cbbA was disrupted in four clinical isolates
of N. meningitidis. Importantly, both cbbA and gapA-l mutant strains were shown to
exhibit unexpected phenotypes in characterisation experiments (Chapter 4 & 5),
which initiated further analysis that led to subsequent complementation of both
mutations in their respective isogenic mutants. Complementation of mutants, in
which a wild-type copy of the gene is reintroduced in the respective isogenic-mutant
at an ectopic site, provides an important check that any observed phenotype can be
ascribed to the loss of the mutated gene rather than to polar effects of the mutation
on adjacent genes in the operon or additional undetected secondary mutations.
The complementation of chhA and gapA-l mutations in N. meningitidis strain MC58
was initially attempted using the pAP2-1 based plasmid pNJ095 and pNJ096,
respectively. The plasmid pAP2-1 is based on a gonococcal cryptic plasmid; it has a
porA promoter and a spectinomycin resistance cassette. The plasmid pNJ095 and
pNJ096 constructs were created by Dr Neil Oldfield and shown to express desired
proteins, FBA and GAPDH-l by immunoblot analysis. These plasmid borne genes
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were assumed to be expressed independently on the plasmid rather than integrating
into the chromosome of the bacteria. Several attempts to introduce these plasmid
constructs by either natural transformation or electroporation in respective mutants
were unsuccessful. Alternatively, the complementation strategy based on the allelic
exchange was adopted. Under this strategy, the complementation was performed
using a pYHS25-based ectopic complementation vector in which the expression of
genes of interest is driven under the control of the cbbA promoter. Moreover, these
constructs facilitate insertion of genes of interest into the meningococcal genome at a
site that is unlikely to effect the expression of any other genes.
A pYHS25-based complementation plasmid was generated by cloning a ca.2.7 DNA
fragment, which contained two neisserial DNA uptake sequences and the
erythromycin resistance cassette flanked by the two meningococcal genes:
NMBOI02 & NMBOI03. Although the complementation plasmid contained
promoter sequences upstream of erythromycin resistance cassette, the sequences
were found to differ from that which was expected. Therefore, the cbbA and gapA-l
genes were cloned under the predicted promoter sequence upstream of cbbA. In an
attempt to identify promoter sequences upstream of FBA, analysis of the
organization of genes at the cbbA locus (NMB1869) was performed. This analysis
demonstrated that cbbA is the first gene in its orientation, so must have its own
promoter. The predicted cbbA gene (based on gene-finding algorithms used at the
Comprehensive microbial resource [CMR] database) starts from an internal ATG
start codon, meaning that the first 25 predicted amino acids in the ORF are not
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predicted to be part of the gene. This is in agreement with a visual inspection, which
shows that there is a good ribososmal binding site (RBS) upstream of the internal
ATG but not at the first ATG. The cbbA was amplified from a position upstream of
the predicted promoter to a position downstream of its stop codon and cloned in a
complementation vector. The resulting complementation plasmid was used to
transform N. meningitidis strain MC58&:bbA, Z4181~cbbA and ST18~cbbA,
returning wild-type copies of cbbA to these mutants. Successful complementation
was confirmed by PCR analysis and immunoblot analysis using RaFBA antiserum.
For complementation of gapA-l mutation, examination of the orientation of the open
reading frame around the gapA-l gene indicated that polar effect could not be
responsible for the attenuation of the gapA-lbecause gapA-l is the second and last
gene in the operon and that the immediately downstream gene is in the opposite
orientation. However, this mutant was also complemented in trans with a single copy
of the wild gene in an ectopic chromosomal location to generate MC58~apA-l
gapA_IEct. The genetic organization at the gapA-l locus (NMB0207), which is
downstream of NMB0208 (predicted to encode ferredoxin) was analysed to identify
potential promoter sequences. This showed that the two genes might be cistronic (i.e.
they may share a promoter). Bioinfonnatics prediction identified a possible promoter
upstream of gapA-l (NMB0207), but with only a weakly identified -35 region. The
gapA-l gene was, therefore, cloned downstream of the cbbA promoter. The gapA-l
gene was amplified from a position upstream of its ribosome binding site to a
position downstream of its termination codon to generate a complementation
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plasmid. The resulting plasmid designated pSAT-14 was introduced into N.
meningiiidis strain MC58~apA-l by natural transformation to reintroduce the wild-
type copy of gapA-l. Complementation of gapA-l at ectopic site was successfully
achieved in the gapA-l isogenic null mutant. Prior to employing the mutants in
characterisation experiments, in vitro assessment of growth rate was undertaken to
determine whether mutation of cbbA or gapA-l had any overt influence on
meningococcal growth. The wild-type MCS8, cbbA and gapA-l mutant and their
complemented strains were shown to grow at a similar rate without any noticeable
differences either in colonial morphology or by growth rate in broth culture.
Moreover, the addition of normal human serum to DMEM or BHI had no effect on
the growth of N. meningitidis strain MCS8 and both mutants. The pattern of growth
remained the same in the presence or absence of human serum in the culture
medium. These findings are consistent with the findings ofBaart et al., who showed
that the glycolytic pathway was non-functional in the meningococcus due to absence
of one of the important enzymes in this pathway: phosphofructokinase (Baart et al.,
2007).
In conclusion, cbbA isogenic mutants were generated in five meningococcal strains.
and a gapA-l isogenic mutant was generated in N. meningitidis strain MCS8. In
addition, the cbbA mutation was complemented in three of the isogenic mutants and
the gapA-l mutant was also complemented. Additionally, the growth of wild-type
MCS8 was shown to be unaffected by the mutation of either cbbA or gapA-l,
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demonstrating that the products of these genes were not required for optimal growth
of N meningitidis.
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CHAPTER 4: Molecular and immunological characterisation
of FBA and GAPDH·1
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4.1 Introduction
The functional, molecular, and immunological characterisation of two of the
glycolytic enzymes namely FBA and GAPDH-l of N. meningitidis is described in
this chapter. It is important to note that recent genome-based studies have revealed
that one of the glycolytic (EMP) pathway enzymes, namely phosphofructokinase
(Ee 2.7.1.11) is absent from N. meningitidis strain Me8S, rendering this pathway
non-functional (Baart et al., 2007). Despite the inability to utilize the glycolysis
pathway, FBA, GAPDH-l and other enzymes required for glycolysis are maintained
in the meningococcal genome, presumably for other roles. In the absence of
alternative roles for these enzymes, spontaneous mutations would be expected to
accumulate in the encoding sequences. This chapter will focus on the
characterisation of both of enzymes with the aim of determining their conservation,
expression, cellular localization, and additional non-glycolytic role(s).
An important property for a putative vaccine antigen is that it should be well-
conserved across divergent isolates of meningococci and expressed naturally. To
confirm that the cbbA and gapA -1 genes were conserved across, and expressed in,
diverse clinical isolates of menigococci, whole cell proteins from a panel of
meningococcal strains and one strain each of N. gonorrhoeae, N. polysacchareae,
and N. lactamica were screened by peR and subsequently by immunoblot analysis
using RaFBA and RaGAPDH-l, respectively. To determine the enzymic activity,
rFBA was successfully purified under native conditions, which was then used to
confirm the functional activity of this enzyme. In keeping with the fact that
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glycolytic enzymes may reach the surface of nwnerous bacterial and fungal
pathogens, in this study surface-location of FBA and GAPDH-l meningococcal
glycolytic enzymes was investigated using a combination of molecular and
immunological techniques, including sub-cellular fractionation of meningococcal
cells, surface-biotinylation of intact meningococcal cells, enzyme-linked
immunosorbant assay (ELISA) and flow cytometry.
In an attempt to determine the surface location and evaluate the vaccine potential of
FBA in meningococci, whole cell ELISA was performed with polyclonal antiserum
raised against the denatured purified rFBA protein. Initial results were promising and
demonstrated that FBA was present in the outer membrane fraction of
meningococcal cells. To confirm these results, and assess surface-exposure we used
a technique that involves the biotinylation of surface-exposed proteins. Although
considered to be an invaluable approach in the identification of surface exposed
proteins, it failed to demonstrate surface-exposure ofFBA and GAPDH-l. To further
investigate the surface location of FBA, the polyclonal antiserum raised against
natively purified FBA was used to evaluate the accessibility of FBA epitopes on the
surface of live encapsulated N. meningitidis serogroup B bacteria using flow
cytometry analysis. Using the polyclonal antisera, raised against denatured purified
FBA and GAPDH-l protein, the susceptibility of meningococci to antibody-
dependent, complement-mediated bacteriolysis using in vitro serum bactericidal
assay was also investigated.
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In addition, to assess whether FBA is essential for bacteraemia in a novel transgenic
mouse model of infection, isogenic cbbA mutants created in five different genetic
backgrounds of N. meningitidis, were used by our collaborators at the Pasteur
Institute in Paris. The results of the animal studies have shown that all cbbA mutant
strains were significantly less able to cause bacteraemia compared to their wild-type
parent strains indicating that FBA may play a role in the pathogenesis of
meningococcal disease.
The aim of this chapter was to characterize the FBA and GAPDH-l enzymes of N.
meningitidis using molecular and immunological techniques. The key aims were to
determine their surface localisation and evaluate the vaccine potential of both
proteins. This chapter also aimed to explore the potential role of FBA in
meningococcal pathogenesis.
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4.2 Materials and methods
4.2.1 Bacterial strains, growth conditions and media
The bacterial strains and plasmids used in this chapter are described in chapter 2 and
3. Culture conditions for the growth of E. coli and N. meningitidis were as described
in sections 2.2.1 and 3.2.1, respectively. All meningococcal strains were clinical
isolates belonging to different serogroups and types (Table 4.1) and included
representative isolates of recognized hypervirulent lineages. The antibiotics were
used as appropriate at the following concentrations: kanamycin 50 flg ml" and
erythromycin 5 ug ml".
4.2.2 Preparation of whole cell proteins
Meningococcal cells (Table 4.1) were grown overnight in BHI supplemented with
Vitox (Oxoid) at 37°C in a shaking incubator (250 rpm). The cultures were harvested
by centrifugation at 13000 x g for 10 min. The pelleted cells were re-suspended in
sterile PBS and 5x SDS-PAGE sample buffer (Appendix A) to achieve Ix final
concentration of whole cell protein extracts. The whole cell lysate was briefly
sonicated using a lOs pulse to obtain a homogenous suspension, boiled for 5 min
and then mixed thoroughly before SDS-PAGE analysis.
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Table 4. 1 Clinical isolates of N. meningitidis.
Strain Country of Serogroup Sequence Clonal complex
origin type
ZIOOI USA A 4 ST-4 complex/subgroup IV
Zl035 Pakistan A ST-1 complex/subgroup VII
Z1054 Finland A 5 ST-5 complex/subgroup III
Z1213 Ghana A 4 ST-4 complex/subgroup IV
Zl269 Burkina Faso A 4 ST-4 complex/subgroup IV
Z1503 China A 5 ST-5 complex/subgroup III
Z3771 UK A 5 ST-5 complex/subgroup III
Z3842 Norway B 32 ST-32 complex/ET-5 complex
Z4181 Mali C 11 ST-ll compleX/ET-37 complex
Z4323 Israel C 11 ST-ll compleX/ET-37 complex
Z4662 Netherlands B 8 ST-8 complex/Cluster A4
Z4667 Netherlands B 48 ST-41144 complexILineage 3
Z4673 Netherlands B 41 ST-41/44 complexILineage 3
Z4676 Denmark B 37 ST-37 complex
Z4678 Germany B 19 ST-18 complex
Z5826 China A 7 ST-5 complex/subgroup III
Z6413 South Africa C 8 ST-8 complex/Cluster A4
Z6414 New Zealand C 66 ST-8 complex/Cluster A4
Z6418 Cuba B 33 ST-32 complex/ET -5 complex
Z6419 Austria B 40 ST-41144 complexlLineage 3
26420 Greece B 41 ST-41144 complexlLineage 3
26417 England C 11 ST-ll complexlET-37 complex
Z4684 Norway B 13 ST-269 complex
24685 Norway B 14 ST-269 complex
24701 Norway B 11 ST-ll compleX/ET-37 complex
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4.2.3 Strain distribution of cbbA and gapA-l in N. meningitidis
A panel of 26 strains of N meningitidis of known MLST-type (Table 4.1) was
selected to determine the expression of cbbA and gapA-l. The whole cell proteins
from these strains were analysed by immunoblotting and probing with anti-FBA or
anti-GAPDH-l serum, respectively.
4.2.4 Kinetic analysis of the fructose bisphosphate aldolase activity
Kinetic analysis studies of FBA protein were performed at the University of Leeds
under the supervision of Dr Alan Berry. A coupled enzymic assay was used to
determine FBP-aldolase activity. The assay was performed in 1 ml of 50 mM Tris-
HCI supplemented with 0.1 M potassium acetate buffer, pH 8.0 containing 0.1-5 mM
fructose 1, 6-bisphosphate, 0.2 mM NADH and 2 III of 10 mg ml" mixture of
glycerol-phosphate dehydrogenase-triosephosphate isomerase at 30DC. The reagents
were added in the following order: buffer, FBP, NADH and coupling enzymes. The
reaction was then started by adding purified FBA enzyme. The reaction mixture was
mixed well before recording the decrease in absorbance at 340 nm as the measure of
enzyme activity on an Uvikon 930 spectrophotometer. Activities were calculated
using the molar extinction coefficient for NADH as 6220 Mlcm·l. One unit of
aldolase activity was defined as the amount of enzyme which catalyses the oxidation
of 2 umol NADH per min in the assay system. Kinetic parameters were estimated
using the Origin Pro 7.5 software program.
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4.2.5 Sub-cellular fractionation of meningococcal cells
To investigate the sub-cellular localisation ofFBA and GAPDH-l in N. meningitidis
Me58, a traditional method of cell fractionation was used to prepare cytoplasmic,
periplasmic, inner membrane and outer membrane fractions of the celJ and each
fraction was probed with the anti-FBA or anti-GAPDH-l antiserum in order to
identify the cellular localisation of FBA and GAPDH-l, respectively, in N.
meningitidis. Meningococcal cells were grown overnight at 37°C in BHI broth with
or without supplement and DMEM supplemented with 10%human serum.
Periplasmic proteins were prepared by a modification of the method of Nossal and
Heppel (Nossal & Heppel, 1966) or a chloroform extraction method (Ames et al.,
1984). Briefly, cells from lOOml overnight cultures were harvested at 13000 x g for
2 min and the pellet was re-suspended in 1 ml of EB buffer (10 mM Tris-HCI pH
7.5, 10 mM MgCh, 25% sucrose), and washed twice in the same buffer. Finally, the
pellet was re-suspended in EB buffer and incubated for 10 min on ice. The
preparation was centrifuged at 13000 x g for 4 min, following rapid re-suspension in
0.4 ml of ice cold water and incubation on ice for a further 10 min, followed by
centrifugation at 13000 x g for 2 min. The upper fraction of the supernatant
consisting of periplasmic proteins was transferred to a fresh eppendorf and stored at -
20oe. After collection of the periplasmic fraction, the cell pellets (spheroplasts) were
re-suspended into 0.4 ml Tris-HCI (PH 7.5) and sonicated to release the cytoplasmic
contents. Non-disrupted cells were removed by centrifugation at 5000 x g for I min.
The upper clear supernatant was transferred to a fresh eppendorf and centrifuged at
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17000 x g for 30 min. The supernatant was collected as the cytoplasmic protein
fraction and stored at -20°C. The remaining pellet was re-suspended in 0.2 ml of 10
mM Tris-HCI pH 7.5,10 mM MgChand 0.2 ml of 10mM Tris-HCI pH7.5, 10mM
MgCh and 4% Triton X-100. The sample was incubated at 37°C for 30 min and then
centrifuged at 17000 x g for 30 min. The supernatant was collected as the
cytoplasmic membrane fraction and stored at -20°C. The final pellet (yielded after
collection of the cytoplasmic membrane fraction) was deemed the outer membrane
protein-enriched fraction. This pellet was re-suspended by brief sonication in 10mM
Tris-HCI pH 7.5, 10 mM MgChand then 0.5 ml of 10mM Tris-HCI pH7.5, 10 mM
MgCh and 2% Triton X-lOOwas added. The suspension was incubated at 37°C for
30 min and then centrifuged at 17000 x g for 30 min. This step was repeated to
remove any remaining soluble proteins to ensure the purity of fraction. Final pellet
was re-suspended in 0.2 ml IOmM Tris-HCI pH 7.5 and stored at -20°C.
4.2.6 Methodologies to assess surface exposure of FDA and GAPDH-l
4.2.6.1 Cellsurfacebiotinylationofmenmgococci
Cells of N. meningitidis strain MC58 were grown overnight on chocolate agar.
Colonies were collected and placed into 1ml of sterile PBS in an eppendorf tube (1.5
ml). Cells were harvested by centrifugation at 13000 x g for 5 min. Before being re-
suspended in carbonate buffer (Appendix A), cells were washed three times with
fresh ice-cold PBS. The optical density (OD6oo) was adjusted to 0.2 and biotin-
streptavidin (Sigma) was added to a final concentration of 0.5 mg mr'. The cells
were incubated at RT for 30 min and then harvested by centrifugation at 13000 x g
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for 5 min. In order to remove excess unbound biotin, the cells were washed two
times with sterile PBS. The cell pellet was briefly sonicated (10 s pulses). The
biotinylated samples were analysed by SDS-PAGE followed by immunoblotting
using anti-goat anti-biotin conjugated to alkaline phosphatase at a dilution of
1:30000. Membranes were developed using BCIP substrate (Section 2.2.15 and
2.2.16).
4.2.6.2 Enzyme linked lmmunosorbant assay (ELISA)
An ELISA was used to analyze the ability of polyclonal antisera raised against
recombinant proteins to bind to intact meningococcal cells. The antiserum was pre-
adsorbed with the mutant strain and serially diluted (1: 10, 1:100, and 1:1000) in
coating (carbonate) buffer (Appendix A), before being added in 100 J.l.1aliqoutes to
plate wells (Nunc 96-well plates, PolySorp) for 1 h at RT. Control wells were coated
with PBS containing 1% BSA (PBS-BSA) (negative control). Plate was washed
three times in PBS containing 0.05% Tween 20 (PBS-Tween) buffer. To block the
remaining binding sites 100 J.l.1of PBS-BSA was added to each well and incubated
for 1 h at RT. Microtiter plate wells were again washed three times with PBS-Tween
before adding the digoxygenin-Iabeled bacterial cells. For labeling, N. meningitidts
strains were grown in liquid culture and washed 3 times in PBS-Tween before being
resuspended in carbonate buffer to an OD of 0.1 at 600 nm. Bacteria were labeled by
adding 10 ug of digoxygenin (Roche) per 1 ml bacterial suspensions for 2 h at RT.
One hundred microlitres labeled cells were added to each well, and plates were
incubated for 2 h at RT. Plates were washed 5 times with PBS-Tween and incubated
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with anti-digoxigenin Fab fragment-conjugated antibody (1:5,000; Roche) in 1%
BSA in PBS-Tween (blocking buffer) at 100 III per well . Plates were incubated at
RT for an additional 1 hour and washed 5 times. One hundred microliters of 2, 2'-
azino-bis; 3-ethylbenzthiazoline-6-sulphonic acid (ABTS) (Chemicon international
ES004) substrate (5 mg ml"; Roche) were added to each well, and the absorbance
was measured at 405 nm after 30 min using an ELISA plate reader (BioTek).
4.2.6.3 Flowcytometryanalysis
The ability of antisera elicited by the recombinant FBA and GAPOH-l to bind to the
surface of pathogenic strains of N. meningitidis group B was determined by flow
cytometry using an indirect fluorescence assay. N. meningitidis strain MCS8 wild-
type and MC58~cbbA cells were grown to 00600 <0.7 to obtain mid-log phase
bacteria. Four samples per strain, each containing I x 107 CFU ml" in PBS, were
prepared for the flow cytometry analysis. In each case one sample was: untreated;
treated with primary antibody only; treated with secondary antibody only; or treated
with both primary and secondary antibodies. The cells were washed twice in sterile
filtered PBS by centrifugation at 5000 x g for 5 min. The test sample cells were
treated with either RaFBA or RaGPADH-l polyclonal antiserum (1:500) diluted in
PBS containing 0.1% BSA, 0.1% sodium azide and 2% foetal calf serum (PBS-BSA-
FCS buffer), whereas the control cells were re-suspended without antibody, and
incubated on ice for 2 h. The samples were washed 3 times in PBS and the test
sample pellets were mixed with secondary antibody, goat anti-rabbit IgO conjugated-
Alexa Flour 488 (Invitrogen) diluted 1:50 in PBS-BSA-FCS buffer. The control
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sample pellets were re-suspended in PBS-BSA-FCS buffer, and all samples were
incubated on ice for 2 h in the dark. Finally, the samples were washed in PBS twice
before being re-suspended in 1 ml PBS containing 0.5% formaldehyde to fix the
cells. The samples were then analysed for fluorescence using Coulter Altra Flow
Cytometer. The cells were detected using forward and log-side scatter dot plots, and
a gating region was set to exclude cell debris and aggregates of bacteria. A total of
50,000 bacteria (events) were analyzed for fluorescence signals. All buffers and
solutions were filtered using 0.2 um tilter to eliminate any small particles. As
negative controls, one sample was untreated, one sample was treated with primary
antibody only and one sample was treated with secondary antibody only.
4.2.7 Serum bactericidal assay
N. meningitidis strain MC58 was grown on chocolate agar overnight. Ten colonies
were inoculated into 5 ml MHB (without supplement) and incubated for two hours at
37°C in a shaking incubator. The 00600 run was measured and cells were harvested
(8000 x g for 5 min) from a 500 J.lI aliquot of the culture. The cells were re-
suspended in PBS/bovine serum albumin (BSA) to achieve an 00600 of 0.1.
The assay was performed in a sterile 96-well tissue culture plate, to which the assay
components (antibody, complement, and bacteria) were added sequentially. Each
well contained: 20 ).11of RaFBA or RaOAPDH-l antiserum (or pre-immune serum
taken from the same rabbit) pre-adsorbed with the cells of strain MC5McbbA or
MC58ilgapA-l, respectively (and de-complemented by heating to 56°C for 30 min),
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10 J.l.1of bacteria (diluted to ca. 800 colony-forming-unites [CFU] per well), and 10
J.l.1of sterile baby rabbit serum (Pel-Freeze) as a source of complement. Sera were
used at the final dilution of 1:2, 1:4, 1:8, and 1:16. After the addition of all
components to the wells, the plates were covered and incubated for 60 min at 37°C
on a microplate shaker (150 rpm). Ten microliters from control wells were
inoculated on to chocolate agar at time zero. After 60 min incubation serial dilutions
were performed and 10 ,.11 aliquots were inoculated onto chocolate agar. The
chocolate agar plates were incubated as previously described (Section 3.2.1).
After overnight incubation, the number of colonies at each dilution of RaFBA and
RaGAPDH-l were counted, and the serum bactericidal titer was reported as the
reciprocal of the serum dilution yielding 2: 50% killing of the bacteria. Control wells
included: a serum with known bactericidal activity (anti-meningococcal whole cell);
a complement control containing PBS-BSA, complement and bacteria; an inactive
complement control containing RaFBA or RaGAPDH-l serum, heat inactivated
complement, and bacteria; an antibody control containing PBS-BSA, RaFBA or
RaGAPDH-l serum and the bacteria to determine that the organisms were viable in
antibody in the absence of complement).
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4.2.8 Transgenic mouse model of meningococcal bacteraemia
Murine bacteraemia studies were performed at the Pasteur institute by Or M. K. Taha
as previously described (Zarantonelli et al., 2007). Briefly, prior to challenging with
meningococcal isolates, mice were kept in a biosafety containment facility in cages
with sterile litter, water, and food according to institutional guidelines. The
experimental design was approved by the lnstitut Pasteur Review Board (France).
Mice were infected at 6 weeks of age by intraperitoneal challenge with standardized
inocula (5 x 106 CFU). Bacterial counts in the blood were determined 2,6, and 24 h,
after meningococcal challenge by plating serial dilutions of blood samples on GCB
medium and were expressed in loglO CFU ml" of blood. Student's t-test and analysis
of variance were used to examine the data. A P value of 0.05 was considered
statistically significant.
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4.3 Results
4.3.1 Fructose bisphosphate aldolase activity
A coupled enzymic assay using native recombinant FBA was used to confirm that
the purified meningococcal FBA was active as a fructose bisphosphate aldolase (Fig.
4.1), despite the apparent lack of an intact EMP pathway in this organism. The
kinetic parameters for the purified enzyme for the cleavage of FBP were estimated as
Km (FBP) = 0.05 mM and kcat = 126 min-toThese values are similar to those found
for FBA enzymes from a variety of sources such as E. coli (Km (FBP) - 0.19 mM
and kcat - 490 min-I) (Plater et al., 1999).
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Figure 4. 1 Kinetic analysis of the rFBA The enzyme activity was measured using
different substrate (FBP) concentrations (0.1 mM-S.O mM) under standard reaction
conditions for one min. A decrease in absorbance at 340 nm was recorded as the
measure of enzyme activity. Activities were calculated using the molar extinction
coefficient for NADH as 6220 M-t cm-toKinetic parameters were estimated using the
Origin Pro 7.5 software program.
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4.3.2 Distribution and expression of cbbA in N.meningitidis
Due to the accessible outer membrane location, immunogenic nature and potential
roles in pathogenesis, glycolytic enzymes have been suggested as possible candidate
vaccine antigens against several infections caused by Gram-positive bacteria and
fungi (Gil-Navarro et al., 1997; Kim & Dang, 2005; Ling et al., 2004; McCarthy et
al., 2002). One important prerequisite for a vaccine candidate is that a large
proportion of target strains should possess and express the relevant antigen. To
assess the presence of the cbbA gene and FBA expression in the N. meningitidis
population, 26 clinical isolates of N. meningitidis, representative of the three main
disease-associated serogroups (A, B, C,), were screened by PCR and/or immunoblot
analysis. The analysis also included one strain each of N. gonorrhoeae, N.
polysacchareae and N. lactamica. All of the isolates examined were positive by PCR
for the presence of cbbA. The PCR resulted in amplification of a single DNA
fragment of ca. l-kb in all assayed strains (Fig. 4.2 A and B). Having established that
cbbA is present in all strains tested, we investigated expression of its gene product
FBA. Total cellular proteins were immunoblotted using the anti-FBA rabbit serum.
A protein band with an apparent molecular mass of ca. 38-kDa corresponding to
FBA was detected in all strains tested (Fig 4.3 A, B, C). In addition, N. lactamica, N.
gonorrhoeae, and N. polysacchareae were also positive for FBA expression (data not
shown).
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Figure 4.2 Distribution of the cbbA gene and prevalence of cbbA in diff r nt clini al
isolates of N. meningitidis of known-MLST type (A) Lane I, DNA marker, lane 2,
MC58-WT, lanes 3-11 Z1035, Z1054, Z1213, Z1503, Z4676, Z1534, Z3771, Z 42,
Z4662 respectively (B) Lane 1, DNA markers, lanes 2-4,- Z467 , Z 41 ,Z641 ,
Lane 5, MC58llcbbA, lanes 6-11, Z6420, N gonorrho ae, Z41 I, Z4667, Z4 7 ,
Clone 12 CST-11), respectively. PCR-amplified products c mpri ing th mplet
cbbA (1065 bp) of 17 meningococcal strains with known ML T-typc were b crvcd
in all strains examined.
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Figure 4. 3 FBA expression in divergent clinical isolates of N. meningitidis. Whole
cell proteins were resolved by 10% SOS-PAGE followed by imrnun bl t analysi
using RaFBA. The FBA is present in whole-cell Iysates of all strain examined (A)
Lane 1, protein markers, lanes 2-5, Z1035, Z1054, Z1213, Z 1269 r sp ctively, lane
6, Me58~cbbA, lanes 7-10, Z1503, Z377l, Z3842, Z4l81, respectively (B) Lane I,
protein markers, lane 2, Me58-WT, lanes 3-10, Z4662, Z4667, Z4673, Z4676,
Z4678, Z5826, Z6413, Z6414, respectively (C) Lane 1, prot in markers, lane 2,
Me58-WT, Lane 3, Me58~cbbA, Lanes 4-8, Z4684, Z4685, Z4701 Z6417, Z4 2 ,
respectively. A band corresponding to FBA was observed in all train examined
except the cbbA null mutant.
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4.3.3 Sub-cellular location of cbbA inN. meningitidis
To localise cbbA in the meningococcus, and to determine whether FBA may be
exported to the surface of N. meningitidis, sub-cellular fractions were probed with
RaFBA. FBA was predominately detected in the outer membrane-enriched and the
cytosolic protein fractions of wild-type MeS8 and complemented cbbA isogenic
mutant strain. (Fig. 4.4 A and B), but was absent from the concentrated culture
supernatant (secreted protein fraction). FBA was not detected in fractions derived
from Me58dcbbA (Fig. 4.4 D). Although experimental artifacts due to partial cell
lysis cannot be ruled out, it is clear that these proteins have a strong propensity to
interact with the cell wal1of many bacteria. However, to exclude the possibility that
the presence of FBA in outer membrane-enriched fraction was due to autolysis with
the attachment of released FBA to the surface of unbroken cells, whole cell lysate of
MeS8- WT cells was mixed with intact MeS8LkbbA cells and incubated at RT
followed by cell fractionation. Interestingly, FBA was not detected in the outer
membrane-enriched fraction of these cells (Fig. 4.4 e) confirming that the FBA does
not bind to the cell surface as a consequence of autolysisicellieakage. Additionally,
immunoblotting experiments with antiserum against PorA, a known outer membrane
protein of N. meningitidis, gave an identical profile except that PorA was absent
from the cytosolic fraction (data not shown). These results confirm that
meningococcal FBA is a cytosolic protein, but is also translocated to the outer
membrane.
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Figure 4.4 Subcellular localization ofFBA (A) MC-WT (B) MC58 cbbA cbbA/~(·'
(C) MC58.1cbbA mixed with MC58-WT sonicated lysate (D) MC5 cbhA ell
fractionation. In all Figs, lane 1, protein markers, lanes 2, peripia mi pr teins, Ian
3, cytoplasmic protein-enriched fractions, lane 4, cytopla mic m mbrane pr t in-
enriched fractions, and lane 5, outer membrane protein-enriched fraction (adju tcd
to ensure equal protein loading). All samples were eparated on a 10% a rylarnid
gel and probed in immunoblotting experiments with RaFBA. A band orresp nding
to FBA was observed in outer membrane enriched fraction of WT-M 5 and th
complemented strain and was absent from the isogenic null mutant.
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4.3.4 Distribution and expression of gapA-l in N. meningitidis strains
The gapA-l gene has been shown to be up-regulated following meningococcal
interaction with host cells demonstrating that it may be involved in a critical step of
pathogenesis. We examined the presence of gapA-l and its expression in population
of N. meningitidis. A total of 17 strains of known MLST-type representing most of
the known virulent lineages were screened by peR for the presence of a gapA-l
homologue. All neisserial isolates tested by this peR screening method yielded a
single amplified product of the expected size ca. l-kb corresponding to gapA-l (Fig.
4.5 A and B). Additionally, after demonstrating that gapA-l was present across all
the meningococcal strains screened by peR, we extended this analysis to
demonstrate that gapA-l is expressed in vitro in the same panel of strains. Whole-
cell lysates of the 17 neisserial isolates were examined by immunoblot analysis to
detect the presence of a GAPDH-l protein using RaGAPDH-l antiserum. All
neisserial isolates expressed an immunoreactive GAPDH-l protein, with the
exception of Me58~apA-l, demonstrating that the gene is expressed in diverse
clinical isolates of meningococci (Table 4.1, and Fig.4.6 A, B and e). In addition,
single isolates of N. gonorrhoeae strain FA1090 was also examined. The protein
band corresponding to the GAPDH-I was detected in this isolate (Fig. 4.6 C).
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Figure 4. 5 Distribution of the gapA-I gene in diverse clinical i olates of N.
rneningitidis (A) Lane 1, DNA markers, Jane 2, MC58- WT, lanes 3-10, Z I035,
Z1054, ZI213, ZI503,Z4676, Z1534, Z3771, Z3842, respectively. (8) Lane I, DNA
markers, lane 2-10, Z4678, Z6413, Z6414, Z6420, N. gonorrho ae FA I090, Z41 I,
Z4667, Z4673, Clone 12 (ST-Il), respectively. PCR-amplified pr du ts r the
expected size of gapA-I (1032 bp) were observed in all 17 meningoc ccal train
examined.
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Figure 4.6. The gapA-l gene is expressed across divergent clinical is latcs of N.
meningitidis. Whole cell extracts were separated by 10% SDS-PAG followed by
immunoblot analysis using RaGAPDH-l. The GAPDH-l i dete tcd in wh I - ell
Iysates of all strains tested. (A) Lane 1, protein mark rs, lane 2, M 5 -WT, lane 3,
MC58tlgapA-l, lanes 4-10, Z1035, Z1054, Z1213, Z1503, Z4676, Zl5 4, Z 771,
respectively (B) Lane 1, protein markers, lane 2, MC58-WT , lane 3, M 5 ap'A-L,
lanes 4-10 Z4678, Z6413, Z6414, Z6420, N. gonorrhoeae strain A I090, Z41 I,
Z4667, respectively (C) Lane 1, protein markers, lane 2, M 5 -W , lane
MC58tlgapA-l, lanes 4-6, Z4673, Z3842, Clone 12 (ST-II), re p ctively. A pr tcin
band corresponding to GAPDH-l was observed in all strains xamin cl c 'pt
MC58tlgapA-l mutant strain.
163
4.3.5 Sub-cellular localization of gapA-l inN. meningitidis
Since the GAPDH has been described to be present on the surface of cells of several
microbial species (Fernandes et al., 1992; Goudot-Crozel et al., 1989; Pancholi &
Fischetti, 1992) and recently three proteins from N. meningitidis (enolase, DnaK, and
peroxiredoxin), which are usually intracellular proteins, have been shown to be
located in the outer membrane of N. meningitidis (Knaust et al., 2007) , we
undertook to investigate the presence of a cell wall-associated form of GAPDH in
outer membrane-enriched fractions obtained from N. meningitidis. The sub-cellular
fractions of wild-type MCS8 were probed using RaGAPDH-l. GAPDH-l was
predominately detected in the cytosolic fraction and a proportion was also present in
the outer membrane-enriched fraction, but was absent from the concentrated culture
supernatant (secreted protein fraction) (Fig. 4.7). A trace amount, possibly
representing transient GAPDH-l during translocation across the inner membrane,
can also be seen in the cytoplasmic-membrane enriched fraction. GAPDH-l was not
detected in fractions derived from MCS8~apA-l (data not shown). These results
confirm that meningococcal GAPDH-l is a cytosolic protein, but is also found in the
outer membrane.
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Figure 4. 7 Sub-cellular localization of GAPDH-l in N meningitidis MC58- WT cell
fractionation Lane 1, protein markers, lanes 2-6, periplasmic protein-enriched
fraction, cytoplasmic membrane protein-enriched fractions, cytoplasmic membrane
protein-enriched fractions, outer membrane protein-enriched fractions, and secreted
proteins (and adjusted to ensure equal protein loading) respectively. Protein wer
separated on a 10% acrylamide gel and probed in immunoblotting experiments with
RaGAPDH-l. A protein band corresponding to GAPDH-l was ob erved in outer
membrane-enriched fractions.
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4.3.6 Determining the surface exposure of FBA and GAPDH-l
4.3.6.1 Biotinylation of surface-exposed proteins
As a complementary approach to investigate the surface exposure of FBA and
GAPDH-l in N meningitidis, a novel biotinylation method was employed. Thi
method has been shown to discriminate truly surface-accessible proteins from
cytoplasmic and peri plasmically oriented proteins (Myers-Morales et al., 2007). This
experiment was aimed to biotinylate the surface of intact N meningitidi -WT, cbbA
and gapA-l null mutant strains followed by SDS-PAGE analysis and
immunoblotting using anti-biotin antibodies. The protein bands corresponding to
FBA and GAPDH-l were anticipated to be present only in MC58-WT samples but
should be absent in the respective isogenic null mutants. As can be seen in Fig 4.8
due to either high background or a large amount of biotin-labeled proteins, no clear
difference in the profiles of the three samples was observed on immunoblotting.
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Figure 4. 8 Immunoblot analysis to investigate the surface-expo d bi ntinylat d
proteins of N meningitidis Lane 1, protein markers, lane 2, M 5 -W , lane 3,
MC58t1cbbA, lane 4, MC58t1gapA-l
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4.3.6.2 Whole cell ELISA
To investigate the presence of FBA on the surface of N meningitidis, an FBA
ELISA was performed using whole cells of N meningitidis followed by probing with
different concentrations of anti-FBA antibodies. As the target antigen, the ELISA
included encapsulated N. meningitidis cells from strain Me58 or the same strain in
which the cbbA gene had been deleted (Me58~cbbA). With anti-FBA antiserum,
strain Me58 showed significantly higher binding (P value 0.015) in the whole-cell
ELISA compared to that of its isogenic cbbA mutant strain (Fig. 4.9). The ELISA
demonstrated that the FBA antiserum recognized antigen(s) on the meningococcal
cell surface, indicating that the protein was present and in a conformation that could
be recognized by the serum raised against the recombinant protein.
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Figure 4. 9 Whole bacterial cell ELISA to determine the binding of anti-FBA
antibodies to intact N meningitidis cells. ELISA plates were coated with various
dilutions of rabbit anti- FBA antibodies. The plate contents were reacted with labeled
intact N. meningitidis cells followed by anti-digoxygenin antibodies. ABTS substrate
was added and absorbance was measured at 405 nm in a microplate ELISA reader
(BioTek). Bars denote standard error of the mean. Experiments were repeated three
times, with consistent results.
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4.3.6.3 Flow cytometry analysis
In order to provide confirmatory evidence for the localization of FBA on the
bacterial cell surface, and to substantiate the sub-cellular fractionation results
showing the outer membrane localisation of FBA, the poJycJonal mono-specific
antiserum raised against the natively purified rFBA (nRuFBA) was used to probe
intact N. meningitidis strain MCS8 cells followed by treatment with secondary
antibody conjugated with Alexa Flour 488. The stained cells were visualized by flow
cytometry. Control cell samples that were either treated with nRuFBA polyclonal
antiserum alone or with Alexa Flour conjugated secondary antibody alone did not
produce significant fluorescence signals. In comparison, the cells stained with both
nRaFBA antibody followed by Alexa Flour 488 conjugated secondary antibody,
demonstrated a significant shift in the fluorescence signals (approximately 79% of
cells in the population were strongly fluorescent), indicating cell surface localization
of FBA (Fig. 4.10 A). As an additional negative control, MC58~cbbA mutant cells
were also examined using the same conditions. The FBA mutant cells showed no
significant fluorescence signal (Fig. 4.10 B). The proportion of surface expressed
FBA seems to be promising and may be sufficient to endow a biologically distinct
phenotype to the bacterium. These results are also consistent with data obtained from
the association assays, which showed that FBA is required for optimal in-vitro
interactions with cultured epithelial and meningothelial cells.
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Figure 4. 10 Flow cytometry analysis of MC58 wild-type (A) or MC58~cbbA cells
(B) for FBA surface localization. Cells were stained with nRaFBA alone, (control 1)
anti-rabbit IgG-Alexa Flour 488 conjugate alone (control 2) or both (test).
Flourescence was displayed as a histogram. The histogram area in M2 represents the
population offluorescently labeled meningococci.
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To investigate the surface exposure of GAPDH-I, flow cytometry analysis was
performed on live bacteria during the logarithmic phase of growth, using GAPDH-l
antiserum. The encapsulated wild-type MCSS and isogenic gapA-I mutant strains
were stained with anti-GAPDH-l followed by Alexa Flour 488. The fluorescence
intensity was measured by flow cytometry. As shown in Fig. 4.11 A and B,
polyclonal anti- GAPDH-l antibodies failed to bind to either the encapsulated
MCS8-WT or the MC5S.1.gapA-I strain demonstrating that GAPDH-l was not
surface exposed in capsulated strains. There can be several reasons for failure of
GAPDH-l to bind to the surface of encapsulated meningococci. RaGAPDH-l was
raised against the denatured purified protein and linear proteins may lack important
conformational epitopes present in the naturally folded protein, or the protein may
reach to the surface transiently and at specific phases of growth. Additionally, it is
also known that the polysaccharide capsule can functionally mask membrane
proteins. We, therefore, used a capsule mutant MCS8 strain and followed the binding
of the antibodies to the surface of intact cells by flow cytometry. The data
demonstrated a significant shift in the fluorescence signal (Fig. 4.12) (approximately
25% of cells in the population were fluorescent) indicating that GAPDH-I was
available for binding in the absence of polysaccharide capsule suggesting that the
presence of the capsule may hinder the binding of the antibody. In summary.
GAPDH-I is an outer membrane localized protein which is only surface exposed in
the non-capsulated strains. In contrast, in a capsulated background the OAPDH-l
could be masked by the capsule.
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Figure 4. 11 Flow cytometry analysis ofMC58 wild-type (A) or MC58~gapA-l cells
(B) for GAPDH-l surface localization. Cells were stained with RaGAPDH-l alone,
(control 1) anti-rabbit IgG-Alexa Flour 488 conjugate alone (control 2) or both (test).
Flourescence was displayed as a histogram.
--- :\IC5Msi.aD(Controll)
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Figure 4. 12 Flow cytometry analysis showing binding of mouse polyc1onal anti-
rGAPDH-l antiserum to live nonencapsulated N. meningitidis strains Cells were
stained with RaGAPDH-l alone, (control 1) anti-rabbit IgG-Alexa Flour 488
conjugate alone (control 2) or both (test). Flourescence was displayed as a
histogram. The histogram area in M2 represents the population of fluorescently
labeled meningococci.
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4.3.7 Serum bactericidal assay (SBA)
The ability of RaFBA and RaGAPDH-I antisera to kill meningococcal cells in
presence of complement was determined. Prior to using the sera in bactericidal
assays, both polyclonal antisera were pre-adsorbed with their respective isogenic
mutant strains to remove non-specific antibodies that might result in non-specific
killing. The antisera were used at various dilutions: 1:10, 1:50, and I: 100.
Bactericidal activity was not observed with antisera raised against either FBA or
GAPDH-l (data not shown). Positive control assays using anti-whole meningococcal
serum consistently gave 100% killing. No killing was seen in control wells lacking
active complement, serum, or both. To exclude the possibility that capsule may limit
the accessibility of the proteins on the surface, a siaD (encoding capsule) mutant N.
meningitidts strain MeS8 was used in the assay. Unfortunately, this strain seemed to
be sensitive to both pre-immune and immune sera, thus, it was not possible to
interpret the impact of either of the antisera on the killing of N. mentngitidis siaD
mutant strain.
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4.3.8 Evaluation of cbbA mutant strains using a transgenic mouse model of
infection
A transgenic mouse model expressing human transferrin (bTf) bred under specific-
pathogen-free conditions was established from line 803 C57B6/SJU mice at the
Institut Pasteur (Zarantonelli et al., 2007) to use as a model of meningococcal
bacteraemia. To provide further insights into the potential role of FBA in the
development of bacteraemia, six-week-old female B6/SJL mice expressing (hTf)
were infected by intraperitoneal injection of N. meningitidis-WT, Z4181-WT, Clone
12-WT (ST-18), 24198-WT (ST-ll) (Zarantonelli et al., 2007), and their isogenic
cbbA-mutant strains at a dose (5 x 106 CFU) in groups of five mice for each wild-
type, and compared to a group of five mice that were administered cbbA mutant
strain. Mice were able to survive with the 5 x 106CFU dose, and bacteraemia could
therefore be assessed by blood cultures at 2, 6, and 24 h post inoculation. All
meningococcal wild-type isolates examined were shown to induce bacteraemia in the
transgenic mouse model whereas the isogenic mutant strains showed a reduced
capacity to establish bacteraemia. The number of bacteria recovered at different time
points is shown in (Fig. 4.13 and Table 4.2) and demonstrate that there were
significant differences in the level of bacteraemia established by the mutant strains
compared to the wild-type.
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Table 4.2 Meningococcal strains used for mouse model of meningococcal
bacteraemia. The data denote bacteria per milliliter of blood using means of 5 mice
per time point and per strain.
Strains t=O 2h 6h 24h
. . .MC58-wt
MC58-tlFBA
Z4181-wt
Z4181-MBA
Clone 12 -wt (ST-I8)
Clone12-MBA
24198wt (ST-11)
24198L'1FBA
3.45 x 10
1.25 X 107
1.10x107
2.40 x 106
5.50 x 106
2.60 x 106
5.75 x 106
1.90 x 106
2.82 x 10
1.46 x 105
2.38 x 106
1.20 x 104
2.45 x 106
2.10 x 104
2.16 x 106
3.60 x 106
2.54 x 10
1.05 x 105
3.50 x 106
2.72 x 103
1.31 x 106
1.60 x 104
4.03 x 106
2.90 x 104
2.60 x 10
1.78 x 102
2.51 x 106
1.00 x 101
2.21 x 105
4.20 x 101
3.50 x 105
1.00 x 101
1.0E+'08
1.0E+'07
1.0E+06
E 1.0E+05
~
o 1.0E+04
-Cl!!: 1.0E+'03
1.0E+'02
1.0E+01
1.0E+OO
Time (hrs)
-+-MC58·wt
-+-MC58. ~FBA
-+-Z4181 . wt
~Z4181 . ~FBA
-Io-Clone12 -wt (ST.18)
Clone12 . ~FBA
-+-24198wt (ST.11)
24198~FBA
Figure 4. 13 Bacteraemia in hTf transgenic mice after intraperitoneal meningococcal
challenge. Transgenic mice expressing hTf (B6/SJL hTt) were challenged
intraperitoneally with 5 x 106 CFU of N meningitidis- WT, Z4181- WT, Clone 12-
WT (ST-18), 24198-WT (ST-ll) and their isogenic cbbA-mutant strains. The data
are the means and standard deviations from five independent experiments with
groups of five mice per time point in each experiment.
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4.4 Discussion
This chapter describes the molecular and functional characterisation of FBA and
GAPDH-l of N. meningitidis, with the aim of identifying their additional non-
glycolytic roles. Recent qualitative proteomic studies of N. meningitidis have shown
that OMV vaccines also contain a high number of periplasmic and cytoplasmic
proteins (Ferrari et al., 2006; Jun et al., 2007; UIi et al., 2006; Vipond et al., 2006).
For example in OMVs from serogroup B N. meningitidistlgna33, although the vast
majority of proteins belonged to the outer membrane compartment, the minority of
cytoplasmic proteins were experimentally shown to be surface-associated and
exposed in N. meningitidis, Here we demonstrate that FBA and GAPDH-l of N.
meningitidis, besides being present in the cytoplasmic compartment, are also outer
membrane localised proteins.
According to our in silico sequences analysis, cbbA and gapA-l appears to be highly
conserved genes in N. meningitidis. peR analysis confirmed the presence of cbbA
and gapA-l in all clinical isolates tested. Expression ofFBA and GAPDH-l (ca. 38-
kDa and ca. 37-kDa, respectively) was detected in whole cell proteins preparations
from all meningococcal strains, representative of different hyper-virulent lineages,
examined in this study. In an effort to establish whether FBA and GAPDH-l localise
on the surface of meningococci, a cell fractionation approach was employed (Nossal
& Heppel, 1966). The fractionation results demonstrated a protein band of apparent
molecular mass of ca. 38-kDa corresponding to FBA in the cytosolic and outer
membrane fractions. This indicates that FBA is localised to the outer membrane as
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well as the cytoplasm of N. meningitidis. Similarly, GAPDH-l was also found
localised to the outer membrane of N. meningitidis. In spite of a growing list of
cytoplasmic proteins identified on the bacterial surface, the mechanism(s) of their
surface localization and attachment to the bacterial envelope remain unclear. These
proteins do not appear to possess signal peptides that direct proteins into secretory
pathways, and nor do they appear to have any known cell wall-anchoring motifs.
Further experiments are needed to elucidate the mechanism(s) of delivery and
attachment of these proteins to the bacterial surface.
Based on the sub-cellular fractionation results indicating the outer membrane
localisation ofFBA and GAPDH, surface expression ofFBA and GAPDH-I proteins
was further investigated by using a combination of immunological and molecular
techniques. Initially, a biotin labelling technique was applied to intact bacterial cells
(Myers-Morales et al., 2007). The data from immunoblot analysis profile showed a
large number of biotinylated proteins which masked the protein bands corresponding
to FBA or GAPDH-l. Subsequently, a whole-cell ELISA was used to determine the
accessibility of polycIonal antiserum to bind to the surface of encapsulated
meningococci. The data provided evidence that the binding of polyclonal anti-FBA
serum to the intact Me58 wild-type cells was significantly higher compared to the
isogenic null mutant indicating the surface expression of FBA in N. meningittdis. To
further support these findings, flow cytometry analysis was performed, The data
presented here demonstrates that FBA protein was abundantly associated with the
external side of the bacterial membrane and accessible to antibodies as indicated by
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the fluorescence intensity shift observed upon antibody binding. FBA was available
at the cell surface with levels of fluorescence comparable to those found with
recognised surface antigens such as NMBI468 (Chi-An et al., 2008), NMB2132 and
NMB2091 (Giuliani et al., 2006), although considerably lower than other surface
antigen such as fHbp (Giuliani et al., 2006). Despite being found localised to the
outer membrane by the cell fractionation method, the results of flow cytometry
indicated that the GAPDH-I was not accessible to antibodies on the surface of
encapsulated wild-type cells. A possible explanation of the failure of GAPDH-l
antiserum to bind to the bacterial surface could be that surface exposure of this
protein may be transient or only occurring during specific phase of the
meningococcal cell cycle, or it may indeed be located on the outer surface of the
membrane, but inaccessible from the antibodies due to the polysaccharide capsule. In
a previous study, Grifantini et al. used microarrays to show that expression of gapA-
I was up regulated in meningococcal strain MCS8 (4.8-fold) following contact with
human 16HBE14 epithelial cells (Grifantini et al., 2002a; Grifantini et al., 2002b).
Subsequent flow cytometry experiments showed that GAPDH-l could be detected
on the cell surface of free grown and adherent meningococci (Grifantini et al.,
2002b). However, the methodology used involved a pre-treatment of cells with 70%
ethanol to permeabilize the capsule layer, thus making it unclear if GAPDH-l is
antibody-accessible in encapsulated meningococci. To address this issue, a siaD
(encoding capsule) mutant meningococcal strain was probed with GAPDH-l
antiserum followed by flow cytometry analysis. The data showed a significant shift
in the intensity of fluorescence indicating that GAPDH-l could only be detected on
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the meningococcal cell surface in mutants lacking capsule, suggesting that
GAPDH-I is usually masked.
The induction of functional antibodies after immunization with recombinant proteins
has been a tremendous challenge during the evaluation and development of
meningococcal vaccine candidates. Anti-FBA and anti-GAPDH-l were tested for
their ability to promote in vitro complement-mediated killing of N. meningitidis
MCS8. Unfortunately, neither of the antibodies was found to exhibit bactericidal
activity against N. meningitidis. The reason for lack of bactericidal activity could be
due to the fact that the FBA and GAPDH-l antisera used in the serum bactericidal
assay were raised against denatured purified recombinant proteins. Several studies
with recombinant meningococcal antigens, including PorA (Christodoulides et al.,
1998; Niebla et al., 2001) and PorB (Wright et al., 2002), have clearly demonstrated
that the production of bactericidal antibodies is dependent on refolding of the protein
to produce a native conformation. Hence, these antibodies were unlikely to recognise
surface-exposed, conformational epitopes, which may be important in vivo.
Antibodies raised against histidine-tagged NspA were shown to recognise epitopes
that are present in denatured NspA but not in native NspA on the surface of live
meningococcal cells (Moe et al., 1999). In future work, the bactericidal activity of
anti-FBA serum raised against natively purified rFBA will be determined.
This study demonstrates that both FBA and GAPDH-l, well-known cytoplasmic
proteins, are present on the surface of neisserial cells and so may be involved in the
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normal in vivo immune response to live meningococcal cells. The presence of
neisserial "cytoplasmic" proteins on the surface has been reported previously. For
example, Ferrari et al. (Ferrari et al., 2006) found enolase, Hsp60, TufA and
glyceraldehyde 3-phosphate dehydrogenase (gapA-2 not gapA-l) on the neisserial
surface by flow cytometry while other researchers have identified RplL (Spence &
Clark, 2000; Spence et al., 2002), and DnaK, (Knaust et al., 2007) as being surface
exposed.
In addition, FBA was shown to be essential for bacteraemia in a novel transgenic
('humanised') mouse model of infection. All five isogenic cbbA mutants created in
five different genetic backgrounds of N. meningitidis were impaired in their ability to
sustain bacteraemia compared to their wild-type parent strains indicating that FBA
may play a potential role in the pathogenesis of meningococcal disease. This result
suggests that the mutants were less able to access the bloodstream and/or to survive
in the bloodstream after intraperitonial inoculation compared to Wild-type. In future
work, the antiserum raised against purified FBA in native form (retaining aldolase
activity) will be used in a passive protection experiment using the transgenic mouse
model to determine whether anti-FBA antibodies elicit a protective response against
N. meningitidis.
In summary, purified recombinant FBA protein was found to be ezymatically active.
The data represented in this chapter indicates that FBA and GAPDH-I are both
highly conserved in pathogenic N. mentngitidis strains and that FBA and GAPDH-l
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are constitutively expressed in all N. meningitidis strains examined. Besides their
cytosolic location they are also localised to the outer membrane of N. meningitidls.
Additionally, FBA was shown to be available to antibodies on the surface of intact
capsulated N. meningitidis cells. This is the first time that FBA has been
demonstrated on the surface of a Gram-negative bacterium. However, GAPDH-l
was only accessible to antibodies on the surface of non-capsulated meningococci.
Furthermore, in vivo studies demonstrated the potential role of FBA in the
pathogenesis of the meningococcal disease.
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CHAPTER 5: Determining the roles of FBA and GAPDH·1 In
meningococcal association to human cells
181
5.1 Introduction
In this chapter the potential roles of FBA and GAPDH-l in meningococcal adhesion
to, and invasion of, cultured human epithelial and endothelial cells are discussed.
Adhesion of pathogens to host tissue has gained increasing attention as an important
initial event in the pathogenesis of bacterial infections before colonization and
eventual invasion of these surfaces (Beachey, 1981). The meningococcus is a
common commensal of the human nasopharynx, which in a smaIl percentage of
carriers, crosses the epithelial barrier and gains access to the bloodstream.
Colonization of the nasopharynx is a complex and incompletely understood process,
which involves long-range attachment to host epithelial cells via type IV pili,
remodeling of the meningococcal outer membrane, and interactions between several
additional bacterial adhesins including Opa, Ope, LOS, tHbp, PorA, HrpA, PorB and
NadA and proposed or demonstrated host cell receptors including platelet activating
factor, CD46, CEACAM 1, vitronectin and u-actinin integrins, complement receptor
3, laminin and the GP96 scavenger receptor (reviewed in Stephens, 2009). Following
bacteraemia, N. meningitidis may bind to and subsequently cross the blood-
cerebrospinal fluid (B-CSF) barrier to enter the sub-arachnoid space, resulting in
acute and purulent meningitis (Nassif et al.• 2002).
Glycolytic enzymes, such as GAPDH, enolase and FBA have been reported as
potential virulence factors in a variety of organisms (Pancholi & Chhatwal, 2003).
Although long recognized for their cytosolic role in glycolysis and gluconeogenesis,
additional or 'moon-lighting' functions have been increasingly recognized. In
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particular, despite lacking identifiable secretion signals, glycolytic enzymes have
been found on the bacterial cell surface where they interact directly with host soluble
proteins and surface ligands. In Mycoplasma genitalium, surface-associated GAPDH
was shown to be important for adhesion to human mucin (Alvarez et al., 2003). In S.
pyogenes and C. albicans surface-associated GAPDH was shown to bind to
fibronectin (Gozalbo et al., 1998; Pancholi & Fischetti, 1992) In S. pneumoniae,
surface-associated FBA was shown to bind to transmembrane receptor belonging to
the cadherin superfamily (Blau et al., 2007). FBA and GAPDH were also shown to
be immunogenic in humans and capable of inducing a protective immune response
against S.pneumoniae in mice (Ling et al., 2004). In addition, FBA was found to be
a surface-localized immunogenic protein in S. suis (Zongfu et al., 2008) and a
potential role for FBA in immunity to nematode parasite Onchocerca volvulus has
also been described (McCarthy et al., 2002).
The aim of this chapter was to explore whether, like these other examples,
meningococcal FBA and GAPDH-l are involved in adhesion to, and invasion of,
host cells.
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5.2 Materialsandmethods
S.2.1 Bacterial strains, growth conditions and media
Bacterial strains described in this chapter are listed in (Table 3.1 and 3.3). Growth
conditions and media for culturing meningococci and E. coli are described in Section
2.2.1. Mutant and complemented strains were created as described in Chapter 3.
Antibiotics were used at the following concentration: kanamycin (SO ug ml") or
erythromycin (5 ug ml"),
S.2.2 Preparation of meningococci
N. meningitidis strains, MCS8-WT, MCS8f1cbbA, MCS8flgapA-l, MCS8f1cbbA
cbbAEcI and MC58&gapA-l gapA-IEcI were streaked onto chocolate agar plates and
incubated as described in section 3.2.1. The following day, a single colony was
inoculated into 10 ml Dulbecco's Modified Eagle Medium (DMEM; Invitrogen)
containing 2% heat-inactivated fetal calf serum (FCS; Invitrogen) and incubated
overnight at 37°C with shaking (200 rpm). The following day, overnight broth
culture was diluted 1:lOin DMEM containing 2% FCS and further grown for 2 h.
5.2.3 Preparation of human cells
Human brain microvascular endothelial (HBME) cells or human larynx carcinoma
(HEp-2) cells were grown to confluence in DMEM supplemented with 10% FCS and
1% antibiotic antimycotic solution (Sigma) in 24-well tissue culture plates (Costar)
at 37°C in an atmosphere of 5% C02. Prior to all experiments, mono-layers were
transferred to DMEM supplemented with 2% FCS to remove the antibiotics.
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5.2.4 Association assay
Association assays were performed essentially as previously described (Oldfield et
al., 2007). Briefly, HBME or HEp-2 monolayers were infected with 1 x 106 CFU
ml" of meningococci (confirmed retrospectively by plating out aliquots of serially
diluted inoculums) and left to associate for 2 h in 5% C02 at 37°C. To assess total
cell association, monolayers were washed four times with 1 ml 1 x PBS per well.
The mono layers were then disrupted and homogenized in 1ml 0.1% saponin in PBS.
Meningococci were enumerated by serial dilution of the homogenized suspensions
and subsequent determination of colony-forming units by plating 10 III spots from
appropriate dilutions of the lysates on agar.
5.2.5 Adhesion inhibition assay
To block bacterial adhesion, meningococci were incubated for 1 h at RT with
polyclonal anti-FBA sera at different dilutions ranging from I: J 00 to 1:500 in PBS.
The bacteria were pelleted by centrifugation (17,000 x g for 1 min) and washed
twice with PBS before being used to infect human cell monolayers as described in
section 5.1.4. Alternatively, monolayers were treated with 25 Ilg ml" of natively
purified rFBA or PBS only (negative control) for J h and the assay continued as
mentioned above (Section 5.2.4)
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S.2.6 Invasion assay
HBME or HEp-2 monolayers were infected as described in section 5.2.4, but were
left to associate for 4 h in 5% C02 at 37°C. The media was then removed and 2 ml
DMEM containing gentamicin (100 Jlgml") added per well to kill the extra-cellular
bacteria. Prior to further steps, aliquots of the gentamicin-containing supernatants
were plated out to confirm killing of extra-cellular bacteria. Furthermore, the
susceptibility of all meningococcal strains to gentamicin at 100 ug ml" was
confirmed prior to testing. To assess cell invasion, monolayers were washed three
times with 1 ml 1 x PBS per well. The monolayers were then disrupted and
homogenized in 1 ml 0.1% saponin in PBS. Meningococci were enumerated by
serial dilution of the homogenized suspensions and subsequent determination of
colony-forming units by plating 10 JlI aliquots from appropriate dilutions of the
lysates on agar.
S.2.7 Statistical methods
Statistical analysis was performed with Microsoft Excel. All experiments were
performed in triplicate unless otherwise stated and were repeated at least three times.
Statistical significance was measured using a two-tailed Student r-test.
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5.3 Results
5.3.1 Association assay of MC58AcbbA using HBME and HEp-l cells
To determine a potential role of FBA in adhesion to epithelial and endothelial cells,
viable counts of bacteria associated with homogenized infected monolayers were
used to compare the capacity of the wild-type and cbbA mutant strain to associate
with either HBME or HEp-2 cells. These experiments showed that cbbA-deficient
meningococci had a significantly reduced capacity to adhere to monolayers of
HBME cells and HEp-2. Experiments were repeated on three separate occasions,
with both cell lines, with consistent results. To confirm that this effect was not due
to reduced growth, the growth rate of both strains was compared by measuring the
optical density at 600 nm (OD600) in triplicate on three separate occasions. No
substantial differences between strains were observed (section 3.3.18 and Fig. 3.27
A).
To exclude the possibility that the impaired adherence was due to a polar effect or
undetected secondary mutation in MC58AcbbA, a wild-type copy of the gene was
introduced in trans into MC58AcbbA using plasmid pSAT-12 (Table 3.1).
Introduction ofpSAT-12 led to similar levels ofFBA expression to the MCS8-WT
(section 3.3.12 and Fig. 3.19) and restored levels of adhesion to both human cell
types to approximately wild-type levels (Fig. 5.1 A and 5.1 B). In summary, these
experiments show that FBA plays a role in the adherence of N. meningitidls with
human cells.
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In addition to complementation, to further rule out the possibility that the impaired
adherence was due to undetected secondary mutation in the original cbbA mutant,
the cbbA mutation was introduced by natural transformation into N. meningitidis
strain Z4673 to create an independent cbbA-deficient derivative. Adherence assays
with meningothelial cells showed that the Z4673 cbbA mutant exhibited a similar
reduction in the number of adherent bacteria compared with its parental strain as did
the Me58tJ.cbbA mutant (Fig. 5.2).
To study whether the impaired adhesion was due to the direct involvement of FBA
i.e. that FBA is an adhesin and binds a specific host cell receptor(s), cultured HBME
cells were incubated with or without rFBA before infection with N. meningitidis. The
adhesion to HBME cells by N. meningitidis Me58 could not be inhibited by rFBA
(data not shown). Alternatively, to further assess the involvement ofFBA in bacterial
adhesion, the wild-type strain Me58 was treated with polyclonal RaFBA serum, pre-
immune serum or not treated (negative control) to investigate whether this would
block adhesion. Treatment with either immune or pre-immune serum demonstrated
no substantial effect on bacterial adhesion (Fig 5.3). A possible reason for increased
number of adherent bacteria observed in the inhibition assay result was that the
bacteria used for infecting the monolayers were twice in number (2 x 106) as
compared to previous adhesion assays
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Figure 5.1. cbbA-deficient meningococci have a reduced ability to associate with (A)
HBME or (B) HEp-2 cells compared to the wild-type or complemented strains. The
number of cbbA-deficient meningococci associating to HBME cells was significantly
lower than the wild-type (P = 0.0011). Bars denote standard deviation. Cfu denotes
colony forming units. In (B), experiments were repeated on two separate occasions
with consistent results, but only one representative experiment is shown. Bars denote
deviation from the mean of quadruplicate samples from experiments repeated on two
separate occasions.
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Figure 5.2. cbbA-deficient Z4673 has a reduced ability to associate with HBME cells
compared to the wild-type strain. Mean levels shown from a representative
experiment using quadruplicate wells. Cfu denotes colony forming units. Bars denote
standard deviation from the mean of quadruplicate samples from experiments
repeated on two separate occasions. Experiments were repeated on two separate
occasions, with consistent results
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Figure 5.3. Inhibition of meningococcal association to HBME cells using RaFBA.
Wild-type MC58 was treated with RaFBA sera or pre-immune sera before infection
of HBME cells. Mean levels shown from a representative experiment using
quadruplicate wells. Cfu denotes colony forming units. Bars denote standard
deviation from the mean of quadruplicate samples Experiments were repeated on two
separate occasions, with consistent results.
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5.3.2 Invasion assay of MC58AcbbA using HBME and HEp-2 cells
To investigate whether FBA is involved in the internalization of N meningitidis into
epithelial and meningothelial cells, HEp-2 and HBME monolayers were infected
with wild-type MC58, MC58~cbbA and MC58~cbbA cbbAEcl• After 4 h of co-
incubation, any unattached or surface-adherent bacteria were killed by exposure to
gentamicin, after which viable intracellular bacteria were enumerated following
release by lysis with saponin. The results from three independent experiments using
the HBME cell line (Fig. 5.4 A) and from one representative experiment using the
HEp-2 cell line (Fig. 5.4 B), demonstrated that the cbbA-deficient MC58 had reduced
capacity to invade the monolayers, but this difference was not statistically significant
and is likely to be a consequence of the reduced adherence of the mutants to the
monolayer.
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Figure 5.4. cbbA-deficient meningococci have a reduced ability to invade into (A)
HBME cells or (B) HEp-2 cells compared to the wild-type or complemented strains.
Numbers of mutant cells invading HBME cells were lower than the wild-type strain,
but this difference was not statistically significant (P = 0.13). Mean levels shown
from three independent experiments, each using triplicate wells. Cfu denotes colony
forming units. Bars denote standard deviation. In (B), experiments were repeated on
two separate occasions with consistent results, but only one representative
experiment is shown. Bars denote standard deviation from the mean of quadruplicate
samples.
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5.3.3 Association assay of MCS8AgapA-l using HBME and HEp-2 cells
Viable counts of bacteria associated with homogenized infected monolayers were
also used to compare the capacity of the wild-type and gapA-l mutant strain to
associate with either HBME or HEp-2 cells. These experiments showed that
GAPDH-deficient meningococci had a significantly reduced capacity to adhere with
monolayers of HBME (Fig. 5.4 A) and HEp-2 cells (Fig 5.4 B). Experiments were
repeated on more than three separate occasions, with both cell lines, with consistent
results. Once again, to confirm that this effect was not due to reduced growth, the
growth rate of both strains was compared by measuring the optical density at 600
nm (OD6(0) in triplicate on three separate occasions. No substantial differences
between strains were observed (section 3.3.18 and Fig. 3.27 B).
The ability of the complemented strain to adhere to HEp-2 and epithelial cells was
then analysed. As shown in Fig. 5.5 A and B; complementation reversed the
adhesion defect of the mutant to wild-type levels. Taken together, the results strongly
suggest that gapA-l is involved in adhesion of meningococci to both epithelial and
endothelial cells.
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Figure 5.5. GAPDH-l-deficient meningococci have a reduced ability to associate
with (A) HBME and (B) HEp-2 cells compared to the wild-type or complemented
strains. The number of GAPDH-l-deficient meningococci associating was
significantly lower than the wild-type (HBME cells P = 0.0018, HEp-2 cells 0.017).
Mean levels shown from three independent experiments using quadruplicate wells.
Bars denote standard deviation. Cfu denotes colony forming units.
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5.3.4 Invasion assay of MC58L\gapA-I using HBME and HEp-2 cell line
To evaluate the role of gapA-l in the invasion of meningococcus into epithelial and
meningothelial cells, viable counts of bacteria released from homogenized infected
monolayers were used to compare the capacity of the Me58 wild-type,
MC58L\gapA-l and Me58L\gapA-lgapA-1Ect complemented strains to invade either
HBME or HEp-2 cells. The results from three independent experiments using the
HBME cell line (Fig. 5.6 A), and from one representative experiment using the
HEp-2 cell line represented in Fig. 5.6 B, show that the gapA-l-deficient Me58 are
less invasive than the parent strain and the complemented isogenic mutant strains,
however, this difference was not statistically significant. The reduced capacity to
invade is likely to be a consequence of the reduced adherence of the mutants to the
monolayer.
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Figure 5.6. GAPDH-l-deficient meningococci have a reduced ability to invade to
(A) HBME or (B) HEp-2 cells than the wild-type or complemented trains. The
number ofGAPDH-l-deficient meningococci invading HBME cell compar d t th
wild-type was not significantly different (P = 0.1338). Mean level hown fr m thr e
independent experiments, each using triplicate wells. Bars denote tandard d viati n.
Cfu denotes colony forming units. In (B) mean levels shown from a repre entative
experiment using quadruplicate wells. Bars denote standard deviation from the mean
of quadruplicate samples. Experiments were repeated on two eparat occa i n
with consistent results.
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5.4 Discussion
This chapter describes the characterisation of the potential roles of meningococcal
FBA and GAPDH-l in adhesion to, and invasion into, host cells in vitro using the
well-established HBME cells and HEp-2 cell models. Although regarded as an
extracellular pathogen generally, N. mentngitidis has the capacity to enter eukaryotic
cells by interacting with several distinct cellular receptors. This has been
demonstrated in numerous in vitro studies (Claudia Sa et al., 2009). The ability of
bacteria to colonize their hosts and cause infection is often linked to their ability to
express several different adhesins with different receptor specificities (Scarselli et
al., 2006). N. meningitidis has evolved a diverse array of surface structures to
interact with host cells. These include Type IV pili, which are considered to be the
prime attachment-promoting factor for capsulated meningococci to the
nasopharyngeal mucosa (ViIji et al., 1991), LOS and a number of outer membrane
proteins, such as Ope and Opa opacity proteins (Virji et al., 1992; Virji et al., 1993),
App (Hadi et al., 2001), NadA (Capecchi et al., 2005), NhhA (Scarselli et al., 2006).
and MspA (Turner et al., 2006), mediating interaction of meningococcus to host
cells. Since the genome of N. meningitidis strain MC58 contains genes encoding
several known adhesins (Virji, 2009), it is perhaps not surprising that ablation of
additional putative adhesins (i.e. FBA and GAPDH-l) did not dramatically reduce
adhesion in this model. Nevertheless, there was a significant reduction in adhesion
for the cbbA and gapA-l mutants compared to their wild-type parent strain.
indicating that cbbA and gapA-l playa role in association with human endothelial
and epithelial cells.
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Multifunctional, extra-cytoplasmic glycolytic enzymes acting as adhesins is not
unprecedented. For example, in Streptococcus spp. an extra-cytoplasmic GAPDH
has been described to mediate binding to plasmin and shown to possess an ADP-
ribosylating activity (Pancholi & Fischetti, 1992), while in C. albicans the
extracellularly localized GAPDH has been shown to bind fibronectin and laminin
(Gil-Navarro et al., 1997; Gozalbo et al., 1998). Likewise, FBA of S. suis (Zongfu et
al., 2008) and S. pneumoniae (Ling et al., 2004) has been shown to be immunogenic
and surface-localized proteins. In addition, S. pneumoniae FBA has, recently, been
demonstrated to act as adhesin mediating in vitro adhesion to host receptor Flamingo
cadherin on A549 type IIlung carcinoma epithelial cells (Blau et al., 2007).
In the present study, a potential role of cbbA and gapA-l in mediating interaction
with host cells was investigated using a mutational analysis and functional
complementation of both genes in N. meningitidis strain MC58. To assess the
adhesive properties of FBA and GAPOH-l, cbbA and gapA-l knock-out mutants
were created in N. meningitidis strain Me58 and cbbA was also mutated in four
additional genetic backgrounds representative of clinical isolates of N. meningittdis
(see Chapter 3). Before using in association assays, mutant strains were assessed for
the attenuation of growth in liquid culture and colony morphology on solid agar. The
cbbA and gapA-l deficient strains appeared to grow at the same rate in liquid culture
as well as showed the same colony morphology, as determined by measuring the
optical density 00600 of broth culture and visual inspection of colony morphology
after 24, 48 and 72 h respectively. This indicated that both of these enzymes are
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unlikely to contribute to the glycolysis in N. meningitidis, consistent with the finding
by Baart et al., (Baart et al., 2007), and that the mutation of both enzymes
individually do not affect in vitro maximal growth of N. meningitidis.
In previous chapters, FBA and GAPDH-l have been identified as outer membrane
localized proteins. Additionally, flow cytometry analysis confirmed that FBA was
available to antibodies on the surface of encapsulated N. meningitidis, whilst
GAPDH-l was also accessible to antibodies, but only in the absence of capsule. It
was speculated that these proteins may play a role in adhesion to host cells.
Association assay were then carried out with different cell lines, including HBME
and HEp-2 cell lines. In adhesion experiments, nonetheless, both mutants
demonstrated a significantly reduced capacity to adhere to HBME and HEp-2 cells.
Although results of invasion experiments using cbbA and gapA-l mutants
demonstrated a reduced capacity in both cell lines, this difference was not
statistically significant. The reduced capacity to invade is likely to be a consequence
of the reduced adherence of the mutants to the monolayer. Due to time constraints,
experiments using HEp-2 cells were carried out only two times and ideally they
should be repeated at least three to five times at different occasions to allow
statistical significance to be assessed. It was hypothesized that if FBA has a direct
role in adherence, exogenously added purified rFBA or anti-FBA may competitively
inhibit FBA-mediated meningococcal adherence. To investigate this, adherence to
HBME cells was determined in the presence of free rFBA and anti-FBA antiserum.
Both (rFBA and anti-FBA) failed to interfere in vitro with meningococcal adhesion
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to HBME cells. One possible explanation to the inability of either rFBA or anti-
rFBA antiserum to inhibit the adherence process could be that the FBA may have
indirect role in adhesion. This can be addressed by determining the ability of
meningococci expressing a non-enzymatically functional, but structurally identical
FBA to adhere to host cells. To exclude the possibility that the defective adhesion
was due to polar effects of both mutations, functional complementation of both
mutations was performed to prove unequivocally the involvement of FBA and
GAPDH-l in binding to host cells and to verify that the observed phenotypic effect
was not due to an unanticipated effect on another gene. Single wild-copies of desired
genes were reintroduced in respective mutants at an ectopic site. The complemented
strains were then analyzed to determine their adhesive properties. The results
demonstrated a restoration of adhesion levels to those observed for the wild-type
strains indicating that the reduced capacity in adherence of mutants with both cell
lines was the outcome of the loss of the expression of cbbA and gapA-l. The
impaired adhesion of cbbA knock-out strain to host cells also correlate to our
previous finding of animal studies showing that the cbbA mutants were impaired in
their ability to sustain bacteraemia compared to their wild-type parent strains.
Together, these results indicate that FBA may play a potential role in the
pathogenesis of meningococcal disease.
In addition to the viable count methodology used in this study, which measure levels
of cell-associated (i.e. adherent and internalized) bacteria, several other methods can
be employed to investigate adhesive properties of N. meningitidis. Future
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experiments could be performed using different approaches such as immuno-
fluorescence microscopy, assay using micro-beads coated with purified protein, and
environmental scanning electron microscopy (ESEM), which can be used to
visualize surface-associated bacteria alone, to validate the results independently.
In summary, FBA and GAPDH-l are highly conserved proteins and universally
expressed by meningococci, and are required for optimal adhesion to human cells.
To the best of our knowledge, this is the first study demonstrating the contribution of
FBA and GAPDH-l of N. meningitidis in adhesion to the host cells. Future studies
are required to determine the mechanism( s) by which these proteins modulate
adhesion to host cells.
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CHAPTER 6: Genaral Discussion
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6.1 Generaldiscussion
There are an increasing number of reports showing that classical cytoplasmic house-
keeping enzymes, without any identifiable secretion signals, are often localized to
the surface of microbial pathogens, where they exhibit various functions, unrelated to
glycolysis, such as surface localization and adhesion to host cell receptors, thus,
contributing to the pathogenesis of disease (Pancholi & Chhatwal, 2003). In order to
gain a deeper understanding of microbial pathogenesis, there is considerable interest
in identifying the additional roles of these glycolytic enzymes. Given their surface
localisation and immunogenicity, these enzymes may represent potential vaccine
candidates. The work presented in this thesis details molecular, functional and
immunological characterisation of two of the meningococcal glycolytic enzymes
namely, fructose 1,6-bisphosphate aldolase (FBA) and glyceraldehydes-3-phosphate
dehydrogenase (GAPDH-l).
The discussion of the results of this study will include the validity of the approach of
selecting both genes under analysis, the strategies used to achieve the aims/goals and
discussion of the fmding achieved. The choice of genes for investigation in this
project was based on the premise that glycolytic enzymes are often found localized
to the surface of variety of bacterial and fungal pathogens and shown to have
potential roles in adhesion to various host molecules such as fibronectin (EsgJeas et
al., 2008), laminin (Gozalbo et al., 1998; Pancholi & Fischetti, 1992), plasminogen
(Agarwal et al., 2008), mucin (Alvarez et al., 2003) and cadherin (Blau et al., 2007).
It was hypothesized that similar to glycolytic enzymes from other pathogens,
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meningococcal FBA and GAPDH-l may be multi-functional proteins and localized
to the outer membrane of N. meningitidis. The strategy that was adopted towards
characterizing both enzymes included cloning the respective genes, cbbA and
gapA-l, and subsequent purification of recombinant FBA (rFBA) and rGAPDH-I
proteins to generate polyclonal rabbit antiserum. In addition, knock-out mutants of
cbbA and gapA-l were created in N. meningitidis. The antiserum and mutant strains
were then employed in undertaking phenotypic analysis to facilitate the
characterisation of both proteins. The following sections will explore the subsequent
characterisation of these proteins, and, in particular, describe the evidence for their
surface localisation, and the potential roles of FBA and GAPDH-l in the
pathogenesis of meningococcal disease.
6.1.1 Fructose bisphosphate aldolase (FBA)
There have now been a number of studies showing that certain glycolytic proteins,
such as GAPDH, enolase, and FBA, which can be usually found in the cytoplasm of
the cell, are involved in various other functions unrelated to their primary function in
glycolysis (Agarwal et al., 2008; Alvarez et al., 2003; Bergmann et al., 2001;
Bergmann et al., 2004; Ling et al., 2004; Pancholi & Chhatwal, 2003). One such
protein, fructose-I, 6-bisphosphate aldolase (FBA) has been previously reported to
be localized to the surface of some Gram-positive bacteria. In S. pneumoniae, for
example, surface-exposed FBA (Class lIB) was demonstrated to act as an adhesin,
specifically binding to a large 7-transpass transmembrane receptor belonging to the
cadherin superfamily (Blau et al., 2007) . InN. meningitidis, two cytoplasmic house-
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keeping enzymes, GAPDH and enolase (Grifantini et al., 2oo2a; Knaust et al., 2007)
have been shown to be surface-localized, but their non-glycolytic roles are
undefined. We undertook to investigate whether FBA was also surface-localized in
N. meningitidis, as has been described for GAPDH and enolase, and to determine
whether FBA plays a role in meningococcal pathogenesis.
In the published meningococcal and gonococcal genome sequences, there is only one
gene cbbA, predicted to encode a putative FBA enzyme. Despite being predicted to
be part of a non-functional metabolic pathway, cbbA has not acquired spontaneous
mutations in any of the Neisserial genomes examined, which suggests that the gene
was acquired recently, that the glycolytic pathway became non-functional recently,
or that the protein has one or more additional functions. Sequence analysis shows
that FBA is highly-conserved at the amino acid level. The deduced protein sequence
exhibited high identities to Class-II FBA from Xanthobacter flavus and
Synechocystis sp (67 and 65%, respectively) suggesting that the meningococcal FBA
belongs to bacterial Class-II FBP aldolases. The enzyme was highly related to FBP
aldolases from other meningococcal strains (in the range of 93-98% identity at the
amino acid level). In addition, a 2l-amino acid insertion sequence, which is present
in two subclasses of the Class lIB FBA enzymes, was also present in the Neisserial
sequences. The presence of this sequence suggests that the neisserial FBA enzyme is
a tetrameric, rather than a dimeric enzyme; a feature which is present in
extremophiles, and which has been suggested to confer thermal stability (Izard &
Sygusch, 2004; Sauve & Sygusch, 2001).
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In this study, rFBA was successfully expressed with an N-tenninal histidine-tag in
host E. coli; however, the expression resulted in insoluble proteins (inclusion
bodies). Modification of the expression parameters including induction temperature,
time, and IPTG concentration failed to result in the production of soluble proteins.
The reason for this insolubility is unclear; however, it might be related to the nature
of the vector promoter (T7 promoter) or be intrinsic to the FBA protein. Attempts to
purify rFBA under native conditions were unsuccessful. Therefore, the expressed
protein was purified under denaturing conditions and used to raise rabbit poJycJonaJ
anti-FBA serum (RaFBA).
To examine the aldolase activity and generate polyclonal antiserum against native
purified FBA, the protein was expressed with a histidine-tag at the C-terminal and
purified under non-denaturing conditions. The purified rFBA was shown to have
aldolase activity confirming that the enzyme was in native conformation after
purification. In accordance with the in silico prediction of tetrameric structure of
FBA, the purified native protein was used to investigate the tetrameric nature of
meningococcal FBA using native gel analysis. However, due to the either
aggregation of native proteins or other unknown reasons, the results did not show an
intact protein band. The purified protein was also used to generate rabbit polyclonal
anti-FBA antiserum (nRaFBA), which was used to confirm that FBA is expressed in
vitro in each of a range of Neisserial strains tested including commensal species.
This suggests that FBA plays an important role which is required by both non-
pathogenic and pathogenic species.
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Many studies have now reported that, in addition to the cytosol, FBA is localized to
the outer membrane of the some Gram-positive bacterial pathogens, but no such
evidence is available for Gram-negative bacteria. This study thus aimed to
investigate sub-cellular localisation of FBA in N. mentngitidis. Cell fractionation
studies demonstrated that FBA was present in both the cytosol and in an outer
membrane-enriched fraction. Although the cell fractionation results indicated that
FBA was localized to the outer membrane of N. meningitidis, we further investigated
the possibility that cytosolic enzyme released following cell lysis may adhere to
intact N. meningitidis cells. Incubation of cbbA-deficient mutant cells with either
whole cell lysates of wild-type MCS8 or soluble rFBA protein prior to fractionation
failed to show any reactivity, suggesting that FBA is not recruited onto the surface of
intact bacteria. The cell fractionation results showing outer membrane localisation
were substantiated by whole cell ELISA and flow cytometry analysis. Flow
cytometry and ELISA data indicate that FBA is surface exposed in N. meningilidis
and present in a form that was accessible to antibodies, suggesting that, similar to
GAPDH and enolase, FBA is translocated (or diverted) to the outer membrane. To
our knowledge, this is the first report demonstrating that a proportion of FBA is
found on the cell surface of any Gram-negative bacterium.
In N. meningitidis strain MCS8, cbbA is the first of four genes that could be part of
an operon, and thus, polar effects may account for the observed phenotypic
characteristics of mutation of cbbA. To exclude this possibility, the cbbA mutation
was complemented in three isogenic cbbA mutants created in N. meningitidis (MeS8,
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Z4181, and ST-18) by reintroducing a wild copy of cbbA at an ectopic site on the
chromosome of respective mutant strains. As a complementary experiment, to
confirm that cbbA mutation does not affect the expression of downstream genes in
the operon, we determined the expression of the immediately down-stream gene
which encodes tHbp using immunoblot analysis. The expression of fHbp was similar
in both wild-type MeS8 and cbbA mutant strains.
Phenotypic analysis of mutant strains was undertaken to determine the role of FBA
in neisserial biology. In initial growth profiling experiments, the cbbA-deficient
mutant grew at the same rate (in broth culture and on solid media) as the wild-type
and the complemented mutant strains, demonstrating that FBA is not required for
optimal growth of the meningococcus under the in vitro conditions tested. No
differences in either colony or bacterial cell morphology (using light microscopy)
were observed. In adhesion experiments, however, the cbbA-deficient mutant strain
exhibited a significantly reduced capacity to adhere to both HBMB and HEp-2 cells.
This phenotype was completely restored in a complemented strain. Although cbbA
mutant strain showed a reduced capacity to invade both monolayers, this difference
was not statistically significant. It is hypothesized that the observed defect in
invasion was likely to have been a consequence of the reduced ability of the mutant
strain to initially adhere to the cell monolayers. The observation that FBA is
involved in adhesion to both epithelial and endothelial cells, and that FBA
expression is conserved in non-pathogenic strains (such as N. polysacchareae) may
suggest a role for FBA during colonization of the nasopharyngeal mucosa by
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commensal Neisserial species. To determine whether the observations of impaired
adhesion of cbbA mutants to host cells were also reflected in vivo, the cbbA knock-
mutant strains created in five different genetic backgrounds (MeS8, Z4181, Z4667,
Z4673, and ST-18) were assessed to determine the potential role of FBA in
establishing bacteraemia in a transgenic (expressing human transferrin) mouse model
of meningococcal disease. The mutant strains were impaired in their ability to sustain
bacteraemia compared to their wild-type parent strains suggesting that the mutants
were less able to access the bloodstream and/or to survive in the bloodstream after
intraperitonial inoculation compared to wild-type parent strains. Together, these
results indicate a potential role for FBA in the pathogenesis of meningococcal
disease. In future work, the antiserum raised against natively purified rFBA will be
used in passive protection experiments using the transgenic mouse model to
determine whether anti-FBA antibodies elicit a protective response against N.
meningitidis. Active protection experiments using mice vaccinated with natively
purified rFBA will also be performed.
It is theoretically possible that the cbbA deletion may affect the expression of
meningococcal genes determining piliation or other factors important for adhesion.
Variation in the expression of these genes, between wild-type and mutant strains,
may be responsible for differences in observed phenotypes. Unfortunately, due to
unavailability of antiserum and time constraints, the expression of these various
genes was not assessed. However, given that type IV pili mediate natural
transformation and that this methodology was successfully used to transform the
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cbbA knock-out strain with the complementation construct, it is assumed that
piliation is not grossly affected by deletion of cbbA. Although this study
demonstrates that FBA is present on the meningococcal cell surface and is required
for optimal adhesion, the role of FBA in this process is unknown. It is possible that
the enzymatic activity of FBA plays an indirect role that is required for optimal
adhesion. However, given that other FBA homologues (such as FBA in S.
pneumoniae) have been shown to directly bind to host cell ligands it is also possible
that the meningococcal protein has direct host receptor binding activity. Determining
the ability of meningococci expressing a non-functional FBA to adhere to host cells
would address this. S. pneumoniae FBA was putatively shown to bind to a cadherin
superfamily receptor (Flamingo cadherin receptor, FeR) on the surface of host
epithelial cells, but it is unknown which FBA residues participate in this interaction
(Blau et al., 2007). Meningococcal FBA is only 40% identical to the pneumococcal
enzyme at the amino acid level, so it is unclear whether meningococcal FBA binds
the same receptor. The preliminary data of serum bactericidal experiments using
antiserum raised against denatured purified FBA showed no bactericidal activity
against N. meningitidis strain MeS8. Future work will be performed with the
antiserum raised against natively purified proteins and bacteria grown under
conditions that mimic in vivo conditions. It is possible that FBA may be up-regulated
in vivo, leading to great level of surface expression, which may be of importance in
relation to bactericidal activity of specific antibodies.
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Pneumococcal FBA has been shown to be immunogenic in humans and capable of
eliciting a partially protective immune response against lethal S. pneumoniae
intranasal challenge in mice (Ling et al., 2004). Given that meningococcal FBA is:
highly conserved, expressed by a wide range of isolates, surface-accessible to
antibodies and structurally and antigenically unrelated to the human (Class I) FBA
protein, meningococcal FBA is worthy of future study as a possible candidate
vaccine component against this important human pathogen.
6.1.2 Glyceraldehyde 3-phosphate dehydrogenase (GAPDH-l)
During last two decades a number of reports have indicated that GAPDH, a classical
cytoplasmic glycolytic enzyme is often present at bacterial surfaces and performs a
variety of non-glycolytic functions (Pancholi, 2001; Pancholi & Chhatwal, 2003;
Sirover, 1996; Sirover, 1999). Surface localization of GAPDH was first
demonstrated in the Gram-positive pathogen, S. pyogenes. In this organism, surface-
exposed GAPDH binds several mammalian proteins including the uPAR/CD87
membrane protein on pharyngeal cells (Jin et al., 2005; Lottenberg et al., 1992;
PanchoIi & Fischetti, 1992; Winram & Lottenberg, 1996), regulates intracellular host
cell signaling events (Pancholi & Fischetti, 1997) and contributes to host immune
evasion (Terao et al., 2006). GAPDH was subsequently identified on the surface of
other Gram-positive bacteria including staphylococci (Modun & Williams, 1999;
Modun et al., 2000), S. agalactiae (Seifert et al., 2003) and Listeria monocytogenes
(Schaumburg et al.. 2004). However, the prerequisites for secretion of GAPDH are
not yet understood. The surface localised GAPDH appears to contribute to the
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virulence of pathogens by means of binding to host proteins including
plasminogen/plasmin, and fibronectin, thus facilitating their colonization and
invasion of host tissue (Bergmann et al., 2004; Egea et al., 2007; Gozalbo et al.,
1998; Pancholi & Fischetti, 1992). In M. genitalium, for example, only a small
proportion of the total cellular GAPDH is trafficked to the bacterial surface,
however, this is sufficient to impart a biologically-significant phenotype (mucin-
binding) on this organism (Alvarez et al., 2003). For organisms with relatively small
genomes, multi-functional proteins may be advantageous to optimize the potential of
the genome. However, non-glycolytic roles of surface-localised GAPDH are poorly
studied in Gram-negative pathogens. Although Grifantini et al. for the first time
demonstreted that GAPDH expression was up-regulated on the meningococcal cell
surface following contact with human epithelial cells; no biological function has so
far been ascribed to this observation. Furthermore, another recent study has shown
that surface-localised GAPDH of a Gram-negative E. coli mediates binding to
human plasminogen and fibrinogen (Egea et al., 2007). It was, thus, speculated that
similar to surface localized-GAPDH enzymes from other microbial pathogens,
surface-exposed meningococcal GAPDH-l may also contribute to pathogenesis of
meningococcal disease due to its functional diversity.
InN. meningitidis, gapA-l is one of the two genes coding for the metabolic enzyme
OAPDH. Although predicted to be part of a non-functional metabolic pathway, the
genes encoding GAPDH and other enzymes required for glycolysis are maintained in
the meningococcal genome, presumably for other roles. Sequence analysis shows
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that GAPDH-l is highly-conserved at the amino acid level. In this study,
recombinant GAPDH-I (rGAPDH-l) was expressed and purified under denaturing
conditions. Purified protein was used to generate rabbit polyclonal antiserum
(RaGAPDH-l). Anti-GAPDH-l was then used to investigate the strain distribution
and sub-cellular localization of the enzyme. A strain survey for distribution and
expression of gapA-l was carried out by peR and immunoblot analysis of whole cell
proteins from different clinical isolates of known MLST-type. Immunoblot analysis
of these strains showed that they all express GAPDH-l, suggesting that GAPDH-I is
constitutively-expressed in N. meningitidis.
To facilitate studies of the potential role of gapA-l in the pathogenesis of
meningococcal disease, a gapA-l knock-out mutant was created in N. meningitidis
strain Me58. The mutant strain was evaluated by screening for defects in growth. on
agar and in broth culture. The gapA-l mutant grew at the same rate (in both broth
culture and on solid media) as the wild-type strain demonstrating that gapA-l is not
required for maximal growth of the meningococcus under in vitro conditions.
Moreover, the colony or bacterial cell morphology of mutant strain (using light
microscopy) was indistinguishable compared to wild-type parent strain.
In accordance with the previous observations that GAPDH is a multi-functional
protein and appears to be translocated to the surface of numerous bacterial and
fungal pathogens (including N. meningitidis), surface-location of meningococcal
GAPDH-I was confirmed using sub-cellular fraction and flow cytometry analysis.
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Sub-cellular fractions were probed using anti-GAPDH-l in immunoblotting
experiments. A band corresponding to GAPDH-I was demonstrated to be present in
both the cytosolic and the outer membrane protein-enriched fraction of wild-type
meningococci, suggesting that, similar to enolase and FBA, a proportion of
GAPDH-l is translocated to the outer membrane. To exclude the possibility that
cytosolic GAPDH-I released from lysed cells is recruited. back onto the surface of
intact meningococci prior to fractionation, gapA-l-deficient meningococci were
incubated with lysates of wild-type MCS8 cells and rGAPDH-I. The fractionated
cells were then probed with RaGAPDH-l in immunoblot analysis and demonstrated
no reactivity. This is in agreement with the recent report by Saad et al.. who showed
that provoked cell lysis of Lactobacillus plantarum did not lead to re-association of
GAPDH onto the cell surface (Saad et al., 2009). Instead, Saad et al.. suggested that
changes in plasma membrane permeability during the growth cycle may facilitate the
movement of GAPDH onto the external surface of the plasma membrane in this
Gram-positive organism (Saad et al., 2009). Clearly, however, such a mechanism
would only permit periplasmic localization in a Gram-negative organism. The results
of sub-cellular fractionation were further validated by flow cytometry analysis. The
data demonstrate that GAPDH-l was not accessible by antibodies on the surface of
capsulated MCS8; however, GAPDH-l was shown to be exposed on the surface and
accessible by antibodies in non-capsulated MeS8. It is important to note that in the
previous report by Grifantini et al., GAPDH-l was shown to be accessible to
antibodies following permeabi1isation of the capsule with 70% alcohol and using
meningococci grown under the conditions mimicking in vivo conditions (i.e. co-
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incubated with host cells). Our flow cytometry data independently confirm that in
capsulated meningococci, GAPDH-l appears to be functionally masked by the
capsule and is only exposed on the surface of non-capsulated N. meningitidis.
However, capsule expression in meningococci is known to be down-regulated
following the initial type N pilus dependant-contact with host cells in order to
facilitate intimate adherence (Deghmane et al., 2002; ViIji et al., 1995). Thus, it is
possible that surface-localised GAPDH-l may be unmasked following this change
allowing it to influence subsequent steps in adhesion. This speculation was supported
by our observation that in adhesion experiments the GAPDH-l mutant strain
exhibited a significantly reduced capacity to adhere to both HBME and HEp-2 cells
compared to the wild-type strain. This phenotype is unlikely to be due to polar
effects arising from the intenuption of transcription of genes that are downstream
from gapA-l in N. meningitidis; given the opposite orientation of immediately
downstream genes and the observation that complementation completely restores the
wild-type phenotype.
In serum bactericidal assays (SBAs), antibodies raised against denatured GAPDH-J
failed to kill meningococci. It is likely that the absence of SBA activity is due to lack
of accessibility of antibody to the antigen owing to the masking of GAPDH-l by the
capsule. Additionally, for the proteins with either low or transient surface expression,
it seems likely that either the level of antigen on the surface is insufficient to promote
bactericidal killing or only a fraction of the population may be killed. In addition,
bactericidal assays in this study were carried out by incubating the immune serum
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and complement with meningococcal cells grown in an enriched broth. Under these
conditions, the bactericidal activity of antibodies induced by antigens that are
specifically up-regulated during adhesion to host cells is expected to be
underestimated. Moreover, antigens appearing on the bacterial surface only after
adhesion or during a later phase of infection may give a negative result in SBAs even
though, in vivo, they may play an important role in protection. In future work, the
bactericidal assays should be performed using bacteria grown under conditions that
mimic in vivo conditions and antibodies raised against the native GAPDH-l protein
will be assessed for serum bactericidal activity.
In conclusion, meningococcal gapA-l is a constitutively-expressed, highly-conserved
protein, which appears to be partially localized to the outer membrane. Loss of gapA-
1 does not affect the in vitro maximal growth rate of N. meningitidis, but
significantly affects the ability of the organism to adhere to human epithelial and
meningothelial cells. Given the surface localisation and a potential role in adhesion
to host cells, GAPDH-l may be involved in the pathogenesis of meningococcal
disease.
6.2 Conclusion
In the present study, cbbA and gapA-l (encoding FBA and GAPDH-l proteins,
respectively) were cloned and the recombinant proteins were subsequently purified
either under denaturing or non-denaturing conditions. Polyclonal antisera were raised
in rabbit against native or denatured rFBA and rGAPDH-l. Both antisera were
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shown to react against the cognate purified proteins in immunoblot experiments.
peR and immunoblot analysis demonstrated that the cbbA and gapA-l genes were
well conserved and expressed in divergence isolates of N. meningitidis, which is an
important property required of a prospective vaccine candidate. Sub-cellular
fractionation results indicated that both FBA and GAPDH-l were localized to the
outer membrane and cytosol of N. meningitidis. The cbbA and gapA-l knock-out
mutants were successfully created in N. meningitidis strain MCS8. Both mutants
grew normally when cultured on solid media as well as in broth culture compared to
the wild-type strain. Both mutants, however, demonstrated a clear phenotype of
reduced capacity to adhere to, and invasion, cultured epithelial and meningothelial
cells.
The cbbA gene was also mutated in four other clinical isolates of N. meningitidis to
act as additional controls in assessing a potential role of FBA in the development of
bacteraemia in a novel transgenic mouse model of meningococcal disease. The cbbA
knock-out mutant in all four genetic backgrounds demonstrated reduced capacity to
establish bacteraemia compared to the parent wild-type strains in the mouse model.
Flow cytometry and ELISA data demonstrated that FBA was surface exposed and
accessible by antibodies on the surface of intact cells. GAPDH-l was shown to be
surface-exposed on the non-capsulated MCS8 strain and was inaccessible to
antibodies on the surface of a capsulated strain. Although insufficient to promote
detectable complement mediated killing, given their surface localisation and
potential role in adhesion, immune responses against FBA and GAPDH-l may still
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be involved in immunity to meningococcal disease. In summary, both cbbA and
gapA-l are constitutively expressed and partially localized to outer membrane of N.
meningitidis. The mutation of both genes (cbbA and gapA-1) did not affect the
growth rate of bacteria, however, the mutant strains showed a significantly reduced
ability to adhere to cultured epithelial and meningotheliai cells. Moreover, the cbbA
mutation was associated with attenuation in the establishment of bacteraemia in a
transgenic mouse model of meningococcal infection.
6.3 Futuredirections
Although this study has demonstrated that both FBA and GAPDH-l are required for
optimal in vitro adhesion of N. meningitidis to epithelial and meningothelial cells,
future experiments, using different independent approaches such as
immunoflourescence microscopy and ESEM (Oldfield et al., 2007), should be
performed to show the validity of the results. Future work should also aim to identify
FBA and GAPDH-l interacting host proteins and clarify the mechanism(s) that are
responsible for the defect in adherence to host cells. A potentially usefuJ approach
may be to compare the gene expression profiles of the cbbA and gapA-1 mutant
strains with the wild-type using microarray technology (Chan et al., 2005; Liu et al.,
2005). Disruption of a single gene may result in changes in gene expression that arise
as a direct consequence of the disruption or as a result of compensatory changes.
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APPENDIX· A: Buffers and reagents
247
TAE buffer (SO x stock)
242 g Tris base (life technologies), 57.1 ml glacial acetic acid (Fisher chemicals) 100
ml 500 mM EDTA (PH 8.0) made up to 1 L with ciH20
Agarosegel
0.8-1.0 % agarose was prepared by dissolving 0.8-1 g of agarose powder (sigma), 2
ml SOx TAB buffer and made up to 100 ml with dH20; melt and add 5 III ethidium
bromide (10 mg ml").
Antibiotics
Antibiotics were purchased from Sigma-Aldrich UK, prepared according to the
manufacturer's recommendations, sterilized by filtration and store at 4°C.
Ampicillin (100 mg ml" stock solution prepared indH20)
Kanamycin
Streptomycin
Erythromycin
(50 mg ml" stock solution prepared in dH20)
(50 mg ml" stock solution prepared in dH20)
(100 mg ml" stock solution prepared in ethanol)
ELISA coating (carbonate) buffer
142mM sodium bicarbonate, 8mM sodium carbonate [PH 9.4]) to Sllg ml")
Sodium dodecyl sulfate (SDS)-resolving buffer
(36.34 g Tris base, 8 ml 10% SOS add de-ionised water (dH20) up to 200 mit pH at
8.8) or 1.5M Tris-Chloride (FW 121.1). pH 8.8, 0.4% SOS.
SDS-staking buffer
12.114 g Tris base, 8 ml 10% SOS) add dH20 up to 200 mi, pH at 6.8 or O.S M Tris-
Chloride (FW 121.1), pH 8.8, 0.4% SOS.
SDS running buffer (lOx)
(30.3 g (0.25 M) Tris base, 187.7 g (2.5 M) Glycine, 9S0 ml dH20, 10 g SOS (1%).
made up to 1000 ml with dH20, mix well.
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SDS-sample buffer (5x)
0.62 M Tris-CI (PH 6.8), 5% SDS, 25% glycerol, 12.5% p- meracaptoethanol,
0.002% Bromophenol blue, or 7.8125 ml (2 M) Tris-CI, 1.25 g SDS, 6.25 ml
glycerol, 3.125 ml p-meracaptoethanol, traces of bromophenol blue, made up to 25
ml with dH20.
Resolving (separating) gel
l.7 ml SDS-resolving buffer, 2.33 ml Acrylamide/Bis-Acrylamide (30%), 2.88 ml
dH20, 30 J.11 10% ammonium persulfate (APS) and 30 J11 Tetramethyl
ethylenediamine (TEMED).
Staking gel
1ml SDS-stacking buffer, 0.8 ml AcrylamidelBis-Acrylamide (30%),2.18 ml dH20,
30 J.110%APS and 30 J.11TEMED.
Semi-dry blotting buffer
5.82 g Tris base, 2.93 g Glycine, 3.75mllO% SDS, 200 ml methanol and make up to
1000 ml with dH20.
Phosphate buffered saline solution (PBS)
1 x PBS was prepared by dissolving 1 tablet of Phosphate buffered saline (Dulbecco,
Oxoid) in 100 ml dH20 and autoclave, this gives sodium chloride 0.16 mol,
Potassium chloride 0.003 mol, Disodiwn hydrogen phosphate 0.008 mol and
Potassium dihydrogen phosphate 0.001 mol with a pH value of7.3
BSA (Albumin from bovine serum, Sigma A3912) as lyophilized powder (M W c.
66 kDa) was prepared in sterile PBS according to the concentration needed.
Blocking buffer
2.52 g skimmed milk powder (Marvel), 50 ml PBS/O.05% Tween-20 (400 ml PBS
with 200 ....1Tween20).
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Washing buffer
400 ml PBS/200 J,llTween-20
Lysogeny broth (LB)
Tryptone 10 g, Yeast extracts 5 g and sodium chloride 10 g for 1000 ml dH20.
LB agar
Tryptone 109, Yeast extract 5 g, Sodium chloride 109, Microbial tested agar 15 g
for 1000ml of dH20, pH 7.0 ± 0.2 at 25°C.
IPTG (Isopropyl-J3-D-I thiogalactopyranoside [FW 238.8])
1 M solution stock solution was prepared by dissolving 0.23 g of IPTO in 1 ml
dH20, sterilized by filtration and stored at -20°C.
LB ampicillinlIPfGIX-gal agar
LB agar cooled at 50°C, 100 J,lgml" Ampicillin, 0.5 mM IPTG (dissolved in dH20)
and 80 ug ml" X-gal (dissolved in dimethylformamide), mix and pour into plates
DNA loading dye (lOx)
10 mM Tris-HCI (PH 7.6), 0.03% Bromophenol blue, 0.03% xylene cyanol FF, 60%
glycerol, 60 mM Ethylenediamine tetraacetic acid (EDTA)
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ButTers used for protein purification under denaturing condition
Lysis ButTer (buffer B)
100 mM NaH2P04, 10mM Tris-Cl, and 8 M Urea, pH 8.0
Wash ButTer (buffer C)
100 mM NaH2P04, 10mM Tris-CI, and 8 M Urea, pH 6.3
Elution Buffer (buffer E)
100 mM NaH2P04, 10mM Tris-Cl, and 8 M Urea, pH 4.5
Buffers (or protein purification under native condition
Lysis Buffer
50 mM NaH2P04, 300 mM NaC}, 10 mM imidazole, and pH adjusted to 7.4 using
NaOH
Wash buffer
50 mM NaH2P04, 300 mM NaC}, 15 mM imidazole, and pH adjusted to 7.4 using
NaOH.
Elution buffer
50 mM NaH2P04, 300 mM NaCl, 300 mM imidazole, and pH adjusted to 7.4 using
NaOH.
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APPENDIX. B: Vectors and plasm Ids
252
Vectors
A- Schematic diagram of pEXP-NT/TOPO (Invitrogen)
pEXP5-NTITOPO
2745 bp
Comments (or pEXPS.NTITOPO
2745 nucleotides
T7 promoter. bases 1-17
T7 forward priming site: bases 1-20
Ribosome binding site (RBS : bases 68-73
Initiation ATG: bases 60-82
Polyhistidi e (6xHis) region: bases 92-109
HisG epitope: bases 92-112
TEV recognition site: bases 122-142
TOPCY recognition site 1: bases 141-145
TOPC)'Il recognition site 2: bases 146-150
T7 reverse priming site: bases 198-217
T7 transcription terminator. bases 159-287
bra promote. bases 399-497
Ampicillin resistance gene: bases 498-1358
pUC origin: 1503-2176
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B- Schematic diagram of pCR® T7/NT-TOPO (invitrogen)
flCRP.OcNct
Res ATC &tHis' )(press" Epltope Et<
pCR®T71
NT-TOPO®
2870 bp
Comments for pCR®T7INT- TOPO®
2870 nucleotides
T7 promoter: bases 20-36
T7 promoter priming site: bases 20-39
Ribosome binding site: bases 87-90
Initiation ATG: bases 100-102
Polyhistidine (6xHis) region: bases 112-129
Xpress™ epitope: bases 169-192
EK recognition site: base 178-] 92
TOPO® Cloning site: bases 204-205
T7 reverse priming site: bases 270-289
T7 transcription termination region: ba s 23] -3 0
f1 origin: 431-886
Ampicillin resistance gene ( RF): ba s 10 I. 7-
1877
pUC origin: 2022-2695
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c- Schematic diagram of pGEM- T Easy vector (Promega)
Tll 1 s rl
Apal 14
Aalll 20
Sphl 26
BslZI 31
Ncol 37
BsIZI 43
pGEM -T Easy Notl 43Sacll 49
Vector EcoRI 52
(3015bp)
Spal 64
EcoRI 70
Noll 77
Bs1Z1 77
PSII a6
Sail 90
Ndal 97
Sacl 109
BstXI 116 ~
Nsd 127 IlsP6 141
pGEM -1 Easy Ve-ctor sequence reference points:
17 RNA po~'merase transcription initiation site
multiple oning region
SP6 R..'JApolymerase promoter (-17 to 3)
SP6 ru A po~'merase transcription inHia 'on site
p C/MB Reverse Sequencing Primer binding ite
", Z start codon
I,' opera or
p ac amase cding ~gion
phageIl region
I operon sequences
p 'C/),113 Fon ...·ardSequen ing Primer binding site
1 RNA polymerase promoter (-17 to +3)
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1
10-1
139-1'"
1 1
176-197
1
200-216
1337-219
2
2836-2996,1 -395
2 9-2972
2999-3
D- Schematic diagram of pQE-70 (Qiagen)
I
::CE:=
Q.O 0)Sal~
PTS lac 0 lac O-RBS~MCS
~~
it
.t pQE.70
3.4 kb
~IEl
pOE·TO
pQE-70 Vector
Position.s of elemen.ts in. bases
Vector size (bp)
Start of numbering at Xh§J (CTCGAG)
T5 promoter/lac operator element
T5 transcription start
6xHis-tag coding sequence
Multiple cloning site
Lambda to transcriptional termination region
rrnB T1 transcriptional termination region
CoIE1 origin of replicotion
~-Iactamase coding sequence
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3426
1-6
7-87
61
133-150
113-132
173-267
1029-1127
1603
3221-2361
E- Schematic diagram of pJMK-30 (source of KanR cassette)
pJMK30
KmR
4185bp HindIII
PstI
Sal!
Xbal
Bamffi
Sma!
KpnI
amp EcoRI
Ssp!
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The moonlighting protein fructose-t, 6-bisphosphate
aldolase of Neisseria meningitidis: surface localization and
role in host cell adhesion
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Summary
Fructose-1, 6-bisphosphate aldolases (FBA) are cyto-
plasmic glycolytic enzymes, which despite lacking
identifiable secretion signals, have also been found
localized to the surface of several bacteria where they
bind host molecules and exhibit non-glycolytic
functions. Neisseria meningitidis is an obligate
human nasopharyngeal commensal, which has the
capacity to cause life-threatening meningitis and
septicemia. Recombinant native N. meningitidis FBA
was purified and used in a coupled enzymic assay
confirming that it has fructose bisphosphate aldolase
activity. Cell fractionation experiments showed that
meningococcal FBA is localized both to the cyto-
plasm and the outer membrane. Flow cytometry dem-
onstrated that outer membrane-localized FBA was
sUrface-accessible to FBA-specific antibodies. Muta-
tional analysis and functional complementation was
used to Identify additional functions of FBA. An FBA-
deficient mutant was not affected in its ability to grow
in vitro, but showed a significant reduction In adhe-
sion to human brain microvascular endothelial and
HEp-2 cells compared to Its Isogenic parent and Its
complemented derivative. In summary, FBA Is a
highly conserved, surface exposed protein that is
required for optimal adhesion of meningococci to
human cells.
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Introduction
Neisseria meningitidis remains an important cause of sep-
ticemia and meningitis and is associated with high mor-
bidity and mortality (Stephens et al., 2007). As an obligate
human commensal, it colonizes the nasopharyngeal
mucosa of a substantial proportion of the population in an
asymptomatic manner. In susceptible hosts, ~~per-
invasive strains of meningococci possess the ability to
invade the nasopharyngeal sub-mucosa and enter the
bloodstream, where they can multiply rapidly to high
levels. Meningococci may also translocate across the
brain vascular endothelium, proliferate in the cerebral-
spinal fluid (CSF) and cause meningitis (Stephens, 2009).
To reach the meninges, N. meningitidis must therefore
interact with two cellular barriers and adhesion to both
epithelial and endothelial cells are crucial stages of
infection. Various bacterial factors including lipooligosac-
charide (LOS), capsule, type IV pili and outer membrane
adhesins such as Opa, Ope, NhhA, App, NadA and MspA
have been shown to have a role in meningococcal adhe-
sion and invasion of epithelial and/or endothelial cells
(reviewed in Virji, 2009).
Glycolytic enzymes, such as glyceraldehyde
3-phosphate dehydrogenase (GAPDH), enolase and fruc-
tose bisphosphate aldolase (FBA) have been reported as
potential virulence factors in a variety of organisms (Pan-
choli and Chhatwal, 2003). Although long recognized for
their cytosolic role in glycolysis and gluconeogenesis,
additional or 'moon-lighting' functions have been increas-
ingly recognized. In particular, despite lacking identifiable
secretion signals, glycolytic enzymes have been found on
the bacterial cell surface where they interact directly with
host soluble proteins and surface ligands. In Mycoplasma
genitalium, surface-associated GAPDH.was shown to be
important for adhesion to human mucin (Alvarez et et.,
2003). In Streptococcus pyogenes and Candida albicans
surface-associated GAPDH was shown to bind to
fibronectin (Pancholi and Fischetti, 1992; Gozaibo et al.,
1998) and in Staphylococcus aureus the cell wall
transferrin-binding protein was found to be GAPDH
(Modun and Williams, 1999). GAPDH was also reported
to be a virulence-associated immunomodulatory protein In
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Streptococcus agalactiae (Madureira et si., 2007).
Surface-associated enolase has been reported as a
plasminogen-binding protein in S. pyogenes (Pancholi
and Fischetti, 1998), a fibronectin and plasminogen-
binding protein in Streptococcus suis (Esgleas et al.,
2008; Tian et al., 2009), and a plasminogen and laminin-
binding protein in Bacillus anthracis (Agarwal et al.,
2008). In Streptococcus pneumoniae, surface-associated
FBA was shown to bind to a large 7-transpass transmem-
brane receptor belonging to the cadherin superfamily
(Blau et al., 2007). FBA and GAPOH were also shown to
be immunogenic in humans and capable of inducing a
protective immune response against S. pneumoniae in
mice (Ling et al., 2004). In addition, FBA was found to be
a surface-localized immunogenic protein in S. suis
(Zongfu et al., 2008) and a possible role for FBA in immu-
nity to Onchocerca volvulus has also been reported
(Mccarthy et al., 2002).
Fructose-1, 6-bisphosphate aldolase catalyses the
reversible cleavage of fructose-1, 6-bisphosphate into
dihydroxyacetone phosphate and glyceraldehyde
3-phosphate (Zgiby et al., 2000; Wehmeier, 2001; Ram-
saywak et al., 2004). Aldolases can be divided into two
groups with different catalytic mechanisms, designated
Class-l and Class-II respectively (Thomson et al., 1998;
Arakaki et al., 2004). Class-I FBAs utilize an active site
lysine residue to stabilize a reaction intermediate via
Schiff-base formation, and are usually found in higher
eukaryotic organisms (animals and plants). Class-ll FBAs
have an absolute requirement for a divalent ion, usually
zinc (Zgiby et al., 2000) and are commonly found in bac-
teria, archae and lower eukaryotes including fungi and
some green algae grown under heterotrophic conditions
(Plater et al., 1999; Sauve and Sygusch, 2001; Ramsay-
wak et al., 2004). Most organisms contain only one class
of FBA, although a few possess enzymes of both classes.
Escherichia coli (Alefounder et al., 1989; Thomson et al.,
1998), S. pneumoniae (Isabel et al., 1999) and Syn-
echocystis sp. PCC 6803 (Nakahara et al., 2003) among
others have been reported to express both types of the
enzyme. The Class-II FBAs can be subdivided into two
groups, Type A and B, depending on their amino acid
sequences (Sauve and Sygusch, 2001; Nakahara et al.,
2003). Because Class-II FBAs are not found in animals, it
has been suggested that they could provide a possible
therapeutic or vaccine target (Blom et al., 1996; Ramsay-
wak et al., 2004).
In N. meningitidis, it is noteworthy that, due to the
absence of the enzyme phosphofructokinase, the
Embden-Meyerhof-Parnas (EMP) glycolytic pathway is
rendered non-functional (Baart et al., 2007). Instead, the
catabolism of glucose has been shown to be carried out
through the Entner Oouderoff (ED) and Pentose Phos-
phate pathways (PP) (Baart et al., 2007). Nevertheless,
the meningococcal genome retains functional genes
for other glycolytic pathway enzymes, presumably for
alternative (non-EMP pathway) functions. Furthermore,
GAPOH expression (GapA1, but not GapA2) was
found to be up-regulated on the meningococcal cell
surface following contact with human epithelial cells (Gri-
fantini et al., 2002), although no biological function has
so far been ascribed to this observation. In addition,
enolase has recently been shown to be a surface-
localized protein in N. meningitidis, where it acts to
recruit plasminogen onto the bacterial surface (Knaust
et al., 2007). The available N. meningitidis genome
sequences contain a single, putative Class II FBA-
encoding gene (cbbA), which has not previously been
characterized. The aim of this study was to characterize
the enzymatic function, sub-cellular localization and
putative role of FBA in the pathogenesis of meningococ-
cal infection.
Results
Sequence analysis of the cbbA gene, flanking DNA and
FBA protein
In N. meningitidis strain MC58, the 1065 bp cbbA gene
(locus tag NMB1869) has a G+C content of 55.18% and
encodes a predicted protein of 354 amino acids (esti-
mated molecular weight 38.3 kOa). The cbbA gene is
downstream of, and in the opposite orientation to, xerC
(NMB1868) encoding the XerC integrase/recomblnase
and upstream of, and in the same orientation as,
NMB1870, which encodes factor H-binding protein, fHbp
(Madico et al., 2006). A similar genomic arrangement is
present in the serogroup A meningococcal strain Z2491
(NMA0588, NMA0587 and NMA0586 encoding XerC,
FBA and fHbp respectively; Parkhill et st., 2000), the
serogroup C strain FAM18 (Bentley et el., 2007) and the
ST-4821 strain 053442 (Peng et a/., 2008), suggesting
that this is a conserved arrangement. In these three
genomes, the cbbA sequences are > 94% Identical to
the MC58 cbbA gene. Additionally, sequences > 92%
identical to MC58 cbbA are found in the gonococcal
strain FA1090 (94% identical) and N. lactamlca strain
ATCC 23970 (93% Identical) confirming that cbbA Is
highly conserved across Neisseria species. At the amino
acid level, FBA sequences from meningococc I str Ins
MC58, FAM18, 053442, Z2491 and the gonococcal
strain FA1090 are > 99% Identical. By alignment, the
neisserial FBA protein (NMB1869) was 70, 67, 65 and
40% identical to Class-liB FBA enzymes from Cuprl vl-
dus metallidurans, Xanthobacter flavus, Synechocystls
sp. and S. pneumoniae, respectively, but was only 21
and 29% identical to the E. coli and Haemophllus inttu-
enzae Class-IIA FBA enzymes, respectively, Indicating
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Fig. 1. SOS·PAGE analysis confirms the purity of the recombinant
FBA purified under native conditions (A). Immunoblot analysis
shows that recombinant FBA is recognized by RaFBA (B) and
anti·pentahistidine antibodies (C).
that the neisserial FBA belongs to Class-liB. Further-
more, the neisserial FBA enzyme contains a 21-amino
acid insertion sequence (S236_Y2S6),which is unique to
two subclasses of the Class liB enzymes. The presence
of this insertion sequence suggests that the neisserial
FBA enzyme may have a tetrameric quaternary struc-
ture, rather than the dimeric structure, which is typical of
Class Ii FBA enzymes that lack this sequence (Sauve
and Sygusch, 2001; Izard and Sygusch, 2004). As
expected for a Class-Ii FBA, a conserved putative zinc/
cobalt-binding site (Berry and Marshall, 1993) was also
identified (H8'-XX-H84).FBA of N. meningitidis was pre-
dicted to be a non-secreted protein by the SignaIP-HMM
program; although a possible 13-amino acid signal
peptide (predicted cleavage site "DHA-AE'S) was iden-
tified by SignaIP-NN. A signal peptide was similarly pre-
dicted for the Class-liB FBA homologue in X. flavus, but
not for the homologue in Synechocystis sp. or the E. coli
Class-IiA FBA.
Cloning, expression and purification of recombinant FBA
To examine the aldolase function of meningococcal FBA,
and to raise FBA-specific antibodies, the cbbA gene from
MCS8 was cloned into the expression vector pQE70 to
facilitate the expression and subsequent purification of 6x
histidine-tagged recombinant FBA (rFBA). After induction
of E. coli cells harbouring the FBA expression plasmid, a
recombinant protein with an apparent molecular mass
consistent with the predicted mass of the tagged protein
was strongly expressed, affinity-purified under non-
denaturing conditions (Fig. 1A) and used to generate
rabbit anti-FBA-specific polyclonal antiserum (RaFBA).
Immunoblot analysis confirmed that RaFBA and anti-
pentahistidine antibodies both reacted to the purified
rFBA (Fig. 1B and C).
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Meningococcal FBA has fructose bisphosphate
aldolase activity
A previously described coupled enzymic assay (Berry and
Marshall, 1993) was used to confirm that the purified
native meningococcal FBAwas active as an FBA (Fig. 2).
Kinetic parameters of the purified enzyme for cleavage of
fructose bisphosphate (FBP) were estimated as Km
(FBP) = O.OSmM and !<cal = 126 min '. These values are
similar to those found for Class-II FBA enzymes from a
variety of sources such as E. coli (Km (FBP) - 0.19 mM
and !<cal - 490 rnirr ') (Plater et al., 1999).
Mutagenesis of cbbA and strain survey
To examine any additional roles of FBA, a cbbA knockout
derivative of N. meningitidis MCS8 was generated. To
achieve this, the cbbA gene plus flanking DNAwas ampli-
fied and cloned, and inverse PCR was employed to
remove the open reading frame. The product was then
ligated to a kanamycin resistance marker .and.t~e result-
ing plasmid used to transform N. menmgltldls MCS8.
Using this strategy, the cbbA gene was successful~y
mutated to yield MCS86.cbbA. The genotype of this
mutant was confirmed by PCR and sequencing (data not
shown). Immunoblotting using AaFBA showed that a ~.
38 kDa protein corresponding to FBA could be detected In
whole ceillysates of wild-type but not MeS8 cbbA (Fig. 3,
lanes 1 & 2) confirming that FBA is expressed under the
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Fig. 2. Coupled enzymic assay to me sure th activity of
meningococcal fructose 1, 6-blsphosph t aldol e Cl avag 01
fructose I, 6·blsphosphate (FBP) was coupl d to
a-glycerophosphate dehydrogenase and NAO oxldatlcn. On unit
of aldolase activity was deli ned as the amount of nzym which
catalysed the oxidation of 21lmOI NAOH min '.
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Fig. 3. Immunoblot analysis of whole cell proteins from the N.
meningitidis MC58 wild-type, 6cbbA mutant derivative and
complemented mutant reveals the absence of FBA in the 6cbbA
mutant preparation.
conditions used and that expression had been abolished
in the mutant. In addition to the strongly reactive FBA
band, immunoblot analysis showed an additional cross-
reactive band at c. 50 kDa (Fig. 3). However, this band
was also present in preparations of the AcbbA mutant
demonstrating that this protein was not FBA. To further
confirm that the c. 38 kDa immuno-reactive protein was
FBA, a wild-type copy of cbbA was introduced in trans into
MC58AcbbA using the pYHS25-based plasmid pSAT-12
Table 1. Bacterial strains and plasm ids.
Strain or plasmid
Strains
E. coli
JM109
Description Source or reforence
(Table 1). Introduction of cbbA at an ectopic site restored
FBA expression (Fig. 3, lane 3). Further immunoblot
analyses using a panel of 25 N. meningitidis strains
(Table 2) including representatives of differing serogroups
and sequence types showed that FBA expression was
conserved across all strains (data not shown). Expression
was also conserved in representative examples of N.
lactamica, N. polysacchareae and N. gonorrhoeae exam-
ined (data not shown). These data complement in silica
predictions that cbbA is universally present and constitu-
tively expressed across Neisseria strains including com-
mensal species.
Meningococcal FBA is localized to the cytoplasm and
outer membrane
The sub-cellular localization of FBA was investigated by
sub-cellular fractionation followed by immunoblot analysis
of the fractions. FBA was predominately detected in outer
membrane and cytosolic protein-enriched fractions, but
was absent from the cytoplasmic membrane-enriched
fraction (Fig. 4). FBA could also be detected in the peri-
plasmic protein-enriched fraction, possibly representing
transient FBA during translocation to the outer membrane
(Fig. 4). FBA was not detected in concentrated culture
supernatants (data not shown). Immunoblotting experi-
ments with antisera against PorA, a known outer mem-
brane protein of N. meningitidis, gave an identical profile
except that PorA was absent in the cytosolic fraction (data
not shown). These results demonstrate that meningococ-
cal FBA is predominantly a cytosolic protein that is also
found in the outer membrane.
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-Table 2. Isolates of N. meningitidis examined for the expression of FBA.
Country of Date of Sequence
Strain' origin isolation Disease Serogroup type Clonal complex
Z1oo1 USA 1937 tnvasive (unspecified) A 4 ST-4 complex/subgroup IV
Z1035 Pakistan 1967 Meningitis and septicaemia A 1 ST-1 complex/subgroup tltt
Z1054 Finland 1975 Invasive (unspecified) A 5 ST-5 complex/subgroup III
Z1213 Ghana 1973 Invasive (unspecified) A 4 ST-4 complex/subgroup IV
Z1269 Burkina Faso 1963 Invasive (unspecified) A 4 ST-4 complex/subgroup tV
Z1503 China 1984 Invasive (unspecified) A 5 ST-5 complex/subgroup III
Z3771 UK 1987 Invasive (unspecified) A 5 ST-S complex/subgroup III
Z3842 Norway 1976 Invasive (unspecified) B 32 ST-32 compleX/ET·S complex
Z4181 Mali 1989 Carrier C 11 ST-11 complexlET-37 complex
Z4323 Israel 1988 Invasive (unspecified) C 11 ST·11 compleX/ET·37 complex
Z4662 Netherlands 1967 Invasive (unspecified) B 8 ST-8 complex/Cluster A4
Z4667 Netherlands 1963 Invasive (unspecified) B 48 ST-41/44 complexILlneage 3
Z4673 Netherlands 1986 Invasive (unspecified) B 41 ST-41/44 comptexILlneage 3
Z4676 Denmark 1962 Invasive (unspecified) B 37 ST-37 complex
Z4678 East Germany 1985 Invasive (unspecified) B 19 ST-18 complex
Z4684 Norway 1988 tnvasive (unspecified) B 13 ST-269 complex
Z4685 Norway 1988 Carrier B 14 ST-269 complex
Z4701 Norway 1969 Invasive (unspecified) B 11 ST-11 complexlET-37 complex
Z5826 China 1992 Invasive (unspecified) A 7 ST-5 complex/subgroup lit
Z6413 South Afriea 1990 Invasive (unspecified) C 8 ST-8 complex/Cluster A4
Z6414 New Zealand 1994 Invasive (unspecified) C 66 ST -8 complex/Cluster A4
Z6417 UK 1993 Invasive (unspecified) C 11 ST-l1 compleX/ET-37 complex
Z8418 Cuba 1992 Invasive (unspecified) B 33 ST-32 compleX/ET-S complex
Z6419 Austria 1991 Invasive (unspecified) B 40 ST-41/44 complexILlneage 3
Z6420 Greece 1992 Invasive (unspecified) B 41 ST-41/44 complex/Llneage 3
a. Further details of streins are available at http://pubmlst.org/
Meningococcal FBA is surface accessible to antibodies
In order to investigate whether the outer membrane-
localized FBA was accessible on the bacterial cell
surface, RaFBA antibodies were used to probe intact
meningococcal cells which were then analysed by flow
cytometry. MeS8 cells treated with RaFBA alone or sec-
ondary antibody alone did not produce high fluorescence
CP pp CM OM
62-
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Fig. 4. Sub-cellular loealization of FBA. Cytosolic protein-enriched
(CP), periplasmic protein-enriched (PP), cytoplasmic membrane
protein-enriched (CM) and outer membrane protein-enriched (OM)
frectlons of MCS8 were separated on a 10% acrylamide gel and
probed In immunoblotting experiments with RaFBA.
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signals (3.4 and 4.4 mean fluorescence intensities,
respectively), while cells treated with RaFBA followed by
anti-rabbit IgG-Alexa Flour 488 conjugate demonstrated a
clear shift in fluorescence signal (55.2 mean fluorescence
intensity) confirming the cell surface localization of FBA
(Fig. SA). No shift in fluorescence signal was observed
when MeS8~cbbA cells were examined under Identical
conditions [Fig. 5B; mean fluorescence Intensity of 12.1
compared to samples treated with primary or secondary
alone (3.6 and 6.7, respectively)]. From the wild-type cells
probed with both antibodies, 79.05% were found In the M1
region (Fig. SA), suggesting that the majority of the popu-
lation had FBA present on the cell surface. Pre-Immune
serum showed no reactivity against wild·typ MeS8 In
immunoblot experiments confirming that the binding of
RaFBA to wild-type MeS8 observed by flow cytometry
was FBA·specific.
FBA is required for efficient adhesion to host cells
Viable counts of bacteria associated with homogenlz d
infected monolayers were used to compare the cap city
of the wlld-type, FBA mutant and complem nted mut nt
strains to associate with, and invade human br In
microvascular endothelial (HBME) cells. FBA·d flcl nt
meningococci had a significantly reduced c p city to
adhere to monolayers of HBME cells (Fig. SA). No st •
tistically significant reduction was observed In th ability
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Fig. 5. Flow cytometric analysis of MC5Swild-type (A) or
MC5St.cbbA cells (B) for FBA surface localization. Cells were
stained with RaFBA (primary alone). anti-rabbit IgG-Alexa Flour
488 conjugate (secondary alone) or both. Fluorescencewas
displayed as a histogram. The histogramarea in Ml represents the
population of fluorescently labelled meningococci.
show that FBA plays a role in the adherence of N. men-
ingitidis to human cells.
Discussion
An increasing number of reports show that classical
cytoplasmic house-keeping enzymes without identifiable
secretion signals may be localized to the surface of
microbial pathogens, where they exhibit various func-
tions, unrelated to glycolysis (Pancholi and Chhatwal,
2003). One such protein, fructose-1, 6-bisphosphate
aldolase (FBA) has been previously reported to be local-
ized to the surface of some Gram-positive bacteria. In S.
pneumoniae, for example, surface-exposed F8A (Class
A
1.E+04
1.E+03
I1.E+02
OMC5Swr
.MC5McbbA
.MC5McbbA cbbAE<:I
1.E+01
B
1.E+03
OMC5Swr
·MC58f.cbbA
.MC58f.cbbA cbbAE<I
of the FBA mutant to invade monolayers of HBME cells
(Fig. 68). Similar results were also obtained using HEp-2
(human larynx carcinoma) cells, confirming that the
effect was not cell-type specific. To confirm that the
observed effects were not due to an impairment in in
vitro growth, the growth rate of the strains was com-
pared by measuring the optical density at 600 nm
(00600) and determining the viable counts of broth cul-
tures sampled during exponential growth over 24 h in
triplicate on three separate occasions. No significant dif- Flg.6. FBA-deflclentmeningococcih v reducod blilly to
ference between strains was observed (data not shown). associate with (A) but not InvadeInto (B) HBM II comp r d
To further exclude the possibility that mutation of cbbA with the Wild-typeor complementodstrains. Th num r 01
FBA-deflclentmeningococciassociatingwas slgnlflc ntly low r th n
affected expression of the downstream gene encoding the wild-type (. P = 0.0011). Numb rs of rrunantC liS Inv ding w r
factor H binding protein, whole cell Iysates of MC58, not significantly lower comparedwith th wltd·type (P. 0.13).
MC58""cbbA and MC58""cbbA cbbAEc1were probed with Similar experiments were also carri d oul using HEp-2 COli with
consistent resurts, Mean levels shown from Ihr Ind p nd nl
anti-fHbp. Expression levels of this protein were similar experiments,each using Irtpllcalew lis. B rs d nOI I nd rei
in the three strains. In summary, these experiments deviation. Cfu denot s colony fonmlngunlls.
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liB) was demonstrated to act as an adhesin, specifically
binding to a large 7-transpass transmembrane receptor
belonging to the cadherin superfamily (Blau et al., 2007).
In N. meningitidis, two cytoplasmic house-keeping
enzymes, GAPDH and enolase, have been shown to be
surface-localized, and enolase has been suggested to
act as a plasminogen receptor (Grifantini et al., 2002;
Knaust et al., 2007). The non-glycolytic role(s) of
GAPDH on the bacterial surface is undefined. We under-
took to investigate whether FBA was also surface-
localized in N. meningitidis, as has been described for
GAPDH and enolase, and to determine whether FBA
plays a role in meningococcal pathogenesis.
In the published meningococcal and gonococcal
genome sequences, there is only one gene, cbbA, encod-
ing a putative FBA enzyme. Despite being predicted to be
part of a non-functional metabolic pathway, cbbA has not
acquired spontaneous mutations in any of the neisserial
genomes examined, which suggests that the gene was
acquired recently, that the glycolytic pathway became
non-functional recently, or that the protein has one or
more additional functions. Sequence analysis shows that
FBA is highly conserved at the amino acid level, and is a
Class-liB enzyme. A 21-amino acid insertion sequence,
which is present in two subclasses of the Class liB FBA
enzymes, was also present in the neisserial sequences.
The presence of this sequence suggests that the neis-
serial FBA enzyme is a tetrameric, rather than a dimeric
enzyme; a feature which is present in extremophiles, and
which has been suggested to confer thermal stability
(Sauve and Sygusch, 2001; Izard and Sygusch, 2004).
Unexpectedly for a presumed cytosolic protein, a possible
signal sequence was predicted for the neisserial FBA
enzyme, suggesting a possible means of translocation
across the cytoplasmic membrane.
In this study, rFBA was expressed and purified under
non-denaturing conditions. Purified rFBA was shown to
have aldolase activity confirming that the enzyme was in
native conformation after purification. The purified protein
was also used to generate rabbit polyclonal anti-FBA anti-
serum (RaFBA), which was used to confirm that FBA was
expressed in vitro in each of a range of neisserial strains
tested including commensal species. This suggests that
FBA plays an important role which is required by both
non-pathogenic and pathogenic lineages. FBA was
shown to be present in both the cytosol and to be exposed
at the cell surface of wild-type meningococci in a form that
was accessible to antibodies, suggesting that, similar to
GAPDH and enolase, FBA is translocated (or diverted) to
the outer membrane. An alternative hypothesis is that
FBA is released from lysed cells and recruited back onto
the surface of intact meningococci; however, we have
pro.bed Iys.atesof cbbA-deficient meninqococcl following
cO-Incubation with rFBA and found no reactivity with
(Q) 2010BlackwellPublishingLtd,Molecular Microbiology, 76, 605-615
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RaFBA (data not shown). In M. genitalium, only a small
proportion of the total cellular GAPDH is traHicked to the
bacterial surface; however, this is suHicient to impart a
biologically significant phenotype (mucin-binding) on this
organism (Alvarez et al., 2003). For organisms with rela-
tively small genomes, multi-functional proteins may be
advantageous to optimize the potential of the genome. To
our knowledge, this is the first report demonstrating that a
proportion of FBA is found on the cell surface of
meningococci.
An FBA-deficient mutant grew at the same rate (in
broth culture and on solid media) as the wild-type and
the complemented mutant strains, demonstrating that
FBA is not required for growth of the meningococcus
under the in vitro conditions used. No diHerences In
either colony or bacterial cell morphology (using light
microscopy) were observed. The FBA-deficient mutant
strain exhibited a significantly reduced capacity to
adhere to both HBME and HEp-2 cells. This phenotype
was completely restored in a complemented strain. Our
observation that FBA is involved in adhesion to both epi-
thelial and endothelial cells, and that FBA expression is
conserved in non-pathogenic strains (such as N.
polysacchareae) may suggest a role for FBA during
colonization of the nasopharyngeal mucosa by commen-
sal neisserial species.
Although we have shown that FBA is present on the
meningococcal cell surface and is required for optlm I
adhesion, the role of FBA in this process is unknown. It Is
possible that the enzymatic activity of FBA plays an Indi-
rect role that is required for optimal adhesion. However,
given that other FBA homologues (such as FBA in S.
pneumoniae) have been shown to directly bind to host cell
ligands it is also possible that the meningococcal protein
has a direct host receptor-binding activity. Determining the
ability of meningococci expressing a non-enzymatically
functional FBA to adhere to host cells would address this.
S. pneumoniae FBA was shown to bind to a c dh rln
superfamily receptor (Flamingo cadherin receptor, FCR)
on the surface of host epithelial cells, but it Is unknown
which FBA residues participate In this Interaclion (BI u
et al., 2007). Meningococcal FBA is only 40% id ntic I to
the pneumococcal enzyme at the amino acid level, so It Is
unclear whether meningococcal FBA binds th m
receptor. Work is currently In progress to d termln
whether meningococcal FBA binds to FCR or dlff rent
host cell receptor.
Pneumococcal FBA has been shown to be Immuno-
genic in humans and capable of eliciting a p rti lIy pro-
tective immune response against lethal S. pn omon;
intranasal challenge in mice (Ling et sI., 2004). Glv nth
meningococcal FBA Is highly conserved, express d by
wide range of Isolates, surface-accessible to ntibodi
and structurally and antigenically unrelated to th hum n
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Table 3. List of primers used in this study.
Primer DNA sequence' Restrictionsite
Expression
FBA_pOE70 (F)
FBA_pOE70 (R)
Mutagenesis
FBA_M1(F)
FBA_M2(R)
FBA_M3(IR)
FBA_M4(IF)
Complementation
FBA_COM(F)
FBA_COM(R)
CGCGGATCCATGGCACTCGTATCCATGCG
CGCGGTACCGTCGTCCGAACGGCGG
Sphl
9gl11
CTGCTGTGCCCGAGC
CCGCTGCTGCAGGCG
GCGAGATCTTGTGTCTCCTTGGGCAATAGG
GCGAGATCTGCTCCATCCAACTGGG
Bgill
Bgill
CGCGGATCCATGAGCTGTTTATGGrnnnTGCTG
CGCGGATCCGGCATTTTGTTTACAGGCAACCTG
BamHI
BamHI
8. All primers were designed from the N. meningilfdisMC58 genome sequence. Sequences in bold Identify restrictionenzyme sites.
(Class I) FBA protein, meningococcal FBA is worthy of
future study as a possible candidate vaccine component
against this important human pathogen.
Experimental procedures
Bacterial strains and growth conditions
Escherichia coli TOP10F' and BL21(DE3) pLysS (Table 1)
were used for the expression of 6x histidine-tagged rFBA
encoded by plasmid pSAT-FBA (Table 1). E. coliJM109 was
used as a host strain for the construction of mutagenic
and complementation plasmids, pSAT-4 and pSAT-12
respectively. E. coli strains were grown at 3JOC in Luria-
Bertani (LB) broth or on LB agar supplemented, where appro-
priate, with ampicillin (100 ~g rnl'], kanamycin (30 ~g mt')
or erythromycin (200 ~g rnr '). Strains of Neisseria (Tables 1
and 2) were grown at 37°C, air plus 5% CO 2, on Brain Heart
Infusion (BHI) agar supplemented with 1% Vitox (Oxoid) and
kanamycin (50 ~g mr ') or erythromycin (5 ~g mr") where
appropriate.
DNA manipulation
Genomic DNA was extracted from N. meningitidis using the
DNeasy Tissue kit (Oiagen). Plasmid DNA was prepared by
using the OIAprep Spin kit (Oiagen). Restriction enzymes
and T4 DNA ligase were purchased from Roche. All enzy-
matic reactions were carried out according to the manufac-
turer's instructions. DNA sequencing was carried out at the
School of Biomedical SCiences (University of Nottingham) on
an ABI 377 automated DNA sequencer.
Preparation of recombinant FBA
The cbbA gene was amplified from N. meningitidis MC5S
using oligonucleotide primers FBA_pOE70 (F) and
FBA_pOE70 (R) (Table 3) using the Expand High Fidelity
PCR system (Roche). The resulting amplicon was digested
with Sphl and BglII, before being ligated into similarly treated
pOE70, and the resulting plasmid, pSAT-FBA, used to trans-
form E. coliBL21 (DE3) pLysS. Transformants were grown to
log phase, induced with 1 mM IPTG for 3 h and harvested by
centrifugation. Recombinant 6x histidine-tagged FBA was
then affinity-purified under native conditions. Briefly, the
culture pellet from an IPTG-induced culture of E. coli BL21
(DE3) pLysS (pSAT-FBA) was dissolved in 20 ml of lysis
buffer (50 mM NaH2PO., 300 mM NaCl, 10 mM Imidazole, pH
7.4) and disrupted by sonication using a MSE Soniprep 150
for 10 cycles (each cycie conslsnnq of a 10 s burst followed
by a 10 s cooling period). The cell lysate was then mixed with
1 mi of HisPur™ Cobalt Resin (Pierce) and incubated over-
night at 4°C. The lysate-resin mixture was then applied to a
column, and washed with 50 mM NaH,PO., 300 mM NaCl,
15 mM imidazole, pH 7.4. Bound protein was then elutod In
elution buffer (50 mM NaH2PO., 300 mM NaCl, 300 mM Imi-
dazole, pH 7.4).
Production of a rabbit antiserum against purified
recombinant FBA
New Zealand White femaie rabbits were Immunized subcu-
taneously four times at 2 week Intervals with 30 j.lg of rFBA
protein emulsified In Freud's complete (first immunization
only) or incomplete adjuvant. After three Injections, th
animals were test bled, boosted once more and sacrllic d 10
days later.
50S-PAGE and immunoblotting
Proteins were electrophoretically separated using 10% poiy-
acrylamide gels (Mini-Protean III; Blo-Rad) and woro st In d
using SimplyBlue Safestain™ (Invitrogen) or transterr d to
nitrocellulose membranes as previously described (Klzil
et al., 1999). Membranes were probed with mous nil-
pentahistidine antibody (Olagen) or rabbit prim ry ntlbody
diiuted 1:10000 or 1:1000, respectively, In blocking buff r
[5% (wI/vol) nonfat dry milk, 0.1% (voIlVOI) Tw n 20 In 1
phosphate-buffered saline (PBS)] and Incub t d for 2 h. Aft r
being washed in PBS with 0.1% Tween 20 (PBST), m m-
branes were incubated for 2 h with 1:30 OOO-dilut d go I
anti-mouse (or anti-rabbit) IgG-alkaline phosph t conju-
gate (Sigma). After washing with PBST, blots w r d v lop d
using BCIP/NBT-Blue liquid substrate (Slgm ).
© 2010 Blackwell Publishing Ltd, Moleculsr Microbiology, 76, 605-615
Kinetic analysis of fructose bisphosphate
aldolase activity
This was done using a previously described methodology
(Berry and Marshall, 1993). Briefly, the assay was performed
at 30°C in 1 ml of 50 mM Tris-HCI supplemented with 0.1 M
potassium acetate buffer (pH 8.0) containing 0.1-5 mM fruc-
tose 1, 6-bisphosphate (FBP), 0.2 mM NADH and 2 ILl of a
10 mg ml-' mixture of glycerol phosphate dehydrogenase/
triose phosphate isomerase (coupling enzymes). The
reagents were added in the order: buffer; FBP; NADH; cou-
pling enzymes. Finally, the reaction was started by adding
0.26 nmol of purified native FBA. A decrease in absorbance
at 340 nm was recorded as the measure of enzyme activity
on an Uvikon 930 spectrophotometer. Activities were calcu-
lated using the molar ex1inction coefficient for NADH as
6220 M-' crrr '. One unit of aldolase activity was defined as
the amount of enzyme which catalysed the oxidation of
2 urnot NADH rnirr '. Kinetic parameters were determined
using Origin Pro 7.5 software.
Construction of MC58L1cbbA
A 2.3 kb fragment of DNA consisting of the cbbA gene and
flanking DNA was amplified using FBA_M1(F) and
FBA_M2(R) (Table 3) from N. meningitidis MCS8 chromo-
somal DNA. The amplified DNA was TA cloned into the
pG~M-T Easy vector to generate pSAT-2. This was then
subject to inverse PCR using primers FBA_M3(IR) and
FBA_M4(IF) (Table 3) resulting in the amplification of a 5 kb
amplicon in which the cbbA coding sequence was deleted
and a unique Bglli site had been introduced. The Bglil site
was used to introduce a kanamycin resistance cassette,
BamHI-digested from pJMK30 (Table 1), in place of cbbA.
One of the resulting plasmids, pSAT-4, containing the resis-
tance cassette in the same orientation as the deleted gene,
was confirmed by restriction digestion and sequencing and
Subsequently used to mutate the meningococcal strain MCS8
by natural transformation and allelic exchange as previously
described (Hadi et al., 2001). The deletion in the resulting
mutant (MCS811CbbA) was confirmed by PCR analysis and
immunoblotting. Growth curve assays carried out using liquid
cuitures showed no significant differences between
MC586cbbA and the Wild-type strain (data not shown).
Complementation of cbbA
A fragment corresponding to the cbbA coding sequence and
upstream promoter was amplified from chromosomai DNA of
st~ain MCS8 with High Fidelity Expand Taq (Roche) using the
pn~ers FBA_COM(F) and FBA_COM(R) (Table 3) lncorpo-
r~!lng BamHI sites into the amplified fragment. The BamHI-
dlge~ted fragment was then introduced into a unique BamHI
site In pYHS2S. This vector contains an erythromycin resis-
tance gene fianked by the MCS8 genes NMB0102 and
NMB0103 (Winzer et al., 2002). The resuiting plasmid
pSAT-12 was used to transform MC5811CbbAby natural trans-
formation, thus introducing a single chromosomal copy of
cbbA ~nd the downstream erythromycin resistance cassette
In the rntergenlC region between NMB0102 and NMB0103.
C 2010 Blackwell Publishing Ltd, Molecular Microbiology, 76,605-£15
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Insertion of the cbbA gene and erythromycin resistance
cassette at the ectopiC site was confirmed by peR analysis
and sequencing. Expression of FBA was confirmed by
immunoblotting.
Sub-cellular localization of FBA
Cells from 100 ml of overnight BHI broth cultures were har-
vested at 13 000 9 for 2 min and the pellet re-suspended in
1 ml of EB buffer (10 mM Tris-HCI pH 7.5, 10 mM Mgel2, 25%
sucrose), and washed twice in the same buffer. Finally, the
pellet was re-suspended in EB buffer and incubated for 10 min
on ice. The preparation was centrifuged at 13 000 9 for 4 min:
following re-suspension in 0.4 ml of ice cold water, the mixture
was incubated on ice for a further 10 min, followed by centrifu-
gation at 13000 9 for 2 min. The supernatant, containing
peri plasmic proteins, was removed and stored at -20°C. The
remaining cell pellet (spheroplasts) were re-suspended Into
0.4 ml of Tris-HCI (pH 7.5) and sonicated using a MSE Sonl-
prep 150 for 10 cycles (each cycle consisting of a 10 s burst
followed by a 10 s cooling period) to release the cytoplasmic
contents. Non-disrupted cells were removed by centrifugation
at 5000 g for 1 min. The upper clear supernatant was trans-
ferred to a fresh tube and centrifuged at 17000 9 for 30 min.
The supernatant (representing the cytosolic fraction) was
removed and stored at -20°C. The remaining pollet was
re-suspended in 0.4 ml of 10 mM Trls-Hel pH 7.5, 10 mM
MgC!" 2% Triton X-100. The sample was Incubated at 37"C for
30 min and then centrifuged at 17000 9 for 30 min. The
supernatant, enriched for cytoplasmic membrane proteins,
was removed and stored at -20°C. The final pellet (enrlchod
for outer membrane proteins) was re-suspended by brief
sonication in 1 ml of 10 mM Tris-HCI pH 7.5, 10 mM MgCla, 10/0
Triton X-100, incubated at 37°C for 30 min and then contrl-
fuged at 17 000 9 for 30 min. The pellet was re-suspended In
0.2 ml of 10 mM Tris-HCI pH 7.5 and stored at -20°C.
Flow cytometry
Neisseria meningitidis strains were grown to mid-log ph so
(00600 approximately 0.7). 1 x 10' cfu allquots were contn-
fuged at 5000 9 for 5 min and resuspendod In 0.2 Ilm-fIIt r d
PBS. The cells were Incubated for 2 h with (lR-FBA [1 :500
diluted in PBS containing 0.1% BSA, 0.1% sodium azid and
2% fetal calf serum (FCS)] and untreated colis woro u d 5
a control. Cells were washed throe timos with PBS nd Incu-
bated for 2 h in the dark with goat anti-rabbit IgG-Alox Flour
488 conjugate (Invitrogen; dllutod 1:50 In PBS cont Inlng
0.1% BSA, 0.1% sodium azido and 2% FCS). Ag in,
untreated cells were used s a control. Fin lIy, th mpl
were washed in PBS twice beforo bolng re-su p nd d In , ml
of PBS containing 0.5% formaldehydo to fix th c II .
Samples were analysed for fluoroscenc u ing Coult r
Altra Flow Cytometer. Cells were dot et d u ing lorw rd nd
log-side scatter dot plots, and a gating r glon w t to
exclude cell debris and aggregates of b ctori . A tot I of
50000 bacteria (events) were analysed.
AssociatIon and invasion assays
Association and invasion assays wero perform d nil lJy
as previously described (Oldfieid t et; 2007), Brl fly, HBME
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or larynx carcinoma (HEp-2) cells were grown to confluence
in DMEM supplemented with 10% heat-inactivated FCS
(Invitrogen) and 2% antibiotic anti-mycotic solution (Invitro-
gen) in 24-well tissue culture plates (Costar) at 37°C in an
atmosphere of 5% CO2. Prior to all experiments, mono-layers
were transferred to DMEM supplemented with 2% FCS to
remove the antibiotics. Meningococci were cultured in MHB
for 2 hand monolayers were infected with 1 x 106 cfu of
meningococci and incubated for 2 h (association) or 4 h
(invasion) in 5% CO2 at 3rC. To assess total cell association,
monolayers were washed four times with 1 ml of PBS per
well. To assess invasion, monolayers were further incubated
in DMEM containing gentamicin (100 l!g rnr ') for 2 h. Prior to
further steps, aliquots of the gentamicin-containing superna-
tants were plated out to confirm killing of extra-cellular
bacteria. Furthermore, the susceptibility of all meningococcal
strains to gentamicin at 100 l!g ml-1 was confirmed prior to
testing. Monolayers were then washed four times with 1 ml of
PBS. In both association and invasion experiments, mono-
layers were then disrupted and homogenized in 1 ml of 0.1%
saponin in PBS. Meningococci were enumerated by serial
dilution of the homogenized suspensions and subsequent
determination of colony-forming units by plating 50 l!1aliquots
from appropriate dilutions of the Iysates on agar. All associa-
tion and invasion assays were repeated at least three times.
Statistical significance was measured using a two-tailed Stu-
dent's t-test.
Protein and nucleic acid sequence analysis
Public databases containing previously published protein and
DNA sequences were searched using the BLAST and PSI-
BLAST algorithms available at http://blast.ncbLnlm.nih.gov/
Blast.cgL The genome database of N. meningitidis MC58 was
interrogated at http://cmr.jcvLorg/cgi-bin/CMRlGenomePage.
Cgi?org=gnm. Sequence homology data were obtained using
the CLUSTALX software (http://www.clustal.orgl). Protein
secretion signals were analysed using the SignalP 3.0 server
available at http://www.cbs.dtu.dklserviceslSignaIP/ (Eman-
uelsson et al., 2007). GenBank accession numbers for the
cbbA sequences analysed in this study are as follows:
YP_974462 (FAMI8), YP_001598513 (ST-4821 strain
053442), YP_002342063 (Z2491), YP_207215 (gonococcal
strain FA1090) and ZP_03723075 (N. lactamica ATCC
23970).
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